Phenytoin B-drug
: O
Serum O
phenytoin B-drug
levels O
may O
be O
increased O
by O
aspirin B-brand
. O

Pharmacologic O
studies O
indicate O
that O
there O
may O
be O
additive O
effects O
in O
prolonging O
AV O
conduction O
when O
using O
beta-blockers B-group
or O
digitalis B-group
concomitantly O
with O
Tiazac B-brand
. O

Amprenavir B-drug

No O
abortifacient O
or O
teratogenic O
effects O
were O
observed O
in O
cynomolgus O
monkeys O
following O
intravenous O
bolus O
injections O
of O
AMEVIVE B-brand
administered O
weekly O
during O
the O
period O
of O
organogenesis O
to O
gestation O
. O

Therefore O
, O
concomitant O
use O
of O
TORADOL B-brand
and O
probenecid B-drug
is O
contraindicated O
. O

( O
54 O
) O
microtubules O
per O
axon O
. O

Primary O
and O
secondary O
magnesium B-drug
deficiencies O
constitute O
the O
sole O
indication O
of O
physiological O
oral O
magnesium B-drug
therapy O
. O

Antacid B-group
: O
The O
effect O
of O
an O
aluminum B-drug
hydroxide- O
and O
magnesium B-drug
hydroxide-containing O
antacid B-group
( O
Maalox B-brand
) O
* O
on O
the O
pharmacokinetics O
of O
capecitabine B-drug
was O
investigated O
in O
12 O
cancer O
patients O
. O

Antacids B-group
, O
kaolin-pectin B-drug
, O
sulfasalazine B-drug
, O
neomycin B-drug
, O
cholestyramine B-drug
, O
certain O
anticancer O
drugs O
, O
and O
metoclopramide B-drug
may O
interfere O
with O
intestinal O
digoxin B-drug
absorption O
, O
resulting O
in O
unexpectedly O
low O
serum O
concentrations O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
are O
required O
when O
this O
drug O
is O
given O
concomitantly O
with O
anticholinergic B-group
or O
sympathomimetic B-group
drugs I-group
. O

Acetaminophen B-drug
diminished O
the O
binding O
of O
theophylline B-drug
to O
human O
serum O
by O
a O
net O
change O
of O
5.7 O
% O
( O
percentage O
increase O
in O
free O
drug O
fraction O
[ O
FDF O
] O
, O
11.0 O
% O
) O
at O
662 O
micromol/L O
and O
by O
a O
net O
change O
of O
7.1 O
% O
( O
percentage O
increase O
in O
FDF O
, O
13.7 O
% O
) O
at O
1324 O
micromol/L O
. O

This O
paper O
attempts O
to O
provide O
a O
basis O
for O
the O
understanding O
and O
identifications O
of O
important O
drug O
interactions O
. O

Effects O
of O
etofibrate B-drug
upon O
the O
metabolism O
of O
chylomicron-like O
emulsions O
in O
patients O
with O
coronary O
artery O
disease O
. O

Hypersensitivity O
Reactions O
: O
Patients O
with O
a O
history O
of O
severe O
hypersensitivity O
reactions O
to O
products O
containing O
Cremophor O
EL O
( O
eg O
, O
cyclosporin B-drug
for O
injection O
concentrate O
and O
teniposide B-drug
for O
injection O
concentrate O
) O
should O
not O
be O
treated O
with O
TAXOL B-brand
. O

Rare O
reports O
of O
more O
severe O
events O
such O
as O
phlebitis O
, O
cellulitis O
, O
induration O
, O
skin O
exfoliation O
, O
necrosis O
, O
and O
fibrosis O
have O
been O
received O
as O
part O
of O
the O
continuing O
surveillance O
of O
TAXOL B-brand
safety O
. O

Cocaine B-drug
sometimes O
proves O
to O
be O
fatal O
when O
used O
in O
combination O
with O
heroin B-drug_n
. O

Nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
aminoglycoside B-group
antibiotics I-group
and O
cephalosporin B-group
antibiotics I-group
. O

Of O
the O
229 O
patients O
who O
had O
potassium B-group
depleting I-group
diuretics I-group
added O
to O
their O
concomitant O
medications O
in O
the O
DIAMOND O
trials O
, O
the O
patients O
on O
TIKOSYN B-brand
had O
a O
non-significantly O
reduced O
relative O
risk O
for O
death O
of O
0.68 O
( O
95 O
% O
CI O
0.376 O
, O
1.230 O
) O
. O

Azlocillin B-drug
should O
not O
be O
administered O
concomitantly O
with O
amikacin B-drug
, O
ciprofloxacin B-drug
, O
gentamicin B-drug
, O
netilmicin B-drug
, O
or O
tobramycin B-drug
. O

Itraconazole B-drug
plasma O
concentrations O
should O
be O
monitored O
when O
Itraconazole B-drug
and O
isoniazid B-drug
are O
coadministered O
. O

Moreover O
, O
its O
activity O
was O
enhanced O
when O
it O
was O
combined O
with O
either O
azithromycin B-drug
or O
minocycline B-drug
with O
90 O
% O
parasite O
reduction O
at O
the O
highest O
concentration O
tested O
. O

Whether O
abnormal O
topoisomerase O
quantity O
and O
specific O
activity O
are O
associated O
with O
resistance O
or O
sensitivity O
to O
topoisomerase-targeted O
chemotherapy O
in O
the O
clinic O
is O
now O
being O
studied O
. O

Cardiac B-group
glycosides I-group

The O
color O
reverses O
when O
the O
test O
sample O
is O
acidified O
in O
vitro O
to O
a O
pH O
below O
4 O
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

Amiodarone B-drug
or O
Verapamil B-drug
: O
The O
risk O
of O
myopathy/rhabdomyolysis O
is O
increased O
when O
either O
amiodarone B-drug
or O
verapamil B-drug
is O
used O
concomitantly O
with O
a O
closely O
related O
member O
of O
the O
HMG-CoA B-group
reductase I-group
inhibitor I-group
class I-group
( O
see O
WARNINGS O
, O
Myopathy/Rhabdomyolysis O
) O
. O

Lithium B-drug
: O
Diclofenac B-drug
decreases O
lithium B-drug
renal O
clearance O
and O
increases O
lithium B-drug
plasma O
levels O
. O

- O
Probenecid B-drug
: O
Pretreatment O
with O
probenecid B-drug
reduces O
both O
the O
natriuresis O
and O
hyperreninemia O
produced O
by O
bumetanide B-drug
. O

The O
interaction O
was O
pharmacodynamic O
; O

Dose O
of O
AED B-group
( O
mg/day O
) O

Concomitantly O
administered O
iron-fortified B-drug_n
infant O
formula O
( O
2.2 O
mg O
elemental O
iron/6 B-drug_n
oz O
) O
has O
no O
significant O
effect O
on O
cefdinir B-drug
pharmacokinetics O
. O

No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-drug
Tablets O
. O

Coadministration O
of O
Itraconazole B-drug
and O
drugs O
primarily O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
drugs O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
. O

Buforin B-drug_n
II I-drug_n
may O
be O
active O
in O
inhibiting O
Cryptosporidium O
parvum O
growth O
in O
vitro O
upon O
combination O
with O
either O
azithromycin B-drug
or O
minocycline B-drug
. O

Lovastatin B-drug
is O
metabolized O
by O
CYP3A4 O
but O
has O
no O
CYP3A4 O
inhibitory O
activity O
; O

The O
effects O
of O
chlordiazepoxide B-drug
, O
amphetamine B-drug
and O
cocaine B-drug
on O
bar-press O
behavior O
in O
normal O
and O
genetically O
nervous O
dogs O
. O

Hydrocodone B-drug
: O
Coadministration O
of O
Neurontin B-brand
( O
125 O
to O
500 O
mg O
; O

There O
are O
a O
number O
of O
steps O
physicians O
can O
take O
to O
ensure O
that O
their O
patients O
are O
not O
being O
undertreated O
. O

Digitalis B-group
: O
Thyroid B-group
preparations I-group
may O
potentiate O
the O
toxic O
effects O
of O
digitalis B-group
. O

Studies O
with O
ACE B-group
inhibitors I-group
in O
combination O
with O
diuretics B-group
indicate O
that O
the O
dose O
of O
the O
ACE B-group
inhibitor I-group
can O
be O
reduced O
when O
it O
is O
given O
with O
a O
diuretic B-group
. O

Monitoring O
of O
liver O
enzymes O
is O
recommended O
when O
SUSTIVA B-brand
is O
used O
in O
combination O
with O
ritonavir B-drug
. O

Severe O
allergic O
reactions O
including O
anaphylaxis O
have O
been O
reported O
in O
patients O
exposed O
to O
a O
variety O
of O
allergens O
either O
by O
repeated O
challenge O
, O
or O
accidental O
contact O
, O
and O
with O
diagnostic O
or O
therapeutic O
agents O
while O
receiving O
beta-blockers B-group
. O

Ketoconazole B-drug
: O
Sensipar B-brand
is O
metabolized O
in O
part O
by O
CYP3A4 O
. O

Erythromycin B-drug
( O
500 O
mg O
every O
8 O
hrs O
) O

In O
the O
present O
study O
, O
evoked O
potentials O
were O
recorded O
at O
5 O
, O
20 O
, O
and O
40 O
min O
following O
IP O
injections O
of O
saline O
, O
ethanol B-drug
( O
2.0 O
g/kg O
) O
, O
physostigmine B-drug
( O
0.6 O
mg/kg O
) O
or O
atropine B-drug
( O
15.0 O
mg/kg O
) O
on O
separate O
days O
. O

There O
is O
little O
if O
any O
clinically O
significant O
interaction O
between O
Acarbose B-drug
and O
metformin B-drug
. O

Edema O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
Itraconazole B-drug
and O
dihydropyridine B-group
calcium I-group
channel I-group
blockers I-group
. O

Thyroid O
hormonal O
replacement O
increases O
metabolic O
rate O
, O
which O
requires O
an O
increase O
in O
digitalis B-group
dosage O
. O

No O
dose O
adjustment O
is O
necessary O
. O

Antihypertensives B-group
: O
Amphetamines B-group
may O
antagonize O
the O
hypotensive O
effects O
of O
antihypertensives B-group
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

Caution O
should O
be O
exercised O
if O
LEUSTATIN B-brand
Injection O
is O
administered O
before O
, O
after O
, O
or O
in O
conjunction O
with O
other O
drugs O
known O
to O
cause O
immunosuppression O
or O
myelosuppression O
. O

As O
a O
false-negative O
result O
may O
occur O
in O
the O
ferricyanide O
test O
, O
it O
is O
recommended O
that O
either O
the O
glucose O
oxidase O
or O
hexokinase O
method O
be O
used O
to O
determine O
blood/plasma O
glucose O
levels O
in O
patients O
receiving O
cefditoren B-drug
pivoxil I-drug
. O

No O
significant O
interactions O
with O
digoxin B-drug
, O
hydrochlorothiazide B-drug
, O
hydralazine B-drug
, O
sulfinpyrazone B-drug
, O
oral O
contraceptives B-group
, O
tolbutamide B-drug
, O
or O
warfarin B-drug
have O
been O
observed O
. O

The O
high O
acquisition O
cost O
of O
olanzapine B-drug
is O
offset O
by O
reductions O
in O
other O
treatment O
costs O
( O
inpatient O
and/or O
outpatient O
services O
) O
of O
schizophrenia O
. O

The O
daily O
dose O
of O
ENABLEX B-brand
should O
not O
exceed O
7.5 O
mg O
when O
coadministered O
with O
potent O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
ritonavir B-drug
, O
nelfinavir B-drug
, O
clarithromycin B-drug
and O
nefazadone O
) O
. O

Treatment O
of O
the O
glands O
with O
cytochalasin B-drug_n
D I-drug_n
redistributed O
type O
3 O
inositol O
1,4,5-trisphosphate O
receptor O
( O
the O
major O
subtype O
in O
the O
parietal O
cell O
) O
from O
the O
fraction O
containing O
membranes O
of O
large O
size O
to O
the O
microsomal O
fraction O
, O
suggesting O
a O
dissociation O
of O
the O
store O
from O
the O
plasma O
membrane O
. O

diuretics* B-group
; O

It O
is O
presently O
not O
known O
whether O
these O
same O
drug O
interactions O
occur O
with O
dirithromycin B-drug
. O

Doxazosin B-drug
mesylate I-drug
has O
been O
administered O
without O
any O
evidence O
of O
an O
adverse O
drug O
interaction O
to O
patients O
receiving O
thiazide B-group
diuretics I-group
, O
beta-blocking B-group
agents O
, O
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
. O

Viable O
counts O
for O
type O
culture O
E O
. O

The O
concurrent O
use O
of O
drugs O
from O
these O
groups O
is O
decreasing O
according O
to O
a O
survey O
of O
200 O
hospital O
medical O
records O
. O

Nephrotoxicity O
associated O
with O
cyclosporine B-drug
may O
also O
be O
enhanced O
. O

Pretreatment O
of O
megakaryocytes O
with O
extracellular O
RR B-drug_n
( O
50 O
microM O
) O
also O
inhibited O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
-induced O
responses O
. O

Dopamine B-group
Antagonists I-group
: O
Since O
apomorphine B-drug
is O
a O
dopamine B-group
agonist I-group
, O
it O
is O
possible O
that O
dopamine B-group
antagonists I-group
, O
such O
as O
the O
neuroleptics B-group
( O
phenothiazines B-group
, O
butyrophenones B-group
, O
thioxanthenes B-group
) O
or O
metoclopramide B-drug
, O
may O
diminish O
the O
effectiveness O
of O
APOKYN B-brand
. O

If O
such O
drugs O
are O
needed O
, O
their O
dose O
should O
be O
reassessed O
and O
, O
where O
appropriate O
, O
plasma O
concentration O
measured O
. O

The O
AUC O
of O
midazolam B-drug
on O
Day O
15 O
was O
similar O
to O
that O
observed O
at O
baseline O
. O

5 O
. O

Appropriate O
doses O
for O
this O
combination O
arenot O
established O
, O
but O
an O
increase O
in O
thedosage O
of O
indinavir B-drug
may O
be O
required O
. O

They O
are O
part O
of O
the O
treatment O
of O
patients O
with O
organ O
transplants O
, O
malignancy O
, O
and O
increasingly O
those O
with O
conditions O
such O
as O
psoriasis O
, O
rheumatoid O
arthritis O
, O
and O
liver O
and O
bowel O
disease O
in O
which O
inflammation O
is O
an O
aetiological O
factor O
. O

Phenytoin B-drug
: O
Etodolac B-drug
has O
no O
apparent O
pharmacokinetic O
interaction O
when O
administered O
with O
phenytoin B-drug
. O

Concomitant O
use O
of O
HIVID B-drug
with O
didanosine B-drug
is O
not O
recommended O
. O

Under O
similar O
conditions O
, O
bexarotene B-drug
concentrations O
were O
not O
affected O
by O
concomitant O
atorvastatin B-drug
administration O
. O

Increased O
stability O
of O
nucleophosmin/B23 O
in O
anti-apoptotic O
effect O
of O
ras O
during O
serum O
deprivation O
. O

H2 B-group
Receptor I-group
Antagonists I-group
: O
Cimetidine B-drug
coadministration O
leads O
to O
an O
increased O
peak O
plasma O
concentration O
and O
AUC O
of O
cisapride B-drug
, O
there O
is O
no O
effect O
on O
cisapride B-drug
absorption O
when O
it O
is O
coadministered O
with O
ranitidine B-drug
. O

Pentamidine B-drug
may O
cause O
hypoglycemia O
, O
which O
may O
sometimes O
be O
followed O
by O
hyperglycemia O
. O

However O
, O
concomitant O
administration O
of O
aspirin B-brand
with O
CELEBREX B-brand
may O
result O
in O
an O
increased O
rate O
of O
GI O
ulceration O
or O
other O
complications O
, O
compared O
to O
use O
of O
CELEBREX B-brand
alone O
. O

Another O
investigator O
found O
no O
increase O
in O
digoxin B-drug
levels O
in O
13 O
patients O
with O
coronary O
artery O
disease O
. O

If O
additional O
adrenergic B-group
drugs I-group
are O
to O
be O
administered O
by O
any O
route O
, O
they O
should O
be O
used O
with O
caution O
because O
the O
pharmacologically O
predictable O
sympathetic O
effects O
of O
BROVANA B-brand
may O
be O
potentiated O
. O

Based O
on O
this O
reported O
activity O
, O
they O
should O
not O
be O
given O
concomitantly O
with O
Coly-Mycin B-brand
M I-brand
Parenteral O
except O
with O
the O
greatest O
caution O
. O

No O
changes O
were O
observed O
in O
the O
degree O
of O
anticoagulation O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

However O
, O
because O
higher O
doses O
( O
up O
to O
360 O
mg O
QD O
) O
of O
omeprazole B-drug
are O
tolerated O
in O
Zollinger-Ellison O
( O
ZE O
) O
patients O
, O
no O
dose O
adjustment O
for O
omeprazole B-drug
is O
recommended O
at O
current O
doses O
. O

After O
14 O
days O
of O
co-administration O
, O
mean O
trough O
concentrations O
of O
clozapine B-drug
and O
its O
metabolites O
, O
N-desmethylclozapine B-drug_n
and O
clozapine B-drug_n
N-oxide I-drug_n
, O
were O
elevated O
with O
fluvoxamine B-drug
by O
about O
three-fold O
compared O
to O
baseline O
concentrations O
. O

In O
a O
study O
involving O
healthy O
subjects O
receiving O
TAMBOCOR B-brand
and O
propranolol B-drug
concurrently O
, O
plasma O
flecainide B-drug
levels O
were O
increased O
about O
20 O
% O
and O
propranolol B-drug
levels O
were O
increased O
about O
30 O
% O
compared O
to O
control O
values O
. O

Because O
of O
its O
lack O
of O
anti-platelet O
effect O
valdecoxib B-drug
is O
not O
a O
substitute O
for O
aspirin B-brand
for O
cardiovascular O
prophylaxis O
. O

The O
management O
of O
infection O
is O
dealt O
with O
as O
a O
separate O
section O
. O

diuretics* B-group
; O

Patients O
should O
be O
advised O
against O
the O
simultaneous O
use O
of O
other O
CNS B-group
depressant I-group
drugs I-group
, O
and O
cautioned O
that O
the O
effect O
of O
alcohol B-drug
may O
be O
increased O
. O

OTHER O
CONCOMITANT O
THERAPY O
: O
Although O
specific O
interaction O
studies O
were O
not O
performed O
, O
in O
clinical O
studies O
, O
cerivastatin B-drug
sodium I-drug
was O
used O
concomitantly O
with O
angiotensin- B-group
converting I-group
enzyme I-group
( I-group
ACE I-group
) I-group
inhibitors I-group
, O
betablockers B-group
, O
calcium-channel B-group
blockers I-group
, O
diuretics B-group
, O
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
( O
NSAIDs B-group
) O
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

Known O
drug O
interactions O
include O
barbiturates B-group
, O
tranquilizers B-group
, O
and O
alcohol B-drug
. O

Concurrent O
administration O
of O
drugs O
possessing O
nephrotoxic O
( O
e.g. O
, O
aminoglycosides B-group
, O
indomethacin B-drug
) O
, O
myelotoxic O
( O
e.g. O
, O
cytotoxic B-group
chemotherapy O
) O
, O
cardiotoxic O
( O
e.g. O
, O
doxorubicin B-drug
) O
or O
hepatotoxic O
( O
e.g. O
, O
methotrexate B-drug
, O
asparaginase B-drug
) O
effects O
with O
PROLEUKIN B-brand
may O
increase O
toxicity O
in O
these O
organ O
systems O
. O

PCP B-drug_n
produced O
distinctive O
effects O
in O
each O
task O
: O
it O
substituted O
for O
the O
training O
dose O
in O
PCP B-drug_n
discrimination O
and O
it O
increased O
the O
number O
of O
responses O
with O
short O
( O
< O
3 O
s O
) O
interresponse O
times O
as O
well O
as O
increasing O
overall O
response O
rates O
in O
the O
DRL O
schedule O
. O

Eprosartan B-drug
( O
up O
to O
400 O
mg O
b.i.d O
. O
or O
800 O
mg O
q.d O
. O
) O
doses O
have O
been O
safely O
used O
concomitantly O
with O
a O
thiazide B-group
diuretic I-group
( O
hydrochlorothiazide B-drug
) O
. O

clinical O
significance O
unknown O
. O

Because O
candesartan B-drug
is O
not O
significantly O
metabolized O
by O
the O
cytochrome O
P450 O
system O
and O
at O
therapeutic O
concentrations O
has O
no O
effects O
on O
P450 O
enzymes O
, O
interactions O
with O
drugs O
that O
inhibit O
or O
are O
metabolized O
by O
those O
enzymes O
would O
not O
be O
expected O
. O

The O
AUC O
and O
Cmax O
of O
descarboethoxyloratadine B-drug_n
, O
an O
active O
metabolite O
, O
averaged O
155 O
% O
( O
27 O
S.D O
. O
) O
and O
141 O
% O
( O
35 O
S.D O
. O
) O
, O
respectively O
. O

No O
significant O
difference O
was O
found O
between O
the O
mean O
values O
of O
the O
volume O
of O
distribution O
of O
cloxacillin B-drug
with O
and O
without O
probenecid B-drug
( O
13.0 O
and O
12.6 O
liters O
, O
respectively O
) O
. O

Toxicity O
of O
cadmium O
and O
zinc B-drug
to O
miracidia O
of O
Schistosoma O
mansoni O
. O

Rifampicin B-drug
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
a O
six-day O
course O
of O
rifampicin B-drug
at O
600 O
mg/day O
followed O
by O
a O
single O
5 O
mg O
dose O
of O
isradipine B-drug
resulted O
in O
a O
reduction O
in O
isradipine B-drug
levels O
to O
below O
detectable O
limits O
. O

and O
, O
rarely O
, O
euphoria O
, O
excitement O
, O
depression O
, O
hallucinations O
, O
paresthesia O
, O
muscle O
pain O
, O
tinnitus O
, O
slurred O
speech O
, O
coordination O
disorder O
, O
tremor O
, O
rigidity O
, O
dystonia O
, O
ataxia O
, O
blurred O
vision O
, O
nystagmus O
, O
strabismus O
, O
miosis O
, O
mydriasis O
, O
diplopia O
, O
dysarthria O
, O
epileptic O
seizure O
. O

Cholecystokinin O
octapeptide O
is O
a O
necessary O
factor O
for O
realization O
of O
this O
action O
of O
neuroleptics B-group
. O

Menstrual O
cycle O
irregularities O
were O
accompanied O
by O
both O
a O
decrease O
and O
delay O
in O
the O
peak O
17b O
-estradiol O
and O
progesterone O
levels O
following O
administration O
of O
PEGASYS B-brand
to O
female O
monkeys O
. O

HMG-CoA B-group
Reductase I-group
Inhibitors I-group
: O
Inhibitors B-group
of I-group
HMG-CoA I-group
reductase I-group
may O
cause O
myopathy O
, O
which O
is O
manifested O
as O
muscle O
pain O
or O
weakness O
associated O
with O
elevated O
levels O
of O
CPK O
. O

Although O
the O
clinical O
significance O
of O
these O
effects O
is O
not O
known O
, O
caution O
is O
advised O
in O
the O
co-administration O
of O
beta-agonists B-group
with O
non-potassium B-group
sparing I-group
diuretics I-group
. O

Since O
animal O
studies O
suggest O
that O
the O
action O
of O
barbiturates B-group
may O
be O
prolonged O
by O
therapy O
with O
chlorpropamide B-drug
, O
barbiturates B-group
should O
be O
employed O
with O
caution O
. O

Antihistamines B-group
may O
have O
additive O
effects O
with O
alcohol B-drug
and O
other O
CNS B-group
depressants I-group
, O
e.g. O
, O
hypnotics B-group
, O
sedatives B-group
, O
tranquilizers B-group
, O
antianxiety B-group
agents I-group
. O

Upon O
administration O
of O
10 O
mg O
of O
Vardenafil B-drug
with O
800 O
mg O
TID O
indinavir B-drug
, O
the O
Cmax O
and O
AUC O
of O
indinavir B-drug
were O
reduced O
by O
40 O
% O
and O
30 O
% O
, O
respectively O
. O

Interaction O
of O
clindamycin B-drug
and O
gentamicin B-drug
in O
vitro O
. O

Anafranil B-brand
should O
not O
be O
used O
with O
MAO B-group
inhibitors I-group
. O

Respiratory O
depression O
, O
hypotension O
, O
and O
profound O
sedation O
or O
coma O
may O
occur O
. O

Therefore O
, O
monitoring O
of O
theophylline B-drug
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-drug
adjusted O
as O
required O
. O

These O
results O
suggest O
that O
oral O
administration O
of O
dmPGE2 B-drug_n
induces O
a O
more O
pronounced O
secretory O
diarrhea O
in O
cecectomized O
than O
in O
control O
rats O
, O
probably O
due O
to O
the O
lack O
of O
the O
reservoir O
function O
of O
the O
cecum O
in O
the O
operated O
animals O
. O

Caution O
should O
be O
used O
when O
CYP3A4 B-drug
inhibitors O
are O
co-administered O
with O
felodipine B-drug
. O

The O
actions O
of O
the O
benzodiazepines B-group
may O
be O
potentiated O
by O
barbiturates B-group
, O
narcotics B-group
, O
phenothiazines B-group
, O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
other O
antidepressants B-group
. O

Effects O
of O
Erythromycin B-drug
on O
Felbatol B-brand
The O
coadministration O
of O
erythromycin B-drug
( O
1000 O
mg/day O
) O
for O
10 O
days O
did O
not O
alter O
the O
pharmacokinetic O
parameters O
of O
Cmax O
, O
Cmin O
, O
AUC O
, O
CI/kg O
or O
tmax O
at O
felbamate B-drug
daily O
doses O
of O
3000 O
or O
3600 O
mg/day O
in O
10 O
otherwise O
healthy O
subjects O
with O
epilepsy O
. O

Small O
differences O
in O
sensitivity O
to O
chemotherapy O
can O
have O
a O
dramatic O
effect O
on O
cure O
rates O
, O
and O
therefore O
subtle O
cell O
type-specific O
differences O
may O
be O
important O
determinants O
of O
drug O
sensitivity O
. O

Potassium O
sparing O
agents O
should O
generally O
not O
be O
used O
in O
patients O
with O
heart O
failure O
who O
are O
receiving O
PRINIVIL B-brand
. O

Methotrexate B-drug
: O
Valdecoxib B-drug
10 I-drug
mg I-drug
BID O
did O
not O
show O
a O
significant O
effect O
on O
the O
plasma O
exposure O
or O
renal O
clearance O
of O
methotrexate B-drug
. O

Medications O
that O
interfere O
with O
your O
bodys O
ability O
to O
use O
folate O
may O
also O
increase O
the O
need O
for O
this O
vitamin B-group
. O

Effect O
of O
estradiol B-drug
on O
endotoxin-induced B-drug_n
changes O
in O
steroid O
hormone O
levels O
and O
lethality O
in O
male O
rats O
. O

In O
noradrenaline-precontracted B-drug
arteries O
from O
dietary-obese O
rats O
, O
responses O
to O
resveratrol B-drug_n
were O
not O
attenuated O
by O
endothelial O
denudation O
, O
indicating O
an O
action O
independent O
of O
the O
endothelium O
. O

Nelfinavir I-drug
M8 O

Drug/Laboratory O
Test O
Interactions O

d-amphetamine B-drug
with O
desipramine B-drug
or O
protriptyline B-drug
and O
possibly O
other O
tricyclics B-group
cause O
striking O
and O
sustained O
increases O
in O
the O
concentration O
of O
d-amphetamine B-drug
in O
the O
brain O
; O

In O
vitro O
studies O
were O
conducted O
to O
investigate O
the O
potential O
of O
gabapentin B-drug
to O
inhibit O
the O
major O
cytochrome O
P450 O
enzymes O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
and O
CYP3A4 O
) O
that O
mediate O
drug O
and O
xenobiotic O
metabolism O
using O
isoform O
selective O
marker O
substrates O
and O
human O
liver O
microsomal O
preparations O
. O

Careful O
supervision O
of O
diabetic O
patients O
under O
treatment O
with O
Soriatane B-brand
is O
recommended O
. O

The O
potential O
for O
clinically O
significant O
drug-drug O
interactions O
posed O
by O
dolasetron B-drug
and O
hydrodolasetron B-drug_n
appears O
to O
be O
low O
for O
drugs O
commonly O
used O
in O
chemotherapy O
or O
surgery O
, O
because O
hydrodolasetron B-drug_n
is O
eliminated O
by O
multiple O
routes O
. O

Aspirin B-brand
: O
Concomitant O
aspirin B-brand
may O
decrease O
the O
metabolic O
clearance O
of O
nicotinic B-drug
acid I-drug
. O

During O
clinical O
trials O
, O
hypoglycemia O
and O
hyperglycemia O
were O
reported O
in O
diabetic O
patients O
receiving O
oral O
hypoglycemics B-group
. O

use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

Administration O
of O
a O
5 O
g O
bolus O
followed O
by O
1 O
to O
1.25 O
g/hr O
should O
achieve O
and O
sustain O
plasma O
levels O
of O
0.13 O
mg/mL O
. O

Dose O
reduction O
of O
CRIXIVAN B-brand
to O
600 O
mg O
every O
8 O
hours O
should O
be O
considered O
. O

Therefore O
, O
a O
starting O
daily O
dose O
of O
25 O
mg O
of O
VIOXX B-brand
should O
be O
considered O
for O
the O
treatment O
of O
osteoarthritis O
when O
VIOXX B-brand
is O
co-administered O
with O
potent O
inducers O
of O
hepatic O
metabolism O
. O

Influence O
of O
Trileptal B-brand
on O
AED B-group
Concentration O
( O
Mean O
change O
, O
90 O
% O
Confidence O
Interval O
) O

Although O
these O
results O
do O
not O
indicate O
a O
significant O
interaction O
between O
TORADOL B-brand
and O
warfarin B-drug
or O
heparin B-drug
, O
the O
administration O
of O
TORADOL B-brand
to O
patients O
taking O
anticoagulants B-group
should O
be O
done O
extremely O
cautiously O
, O
and O
patients O
should O
be O
closely O
monitored O
. O

The O
decision O
to O
prescribe O
this O
agent O
should O
include O
such O
considerations O
as O
the O
cost-risk-benefit O
balance O
, O
patient O
access O
, O
drug O
distribution O
pathways O
, O
and O
prescription O
drug O
coverage O
. O

Aspirin/Acetaminophen B-brand
: O
Pharmacokinetic O
or O
pharmacodynamic O
drug-drug O
interactions O
have O
not O
been O
demonstrated O
between O
Argatroban B-drug
and O
concomitantly O
administered O
aspirin B-brand
( O
162.5 O
mg O
orally O
given O
26 O
and O
2 O
hours O
prior O
to O
initiation O
of O
Argatroban B-drug
1 O
g/kg/min O
. O
over O
4 O
hours O
) O
or O
acetaminophen B-drug
( O
1000 O
mg O
orally O
given O
12 O
, O
6 O
and O
0 O
hours O
prior O
to O
, O
and O
6 O
and O
12 O
hours O
subsequent O
to O
, O
initiation O
of O
Argatroban B-drug
1.5 O
g/kg/min O
. O
over O
18 O
hours O
) O
. O

Pregnancy O
Pregnancy O
: O
Category O
C O
PEGASYS B-brand
has O
not O
been O
studied O
for O
its O
teratogenic O
effect O
. O

Intravenous O
ranitidine B-drug
was O
shown O
to O
double O
the O
bioavailability O
of O
oral O
alendronate B-drug
. O

Caution O
is O
advised O
if O
patients O
receive O
large O
doses O
of O
ethchlorvynol B-drug
concurrently O
. O

Chlorprothixene B-drug
may O
increase O
the O
plasma-level O
of O
concomitantly O
given O
lithium B-drug
. O

Genetic O
variation O
in O
metabolism O
may O
result O
in O
high O
concentrations O
of O
drugs O
and O
an O
increased O
risk O
of O
adverse O
effects O
in O
slow O
metabolizers O
, O
which O
is O
important O
when O
using O
for O
example O
antidepressants B-group
or O
chemotherapy O
. O

Ampicillin/Amoxicillin B-drug
: O
An O
increase O
in O
the O
frequency O
of O
skin O
rash O
has O
been O
reported O
among O
patients O
receiving O
ampicillin B-drug
or O
amoxicillin B-drug
concurrently O
with O
allopurinol B-drug
compared O
to O
patients O
who O
are O
not O
receiving O
both O
drugs O
. O

Hyperglycemia O
has O
also O
been O
reported O
in O
patients O
receiving O
CAMPTOSAR B-brand
. O

Until O
further O
data O
are O
developed O
regarding O
drug O
interactions O
when O
azithromycin B-drug
and O
these O
drugs O
are O
used O
concomitantly O
, O
careful O
monitoring O
of O
patients O
is O
advised O
: O
Digoxin B-drug
elevated O
digoxin B-drug
concentrations O
. O

Oral O
Contraceptives B-group
Multiple O
doses O
of O
cefditoren B-drug
pivoxil I-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
ethinyl B-drug
estradiol I-drug
, O
the O
estrogenic O
component O
in O
most O
oral O
contraceptives B-group
. O

When O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
is O
used O
at O
the O
same O
time O
as O
other O
medicines O
or O
substances O
the O
following O
interactions O
must O
be O
taken O
into O
account O
: O
- O
Bezalip B-brand
and O
Bezalip B-brand
retard I-brand
may O
enhance O
the O
action O
of O
anticoagulants B-group
of I-group
the I-group
coumarin I-group
type I-group
. O

Oral O
Contraceptives B-group
: O
The O
effect O
of O
oral O
contraceptives B-group
on O
the O
pharmacokinetics O
of O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
has O
not O
been O
studied O
. O

Reduced O
response O
to O
metyrapone O
test O
. O

About O
three O
weeks O
prior O
to O
admission O
, O
the O
patient O
was O
started O
on O
clarithromycin B-drug
for O
sinusitis O
. O

The O
unrestricted O
use O
of O
ascorbic B-drug
acid I-drug
for O
these O
purposes O
can O
not O
be O
advocated O
on O
the O
basis O
of O
the O
evidence O
currently O
available O
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

Nonsteroidal B-group
anti-inflammatory I-group
agents I-group

Drugs O
that O
have O
been O
reported O
to O
diminish O
oral O
anticoagulant B-group
response O
, O
ie O
, O
decreased O
prothrom-bin O
time O
response O
, O
in O
man O
significantly O
include O
: O
adrenocortical B-group
steroids I-group
; O
alcohol* B-drug
; O
antacids B-group
; O
antihistamines B-group
; O
barbiturates B-group
; O
carbamazepine B-drug
; O
chloral B-drug
hydrate* O
; O
chlordiazepoxide B-drug
; O
cholestyramine B-drug
; O
diet O
high O
in O
vitamin B-group
K I-group
; O
diuretics* B-group
; O
ethchlorvynol B-drug
; O
glutethimide B-drug
; O
griseofulvin B-drug
; O
haloperidol B-drug
; O
meprobamate B-drug
; O
oral O
contraceptives B-group
; O
paraldehyde B-drug
; O
primidone B-drug
; O
ranitidine* B-drug
; O
rifampin B-drug
; O
unreliable O
prothrombin O
time O
determinations O
; O
vitamin B-drug
C I-drug
; O
warfarin B-drug
sodium I-drug
under-dosage O
. O

This O
transient O
hypotensive O
response O
is O
not O
a O
contraindication O
to O
further O
doses O
which O
can O
be O
given O
without O
difficulty O
once O
the O
blood O
pressure O
has O
increased O
after O
volume O
expansion O
. O

Human O
pharmacokinetics O
data O
indicate O
that O
oral O
ketoconazole B-drug
potently O
inhibits O
the O
metabolism O
of O
cisapride B-drug
resulting O
in O
an O
eight-fold O
increase O
in O
the O
mean O
AUC O
of O
cisapride B-drug
. O

Increasing O
the O
felbamate B-drug
dose O
to O
1800 O
mg/day O
in O
six O
of O
these O
subjects O
increased O
the O
steady-state O
phenytoin B-drug
Cmin O
to O
25 O
7 O
micrograms/mL O
. O

Literature O
reports O
suggest O
that O
oral O
calcium B-group
antagonists I-group
may O
be O
used O
in O
combination O
with O
beta-adrenergic B-group
blocking I-group
agents I-group
when O
heart O
function O
is O
normal O
, O
but O
should O
be O
avoided O
in O
patients O
with O
impaired O
cardiac O
function O
. O

The O
effect O
of O
temperature O
changes O
on O
the O
number O
of O
microtubules O
in O
non-myelinated O
axons O
has O
been O
studied O
in O
cat O
inferior O
mesenteric O
ganglion/hypogastric O
nerve O
preparations O
incubated O
at O
various O
temperatures O
in O
Eagles O
minimal O
essential O
tissue O
culture O
medium O
in O
vitro O
. O

Administration O
of O
thiazide B-group
diuretics I-group
to O
hypoparathyroid O
patients O
who O
are O
concurrently O
being O
treated O
with O
ergocalciferol B-drug
may O
cause O
hypercalcemia O
. O

Until O
further O
data O
are O
available O
regarding O
the O
potential O
interaction O
of O
dirithromycin B-drug
with O
these O
compounds O
, O
caution O
should O
be O
used O
during O
coadministration O
. O

Restoration O
of O
vancomycin B-drug
susceptibility O
in O
Enterococcus O
faecalis O
by O
antiresistance O
determinant O
gene O
transfer O
. O

Other O
common O
adverse O
reactions O
are O
dizziness O
( O
5-15 O
% O
) O
, O
weakness O
( O
5-15 O
% O
) O
and O
fatigue O
( O
2-4 O
% O
) O
. O

Interactions O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
could O
potentially O
occur O
. O

Further O
, O
designs O
can O
be O
expressed O
in O
terms O
of O
proportionate O
responses O
associated O
with O
the O
individual O
compounds O
rather O
than O
dose O
levels O
, O
thereby O
providing O
for O
results O
that O
are O
applicable O
across O
compounds O
. O

therefore O
, O
the O
disposition O
of O
zaleplon B-drug
is O
not O
expected O
to O
be O
sensitive O
to O
alterations O
in O
protein O
binding O
. O

The O
potential O
for O
drug-drug O
interaction O
with O
drugs O
affected O
by O
cytochrome O
P450 O
enzymes O
may O
not O
be O
ruled O
out O
. O

dermatitis O

Lithium B-drug
: O
In O
a O
study O
conducted O
in O
healthy O
subjects O
, O
mean O
steady-state O
lithium B-drug
plasma O
levels O
increased O
approximately O
17 O
% O
in O
subjects O
receiving O
lithium B-drug
450 O
mg O
BID O
with O
CELEBREX B-brand
200 O
mg O
BID O
as O
compared O
to O
subjects O
receiving O
lithium B-drug
alone O
. O

In O
situations O
when O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O

Phosphate-Binding O
Agents O
: O
Since O
vitamin B-group
D I-group
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate-binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O

or O
with O
multivitamins B-group
containing O
zinc B-drug
may O
substantially O
interfere O
with O
drug O
absorption O
and O
result O
in O
insufficient O
plasma O
and O
tissue O
quinolone B-group
concentrations O
. O

Similarly O
, O
patients O
receiving O
the O
drug O
and O
a O
hydantoin B-group
, O
sulfonamide B-group
or O
sulfonylurea B-group
should O
be O
observed O
for O
signs O
of O
toxicity O
to O
these O
drugs O
. O

Antipyrine B-drug
: O
Antipyrine B-drug
pharmacokinetics O
were O
not O
significantly O
different O
before O
and O
after O
tiagabine B-drug
multiple-dose O
regimens O
. O

Phenytoin B-drug
: O
In O
a O
single O
( O
400 O
mg O
) O
and O
multiple O
dose O
( O
400 O
mg O
TID O
) O
study O
of O
Neurontin B-brand
in O
epileptic O
patients O
( O
N=8 O
) O
maintained O
on O
phenytoin B-drug
monotherapy O
for O
at O
least O
2 O
months O
, O
gabapentin B-drug
had O
no O
effect O
on O
the O
steady-state O
trough O
plasma O
concentrations O
of O
phenytoin B-drug
and O
phenytoin B-drug
had O
no O
effect O
on O
gabapentin B-drug
pharmacokinetics O
. O

Zidovudine B-drug
should O
either O
be O
temporarily O
discontinued O
or O
decreased O
by O
50 O
% O
when O
coadministered O
with O
probenecid B-drug
on O
the O
day O
of O
VISTIDE B-brand
infusion O
. O

This O
interaction O
appears O
to O
be O
related O
both O
to O
pressor O
activity O
and O
to O
beta-adrenergic O
stimulating O
properties O
of O
these O
catecholamines B-group
and O
may O
produce O
ventricular O
arrhythmias O
and O
hypertension O
. O

Jacalin B-drug_n
: O
an O
IgA-binding O
lectin O
. O

It O
is O
desirable O
to O
monitor O
TCAplasma B-group
levels O
whenever O
an O
agent O
of O
the O
tricyclic B-group
antidepressant I-group
class I-group
including O
Anafranil B-brand
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
( O
and/or O
P450 O
1A2 O
) O
. O

The O
effect O
of O
cyclosporine B-drug
on O
diltiazem B-drug
plasma O
concentrations O
has O
not O
been O
evaluated O
. O

ERGAMISOL B-brand
( O
levamisole B-drug
hydrochloride I-drug
) O
has O
been O
reported O
to O
produce O
ANTABUSE-like O
side O
effects O
when O
given O
concomitantly O
with O
alcohol B-drug
. O

During O
the O
above O
experiments O
we O
noted O
a O
massive O
precipitation O
in O
cell O
cultures O
stimulated O
with O
greater O
than O
or O
equal O
to O
100 O
micrograms O
of O
lectin O
. O

Other O
drugs O
metabolized O
by O
C.P.A O
. O

Cytochalasin B-drug_n
D I-drug_n
inhibited O
the O
carbachol-stimulated B-drug
intracellular O
Ca O
( O
2+ O
) O
concentration O
( O
[ O
Ca O
( O
2+ O
) O
] O
( O
i O
) O
) O
increase O
due O
to O
release O
from O
the O
Ca O
( O
2+ O
) O
store O
. O

There O
was O
a O
reduction O
that O
reached O
borderline O
statistical O
significance O
in O
the O
group O
that O
received O
150 O
mg/d O
of O
tolbutamide B-drug
. O

Currently O
, O
there O
are O
no O
safety O
and O
efficacy O
data O
available O
from O
the O
use O
of O
this O
combination O
. O

glutethimide B-drug
; O

For O
patients O
receiving O
both O
therapies O
, O
standard O
monitoring O
of O
tacrolimus B-drug
blood O
concentrations O
and O
appropriate O
tacrolimus B-drug
dosage O
adjustments O
are O
recommended O
. O

Patients O
on O
rifampin B-drug
should O
receive O
70 O
mg O
of O
CANCIDAS B-brand
daily O
. O

Sodium B-drug
Iodide I-drug
( O
123I O
and O
131I O
) O
, O
Sodium B-drug
Pertechnetate I-drug
Tc99m I-drug
: O
Uptake O
of O
radiolabeled O
ions O
may O
be O
decreased O
. O

Nevirapine B-drug
is O
principally O
metabolized O
by O
the O
liver O
via O
the O
cytochrome O
P450 O
isoenzymes O
, O
3A4 O
and O
2B6 O
. O

CNS O
Toxicity O
Brain O
hemorrhage O
was O
seen O
in O
a O
female O
dog O
treated O
for O
3 O
months O
at O
120 O
mg/kg/day O
. O

This O
allows O
bitolterol B-drug
to O
open O
air O
passages O
, O
increasing O
the O
effectiveness O
of O
the O
steroid B-group
. O

It O
is O
known O
that O
CYP1A2 O
is O
inhibited O
by O
several O
medicinal O
products O
, O
including O
fluvoxamine B-drug
, O
and O
such O
medicinal O
products O
could O
theoretically O
adversely O
influence O
the O
clearance O
of O
anagrelide B-drug
. O

The O
present O
work O
involved O
the O
administration O
of O
both O
ethynyl B-drug
estradiol I-drug
and O
levonorgestrel B-drug
to O
groups O
of O
rats O
, O
followed O
by O
determination O
of O
the O
homocysteine O
excretion O
rate O
in O
urine O
. O

Theoretically O
, O
the O
naproxen B-drug
anion O
itself O
could O
likewise O
be O
displaced O
. O

Indinavir B-drug
: O
Coadministration O
of O
indinavir B-drug
with O
VIRACEPT B-brand
resulted O
in O
an O
83 O
% O
increase O
in O
nelfinavir B-drug
plasma O
AUC O
and O
a O
51 O
% O
increase O
in O
indinavir B-drug
plasma O
A.C O
. O

Pharmacokinetics O
of O
calcium-entry B-group
blockers I-group
. O

Coumarin-Type B-group
Anticoagulants I-group
: O
Several O
short-term O
controlled O
studies O
failed O
to O
wshow O
that O
ibuprofen B-drug
significantly O
affected O
prothrombin O
times O
or O
a O
variety O
of O
other O
clotting O
factors O
when O
administered O
to O
individuals O
on O
coumarin-type B-group
anticoagulants I-group
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
glipizide B-drug
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O

Flavoridin B-drug_n
alone O
was O
found O
to O
have O
no O
effect O
on O
CAS O
, O
but O
can O
completely O
block O
contortrostatin-induced B-drug_n
phosphorylation O
of O
this O
protein O
in O
MDA-MB-435 O
cells O
. O

If O
a O
patient O
is O
truly O
hypothyroid O
, O
it O
is O
likely O
that O
a O
reduction O
in O
anticoagulant B-group
dosage O
will O
be O
required O
. O

Methenamine B-drug

Therefore O
, O
OMNICEF B-brand
for O
Oral O
Suspension O
can O
be O
administered O
with O
iron-fortified B-drug_n
infant O
formula O
. O

Both O
CRIXIVAN B-brand
and O
atazanavir B-drug
are O
associated O
with O
indirect O
( O
unconjugated O
) O
hyperbilirubinemia O
. O

Alkalinizing O
agents O
: O
Gastrointestinal O
alkalinizing O
agents O
( O
sodium B-drug
bicarbonate I-drug
, O
etc O
. O
) O
increase O
absorption O
of O
amphetamines B-drug
. O

Patients O
taking O
REVIA B-brand
may O
not O
benefit O
from O
opioid B-group
containing O
medicines O
, O
such O
as O
cough O
and O
cold O
preparations O
, O
antidiarrheal O
preparations O
, O
and O
opioid B-group
analgesics I-group
. O

Hormonal B-group
Contraceptives I-group
, O
Including O
Oral O
, O
Injectable O
, O
Transdermal O
, O
and O
Implantable O
Contraceptives B-group
: O
An O
interaction O
study O
demonstrated O
that O
co-administration O
of O
bosentan B-drug
and O
the O
oral O
hormonal B-group
contraceptive I-group
Ortho-Novum B-brand
produced O
average O
decreases O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
levels O
of O
14 O
% O
and O
31 O
% O
, O
respectively O
. O

macrolide B-group
antibiotics I-group
e.g. O
, O
erythromycin B-drug
; O

Radioligand O
binding O
experiments O
using O
the O
uptake O
inhibitor O
hydrogen-3 O
mazindol B-drug
revealed O
a O
significant O
decrease O
by O
approximately O
30 O
% O
in O
norepinephrine B-drug
uptake-1 O
carrier O
density O
in O
functional O
classes O
II O
to O
III O
and O
IV O
myocardium O
versus O
nonfailing O
myocardium O
( O
p O
< O
0.05 O
) O
. O

However O
, O
the O
pharmacodynamics O
of O
coadministration O
of O
zaleplon B-drug
and O
promethazine B-drug
have O
not O
been O
evaluated O
. O

AIM O
AND O
BACKGROUND O
: O
The O
pharmacokinetic O
interaction O
between O
sirolimus B-drug
, O
a O
macrolide B-group
immunosuppressant I-group
metabolized O
by O
CYP3A4 O
, O
and O
the O
calcium B-group
channel I-group
blocker I-group
diltiazem B-drug
was O
studied O
in O
18 O
healthy O
subjects O
. O

only O
ibogaine B-drug_n
enhances O
cocaine-induced B-drug
increases O
in O
accumbal O
dopamine O
. O

Behavioral O
mechanisms O
underlying O
the O
link O
between O
smoking O
and O
drinking O
. O

John O
s O
wort O
) O
may O
increase O
the O
formation O
of O
dapsone B-drug_n
hydroxylamine I-drug_n
, O
a O
metabolite O
of O
dapsone B-drug
associated O
with O
hemolysis O
. O

Like O
ibogaine B-drug_n
( O
40 O
mg/kg O
) O
, O
18-MC B-drug_n
( O
40 O
mg/kg O
) O
decreases O
the O
intravenous O
self-administration O
of O
morphine B-drug
and O
cocaine B-drug
and O
the O
oral O
self-administration O
of O
ethanol B-drug
and O
nicotine B-drug
in O
rats O
; O

increased O
plasminogen O
antigen O
and O
activity O
. O

Permeation O
studies O
were O
performed O
on O
guinea O
pig O
small O
intestinal O
mucosa O
mounted O
in O
Ussing-type O
chamber O
. O

Other O
macrolide B-group
antibiotics I-group
, O
such O
as O
erythromycin B-drug
, O
have O
not O
been O
studied O
in O
combination O
with O
SUSTIVA B-brand
. O

Compounds O
tested O
in O
man O
include O
warfarin B-drug
, O
theophylline B-drug
, O
phenytoin B-drug
, O
diazepam B-drug
, O
aminopyrine B-drug
and O
antipyrine B-drug
. O

Reported O
examples O
include O
the O
following O
: O
Protease B-group
Inhibitors I-group
: O
Protease B-group
inhibitors I-group
are O
known O
to O
inhibit O
CYP3A4 O
to O
varying O
degrees O
. O

therefore O
, O
patients O
who O
may O
be O
adversely O
affected O
by O
such O
an O
action O
should O
be O
carefully O
observed O
. O

In O
patients O
given O
very O
high O
doses O
( O
3900 O
mg O
) O
of O
aspirin B-brand
daily O
, O
increases O
in O
serum O
salicylate B-group
levels O
were O
seen O
when O
nizatidine B-drug
, O
150 O
mg O
b.i.d. O
, O
was O
administered O
concurrently O
. O

Nicotine B-drug
Transdermal O
System O
: O
. O

Rabbits O
failed O
to O
maintain O
pregnancy O
when O
dosed O
with O
1 O
mg/kg/day O
fulvestrant B-drug
IM O
( O
twice O
the O
human O
dose O
on O
BSA O
) O
during O
the O
period O
of O
organogenesis O
. O

- O
Other O
antihypertensive B-group
drugs I-group
: O
Additive O
effect O
or O
potentiation O

The O
physician O
is O
advised O
to O
monitor O
the O
plasma O
concentrations O
of O
itraconazole B-drug
when O
any O
of O
these O
drugs O
is O
taken O
concurrently O
, O
and O
to O
increase O
the O
dose O
of O
Itraconazole B-drug
if O
necessary O
. O

The O
concurrent O
administration O
of O
CAMPTOSAR B-brand
with O
irradiation O
has O
not O
been O
adequately O
studied O
and O
is O
not O
recommended O
. O

Indomethacin B-drug
- O
Concomitant O
use O
of O
L-glutamine B-drug
and O
indomethacin B-drug
may O
ameliorate O
increased O
intestinal O
permeability O
caused O
by O
indomethacin B-drug
. O

Prospective O
studies O
on O
the O
potential O
for O
hydroxyurea B-drug
to O
interact O
with O
other O
drugs O
have O
not O
been O
performed O
. O

There O
is O
, O
however O
, O
currently O
no O
data O
on O
the O
effect O
of O
combined O
hyperglycaemia O
and O
hyperinsulinaemia O
on O
the O
renal O
and O
ocular O
blood O
flow O
seen O
in O
diabetic O
patients O
on O
insulin O
therapy O
. O

Animals O
dosed O
with O
1,3-difluoroacetone B-drug_n
did O
not O
display O
the O
2-3 O
hour O
lag O
phase O
in O
either O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
synthesis O
or O
in O
citrate O
and O
fluoride O
accumulation O
characteristic O
of O
animals O
dosed O
with O
1,3-difluoro-2-propanol B-drug_n
. O

In O
clinical O
trials O
, O
antacids B-group
were O
administered O
concomitantly O
with O
lansoprazole B-drug
delayed-release O
capsules O
; O

DISCUSSION O
: O
Clarithromycin B-drug
is O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
the O
major O
enzyme O
responsible O
for O
simvastatin B-drug
metabolism O
. O

Sodium B-drug
thiosulfate I-drug
is O
a O
neutralizing O
agent O
for O
cisplatin B-drug
that O
protects O
against O
renal O
damage O
. O

Digitalis B-group
glycosides I-group
: O
Patients O
on O
digitalis B-group
glycosides I-group
may O
be O
at O
increased O
risk O
of O
arrhythmias O
due O
to O
hypokalemia O
. O

Phenytoin B-drug
: O
Accutane B-brand
has O
not O
been O
shown O
to O
alter O
the O
pharmacokinetics O
of O
phenytoin B-drug
in O
a O
study O
in O
seven O
healthy O
volunteers O
. O

The O
average O
increase O
was O
45 O
% O
. O

There O
was O
an O
increasing O
incidence O
of O
transient O
thrombocytopenia O
( O
or O
=100 O
x O
10 O
( O
9 O
) O
/L O
) O
with O
increasing O
everolimus B-drug
AUC O
( O
P O
= O
.03 O
) O
. O

MAO B-group
Inhibitors I-group
: O
Serious O
side O
effects O
and O
even O
death O
have O
been O
reported O
following O
the O
concomitant O
use O
of O
certain O
drugs O
with O
MAO B-group
inhibitors I-group
. O

This O
should O
be O
taken O
into O
account O
when O
evaluating O
serum O
amylase O
levels O
for O
diagnosis O
or O
monitoring O
of O
pancreatitis O
in O
patients O
using O
EXTRANEAL B-brand
. O

No O
change O
in O
phase O
was O
detected O
, O
although O
the O
aerosol O
particles O
appeared O
to O
contain O
residual O
solvent B-group
. O

Sympathomimetic B-group
amines I-group
may O
reduce O
the O
antihypertensive O
effects O
of O
reserpine B-drug
, O
veratrum B-group
alkaloids I-group
, O
methyldopa B-drug
and O
mecamylamine B-drug
. O

CYP3A4 O
and O
-2C19 O
Inhibitors O
- O
In O
vitro O
studies O
indicated O
that O
CYP3A4 O
and O
-2C19 O
are O
the O
primary O
enzymes O
involved O
in O
the O
metabolism O
of O
escitalopram B-drug
. O

this O
can O
cause O
headaches O
and O
other O
signs O
of O
hypertensive O
crisis O
. O

Celecoxib B-drug
metabolism O
is O
predominantly O
mediated O
via O
cytochrome O
P450 O
2C9 O
in O
the O
liver O
. O

Digitalis B-group
glycosides I-group
: O
amphotericin B-drug
B-induced O
hypokalemia O
may O
potentiate O
digitalis B-group
toxicity O
. O

Potential O
effect O
on O
anticoagulation O
. O

Androgens B-group
may O
increase O
sensitivity O
to O
oral O
anticoagulahts O
. O

SERUM O
LEVELS O
OF O
PHENYTOIN B-drug
SHOULD O
BE O
DETERMINED O
ON O
DIFFERENT O
DAYS O
FOR O
EVIDENCE O
OF O
AN O
INCREASE O
OR O
FOR O
A O
CONTINUING O
RISE O
IN O
LEVELS O
. O

Absorption O
of O
tetracyclines B-group
is O
impaired O
by O
antacids B-group
containing O
aluminum B-drug
, O
calcium B-drug
, O
or O
magnesium B-drug
, O
and O
iron-containing B-drug
preparations O
. O

The O
effects O
of O
adenosine B-drug
are O
antagonized O
by O
methylxanthines B-group
such O
as O
caffeine B-drug
and O
theophylline B-drug
. O

Oral O
contraceptives B-group
: O
Aprepitant B-drug
, O
when O
given O
once O
daily O
for O
14 O
days O
as O
a O
100-mg O
capsule O
with O
an O
oral O
contraceptive B-group
containing O
35 O
mcg O
of O
ethinyl B-drug
estradiol I-drug
and O
1 O
mg O
of O
norethindrone B-drug
, O
decreased O
the O
AUC O
of O
ethinyl B-drug
estradiol I-drug
by O
43 O
% O
, O
and O
decreased O
the O
AUC O
of O
norethindrone B-drug
by O
8 O
% O
; O

Particular O
caution O
should O
be O
exercised O
in O
using O
preparations O
containing O
sulfur B-drug
, O
resorcinol B-drug
, O
or O
salicylic B-drug
acid I-drug
in O
combination O
with O
DIFFERIN B-brand
Gel O
. O

Ketoconazole B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
40 O
mg O
) O
and O
ketoconazole B-drug
( O
200 O
mg O
) O
decreased O
the O
Cmax O
and O
AUC O
of O
ketoconazole B-drug
by O
21 O
% O
and O
10 O
% O
, O
respectively O
, O
and O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
citalopram B-drug
. O

Terfenadine B-drug
: O
In O
a O
prospective O
study O
involving O
six-healthy-male O
volunteers O
, O
dirithromycin B-drug
did O
not O
affect O
the O
metabolism O
of O
terfenadine B-drug
. O

The O
existence O
of O
PI O
was O
related O
to O
the O
number O
of O
drugs O
prescribed O
to O
each O
patient O
( O
p O
< O
0.01 O
) O
. O

No O
Information O
Provided O

. O

Certain O
other O
antibiotics B-group
( O
aminoglycosides B-group
and O
polymyxin B-group
) O
have O
also O
been O
reported O
to O
interfere O
with O
the O
nerve O
transmission O
at O
the O
neuromuscular O
junction O
. O

Likewise O
, O
gabapentin B-drug
pharmacokinetics O
were O
unaltered O
by O
carbamazepine B-drug
administration O
. O

atorvastatin I-drug
concentration O

Controlled O
and O
uncontrolled O
domestic O
studies O
suggest O
that O
concomitant O
use O
of O
diltiazem B-drug
hydrochloride I-drug
and O
beta-blockers B-group
is O
usually O
well O
tolerated O
, O
but O
available O
data O
are O
not O
sufficient O
to O
predict O
the O
effects O
of O
concomitant O
treatment O
in O
patients O
with O
left O
ventricular O
dysfunction O
or O
cardiac O
conduction O
abnormalities O
. O

It O
is O
recommended O
that O
buspirone B-drug
hydrochloride I-drug
not O
be O
used O
concomitantly O
with O
MAO B-group
inhibitors I-group
Because O
the O
effects O
of O
concomitant O
administration O
of O
buspirone B-drug
HCl I-drug
with O
most O
other O
psychotropic B-group
drugs I-group
have O
not O
been O
studied O
, O
the O
concomitant O
use O
of O
buspirone B-drug
HCl I-drug
with O
other O
CNS-active O
drugs O
should O
be O
approached O
with O
caution O
. O

No O
interaction O
trials O
have O
been O
conducted O
with O
MEPRON B-brand
and O
rifabutin B-drug
. O

Fluconazole B-drug
and O
Ketoconazole B-drug
: O
Ketoconazole B-drug
and O
fluconazole B-drug
are O
predominantly O
CYP O
3A4 O
and O
2C9 O
inhibitors O
, O
respectively O
. O

These O
observations O
strongly O
suggest O
that O
the O
homodimeric O
structure O
of O
contortrostatin B-drug_n
functionally O
distinguishes O
it O
from O
other O
monomeric O
members O
of O
the O
disintegrin O
family O
. O

- O
Impaired O
glucose O
tolerance O

If O
a O
diuretic B-group
is O
also O
used O
, O
it O
may O
increase O
the O
risk O
of O
lithium B-drug
toxicity O
. O

The O
most O
significant O
drug O
interactions O
following O
administration O
of O
Cerebyx B-brand
are O
expected O
to O
occur O
with O
drugs O
that O
interact O
with O
phenytoin B-drug
. O

Corticosteroids B-group
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-group
D I-group
analogues I-group
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-group
, O
which O
inhibit O
calcium O
absorption O
. O

Keys O
to O
maximizing O
benefit O
while O
avoiding O
adverse O
drug O
effects O
. O

When O
given O
concurrently O
the O
following O
drugs O
may O
interact O
with O
thiazide B-group
diuretics I-group
. O

Other O
Drug O
Interactions O
: O
No O
pharmacokinetic O
interactions O
were O
observed O
between O
vardenafil B-drug
and O
the O
following O
drugs O
: O
glyburide B-drug
, O
warfarin B-drug
, O
digoxin B-drug
, O
Maalox B-brand
, O
and O
ranitidine B-drug
. O

Drug/Laboratory O
Test O
Interactions O
: O
Amphetamines B-group
can O
cause O
a O
significant O
elevation O
in O
plasma O
corticosteroid B-group
levels O
. O

When O
cocaine B-drug
is O
the O
primary O
addiction O
, O
after O
withdrawal O
the O
most O
effective O
treatment O
is O
group O
therapy O
with O
other O
recovering O
cocaine O
abusers O
. O

Today O
pharmacological O
magnesium B-drug
therapy O
mainly O
concerns O
the O
obstetrical O
, O
cardiological O
and O
anaesthesiological O
fields O
. O

Compared O
with O
conventional B-group
antipsychotics I-group
, O
it O
has O
greater O
affinity O
for O
serotonin O
5-HT2A O
than O
for O
dopamine O
D2 O
receptors O
. O

Due O
to O
a O
theoretical O
risk O
of O
a O
pharmacodynamic O
interaction O
, O
use O
of O
ergotamine-containing B-drug
or O
ergot-type B-group
medications I-group
( O
like O
dihydroergotamine B-drug
or O
methysergide B-drug
) O
and O
FROVA B-brand
within O
24 O
hours O
of O
each O
other O
should O
be O
avoided O
( O
see O
a O
href= O
frova_od.htm O
# O
CI O
CONTRAINDICATIONS O
) O
. O

Drug O
Name O

The O
following O
similar O
changes O
may O
be O
expected O
with O
larger O
doses O
of O
estrogen B-group
: O
Increased O
sulfobromophthalein O
retention O
; O

Due O
to O
high O
inter-patient O
variability O
and O
limited O
sampling O
, O
the O
extent O
of O
the O
increase O
in O
SN38 B-drug_n
levels O
in O
patients O
receiving O
concurrent O
irinotecan B-drug
and O
AVASTIN B-brand
is O
uncertain O
. O

Hypoglycemics B-group

http O
: O
//www.rxlist.com/cgi/generic3/guanethidine_od.htm O

The O
authors O
examined O
the O
effect O
of O
the O
cyclooxygenase-2 O
( O
COX-2 O
) O
inhibitor O
, O
rofecoxib B-drug
, O
at O
steady O
state O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
following O
a O
single O
dose O
in O
healthy O
subjects O
. O

WelChol B-brand
was O
found O
to O
have O
no O
significant O
effect O
on O
the O
bioavailability O
of O
digoxin B-drug
, O
lovastatin B-drug
, O
metoprolol B-drug
, O
quinidine B-drug
, O
valproic B-drug
acid I-drug
, O
and O
warfarin B-drug
. O

Such O
interactions O
might O
be O
manifested O
by O
increased O
susceptibility O
to O
bruising O
, O
nosebleeds O
, O
hemoptysis O
, O
hematemesis O
, O
hematuria O
and O
blood O
in O
the O
stool O
. O

There O
is O
a O
single O
case O
report O
, O
which O
suggests O
that O
sucralfate B-drug
may O
interfere O
with O
anagrelide B-drug
absorption O
. O

Spontaneous O
reports O
of O
serotonin O
syndrome O
associated O
with O
co-administration O
of O
ZYVOX B-brand
and O
serotonergic B-group
agents I-group
, O
including O
antidepressants B-group
such O
as O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
have O
been O
reported O
. O

Therefore O
, O
4 O
to O
5 O
hours O
should O
elapse O
between O
administration O
of O
cholestyramine B-drug
and O
thyroid B-group
hormones I-group
. O

It O
is O
not O
known O
whether O
alosetron B-drug
might O
induce O
other O
enzymes O
. O

The O
use O
of O
ROMAZICON B-brand
is O
not O
recommended O
in O
epileptic O
patients O
who O
have O
been O
receiving O
benzodiazepine O
treatment O
for O
a O
prolonged O
period O
. O

Caution O
should O
be O
used O
when O
administering O
or O
taking O
TARCEVA B-brand
with O
ketoconazole B-drug
and O
other O
strong O
CYP3A4 O
inhibitors O
such O
as O
, O
but O
not O
limited O
to O
, O
atazanavir B-drug
, O
clarithromycin B-drug
, O
indinavir B-drug
, O
itraconazole B-drug
, O
nefazodone B-drug
, O
nelfinavir B-drug
, O
ritonavir B-drug
, O
saquinavir B-drug
, O
telithromycin B-drug
, O
troleandomycin B-drug
( O
TAO B-drug
) O
, O
and O
voriconazole B-drug
. O

The O
clinical O
significance O
, O
if O
any O
, O
of O
these O
observations O
is O
unknown O
. O

Oral O
Anticoagulants B-group
: O
Thyroid B-group
hormones I-group
appear O
to O
increase O
catabolism O
of O
vitamin O
K-dependent O
clotting O
factors O
. O

Medroxyprogesterone B-drug
Acetate I-drug
- O
L-histidine B-drug
was O
observed O
to O
enhance O
( O
in O
tissue O
culture O
) O
the O
effect O
of O
medroxyprogesterone B-drug
acetate I-drug
in O
reducing O
the O
number O
of O
human O
breast O
cancer O
cells O
that O
were O
in O
the O
S O
phase O
. O

Other O
Drugs O
: O
Based O
on O
the O
results O
of O
drug O
interaction O
studies O
, O
no O
dosage O
adjustment O
is O
recommended O
when O
SUSTIVA B-brand
( O
efavirenz B-drug
) O
is O
given O
with O
the O
following O
: O
aluminum/magnesium B-group
hydroxide I-group
antacids I-group
, O
azithromycin B-drug
, O
cetirizine B-drug
, O
famotidine B-drug
, O
fluconazole B-drug
, O
lamivudine B-drug
, O
lorazepam B-drug
, O
nelfinavir B-drug
, O
paroxetine B-drug
, O
and O
zidovudine B-drug
. O

The O
concurrent O
use O
of O
intravenously O
or O
orally O
administered O
methylxanthines B-group
( O
e.g. O
, O
aminophylline B-drug
, O
theophylline B-drug
) O
by O
patients O
receiving O
BROVANA B-brand
has O
not O
been O
completely O
evaluated O
. O

74.1 O
% O
( O
95 O
% O
CI O
, O
+/- O
9.3 O
) O
of O
the O
total O
PICR O
could O
be O
avoided O
by O
simple O
recommendations O
; O

The O
data O
do O
not O
suggest O
the O
need O
for O
dose O
adjustment O
of O
either O
HUMIRA B-brand
or O
MTX B-drug
. O

Diphenhydramine B-drug
hydrochloride I-drug
has O
additive O
effects O
with O
alcohol B-drug
and O
other O
CNS B-group
depressants I-group
( O
hypnotics B-group
, O
sedatives B-group
, O
tranquilizers B-group
, O
etc O
) O
. O

g/mL O
; O

If O
the O
treatment O
is O
continued O
, O
these O
patients O
should O
be O
particularly O
carefully O
monitored O
for O
adverse O
effects O
, O
especially O
conduction O
disturbances O
and O
exacerbation O
of O
tachyarrhythmias O
, O
as O
amiodarone B-drug
is O
continued O
. O

Probenecid B-drug
Prolonged O
action O
of O
etomidate B-drug

The O
first O
phase O
of O
this O
sequence O
, O
initiation O
, O
is O
considered O
to O
result O
from O
at O
least O
one O
event O
in O
the O
genetic O
apparatus O
. O

Concomitant O
use O
of O
prophylactic O
low O
dose O
heparin B-drug
did O
not O
appear O
to O
affect O
safety O
, O
however O
, O
its O
effects O
on O
the O
efficacy O
of O
Xigris B-brand
have O
not O
been O
evaluated O
in O
an O
adequate O
and O
well-controlled O
clinical O
trial O
. O

Amphotericin B-drug
B I-drug
or O
potassium-depleting B-group
diuretics I-group
( O
benzothiadiazines B-group
and O
related O
drugs O
, O
ethacrynic B-drug
acid I-drug
and O
furosemide B-drug
) O
enhanced O
hypokalemia O
. O

Aspirin B-brand
: O
As O
with O
other O
NSAIDs B-group
, O
concomitant O
administration O
of O
Ponstel B-brand
and O
aspirin B-brand
is O
not O
generally O
recommended O
because O
of O
the O
potential O
of O
increased O
adverse O
effects O
. O

Calcium B-group
Antagonists O
: O
After O
repeated O
co-administration O
of O
Trileptal B-brand
, O
the O
AUC O
of O
felodipine B-drug
was O
lowered O
by O
28 O
% O
[ O
90 O
% O
CI O
: O
20-33 O
] O
. O

Patients O
with O
Crohn O
s O
disease O
who O
received O
immunosuppressants B-group
tended O
to O
experience O
fewer O
infusion O
reactions O
compared O
to O
patients O
on O
no O
immunosuppressants B-group
. O

There O
have O
been O
a O
number O
of O
reports O
in O
the O
post-marketing O
experience O
of O
coma O
and O
death O
associated O
with O
the O
concomitant O
intravenous O
misuse O
of O
buprenorphine B-drug
and O
benzodiazepines B-drug
by O
addicts O
. O

The O
regulation O
of O
the O
level O
of O
the O
glucocorticoid-induced O
gene O
expression O
by O
the O
antioxidative O
gallates O
is O
of O
great O
interest O
from O
a O
therapeutic O
point O
of O
view O
. O

If O
concomitant O
treatment O
with O
frovatriptan B-drug
and O
an O
SSRI B-group
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

Quinolones B-group
form O
chelates O
with O
alkaline O
earth O
and O
transition O
metals O
. O

Beta-adrenergic B-group
Blocking I-group
Agents I-group
: O
Experience O
in O
over O
1400 O
patients O
in O
a O
non-comparative O
clinical O
trial O
has O
shown O
that O
concomitant O
administration O
of O
nifedipine B-drug
and O
beta-blocking B-group
agents I-group
is O
usually O
well O
tolerated O
, O
but O
there O
have O
been O
occasional O
literature O
reports O
suggesting O
that O
the O
combination O
may O
increase O
the O
likelihood O
of O
congestive O
heart O
failure O
, O
severe O
hypotension O
or O
exacerbation O
of O
angina O
. O

Moreover O
, O
as O
noted O
with O
alprazolam B-drug
, O
the O
effect O
of O
fluvoxamine B-drug
may O
even O
be O
more O
pronounced O
when O
it O
is O
administered O
at O
higher O
doses O
. O

In O
vitro O
studies O
indicate O
that O
ertapenem B-drug
does O
not O
inhibit O
P-glycoprotein-mediated O
transport O
of O
digoxin B-drug
or O
vinblastine B-drug
and O
that O
ertapenem B-drug
is O
not O
a O
substrate O
for O
P-glycoprotein-mediated O
transport O
. O

Concurrent O
administration O
of O
vasopressor B-group
drugs I-group
( O
for O
the O
treatment O
of O
hypotension O
related O
to O
obstetric O
blocks O
) O
and O
ergot-type B-group
oxytocic I-group
drugs I-group
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

Thus O
, O
when O
NSAIDs B-group
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

( O
Read O
circulars O
for O
lithium B-drug
preparation O
before O
use O
of O
such O
concurrent O
therapy O
) O
. O

When O
atropine B-drug
and O
pralidoxime B-drug
are O
used O
together O
, O
the O
signs O
of O
atropinization O
( O
flushing O
, O
mydriasis O
, O
tachycardia O
, O
dryness O
of O
the O
mouth O
and O
nose O
) O
may O
occur O
earlier O
than O
might O
be O
expected O
than O
when O
atropine B-drug
is O
used O
alone O
because O
pralidoxime B-drug
may O
potentiate O
the O
effect O
of O
atropine B-drug
. O

Diuretic B-group
agents I-group
may O
decrease O
vascular O
response O
to O
pressor O
drugs O
such O
as O
epinephrine B-drug
. O

- O
Nitrofurantoin B-drug
( O
e.g. O
, O
Furadantin B-brand
) O
or O

Effect O
of O
AEDs B-group
in O
Pediatric O
Patients O
There O
was O
about O
a O
22 O
% O
increase O
of O
apparent O
total O
body O
clearance O
of O
levetiracetam B-drug
when O
it O
was O
co-administered O
with O
enzyme-inducing O
AEDs B-group
. O

Disulfiram B-drug
appears O
to O
decrease O
the O
rate O
at O
which O
certain O
drugs O
are O
metabolized O
and O
therefore O
may O
increase O
the O
blood O
levels O
and O
the O
possibility O
of O
clinical O
toxicity O
of O
drugs O
given O
concomitantly O
. O

Coadministration O
of O
thioridazine B-drug
has O
been O
reported O
to O
worsen O
the O
tremor O
in O
elderly O
patients O
with O
Parkinsons O
disease O
; O

Antihistamines B-group
: O
Amphetamines B-group
may O
counteract O
the O
sedative O
effect O
of O
antihistamines B-group
. O

Changes O
in O
urinary O
homocysteine O
following O
synthetic B-group
steroidal I-group
estrogen I-group
and O
progestogen O
administration O
to O
rats O
. O

Plasma O
concentrations O
of O
azole B-group
antifungal I-group
agents I-group
are O
reduced O
when O
given O
concurrently O
with O
isoniazid B-drug
. O

Hitherto O
unrecognized O
interactions O
between O
homopolyribonucleotides O
and O
complexes O
thereof O
are O
suggested O
by O
interferon O
induction O
data O
obtained O
in O
a O
highly O
sensitive O
assay O
system O
of O
primary O
rabbit O
kidney O
cell O
cultures O
superinduced O
by O
metabolic O
inhibitors O
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

Isoflurane B-drug
potentiates O
the O
muscle O
relaxant O
effect O
of O
all O
muscle B-group
relaxants I-group
, O
most O
notably O
nondepolarizing B-group
muscle I-group
relaxants I-group
, O
and O
MAC O
( O
minimum O
alveolar O
concentration O
) O
is O
reduced O
by O
concomitant O
administration O
of O
N O
2O O
. O

Concurrent O
administration O
of O
etanercept B-drug
( O
another O
TNF O
-blocking O
agent O
) O
and O
anakinra B-drug
( O
an O
interleukin-1 B-group
antagonist I-group
) O
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
, O
and O
increased O
risk O
of O
neutropenia O
and O
no O
additional O
benefit O
compared O
to O
these O
medicinal O
products O
alone O
. O

The O
conversion O
of O
6-deoxy B-drug_n
penciclovir I-drug_n
to O
penciclovir B-drug
is O
catalyzed O
by O
aldehyde O
oxidase O
. O

In O
patients O
receiving O
coumarin-type B-group
anticoagulants I-group
, O
the O
addition O
of O
Nalfon B-brand
to O
therapy O
could O
prolong O
the O
prothrombin O
time O
. O

5 O
. O

. O

Caution O
is O
advised O
in O
patients O
receiving O
concomitant O
high-dose O
aspirin B-brand
and O
carbonic B-group
anhydrase I-group
inhibitors I-group
, O
as O
anorexia O
, O
tachypnea O
, O
lethargy O
and O
coma O
have O
been O
rarely O
reported O
due O
to O
a O
possible O
drug O
interaction O
. O

Tricyclic B-group
antidepressants I-group
may O
block O
the O
antihypertensive O
action O
of O
guanethidine B-drug
and O
similarly O
acting O
compounds O
. O

The O
rats O
treated O
with O
the O
highest O
dose O
of O
TML B-drug_n
manifested O
significantly O
longer O
latencies O
to O
lose O
the O
righting O
reflex O
and O
shorter O
durations O
of O
sleep O
than O
did O
controls O
. O

High-dose O
cyclosporin B-drug
A I-drug
resulting O
in O
concentrations O
above O
2000 O
ng/mL O
administered O
with O
oral O
etoposide B-drug
has O
led O
to O
an O
80 O
% O
increase O
in O
etoposide B-drug
exposure O
with O
a O
38 O
% O
decrease O
in O
total O
body O
clearance O
of O
etoposide B-drug
compared O
to O
etoposide B-drug
alone O
. O

Since O
a O
clinically O
significant O
interaction O
may O
be O
anticipated O
, O
alternative O
antihypertensive B-drug
therapy O
should O
be O
considered O
in O
these O
patients O
. O

The O
clinical O
significance O
of O
these O
changes O
has O
not O
been O
adequately O
studied O
. O

It O
is O
suggested O
that O
there O
is O
a O
minor O
contribution O
of O
adenosine O
receptors O
to O
these O
effects O
, O
although O
theophylline-induced B-drug
anxiogenic O
effects O
were O
antagonized O
by O
an O
A2 O
receptor O
agonist O
. O

Drug/ O
Laboratory O
Test O
Interactions O
: O
It O
is O
not O
known O
if O
MEPRON B-brand
interferes O
with O
clinical O
laboratory O
test O
or O
assay O
results O
. O

These O
levels O
then O
remained O
stable O
for O
up O
to O
1 O
year O
of O
therapy O
. O

Indomethacin B-drug
may O
also O
affect O
plasma O
renin O
levels O
, O
aldosterone O
excretion O
, O
and O
renin O
profile O
evaluation O
. O

The O
extent O
of O
interaction O
depends O
on O
the O
variability O
of O
effect O
on O
CYP2D6 O
. O

Drugs O
that O
Inhibit O
Drug O
Transport O
Systems O
Lapatinib B-drug
is O
a O
substrate O
of O
the O
efflux O
transporter O
P-glycoprotein O
( O
Pgp O
, O
ABCB1 O
) O
. O

Ultimately O
however O
, O
up O
to O
80 O
% O
of O
type O
2 O
diabetics O
die O
from O
macrovascular O
cardiovascular O
disease O
. O

Furthermore O
, O
caution O
should O
be O
exercised O
when O
combining O
digoxin B-drug
with O
any O
drug O
that O
may O
cause O
a O
significant O
deterioration O
in O
renal O
function O
, O
since O
a O
decline O
in O
glomerular O
filtration O
or O
tubular O
secretion O
may O
impair O
the O
excretion O
of O
digoxin B-drug
. O

Effect O

CONCLUSION O
: O
Cisapride B-drug
can O
be O
administered O
safely O
to O
patients O
receiving O
low O
therapeutic O
dosages O
of O
fluoxetine B-drug
. O

The O
optimal O
dose O
of O
indinavir B-drug
, O
when O
given O
in O
combination O
with O
SUSTIVA B-brand
, O
is O
not O
known O
. O

Drug/Laboratory O
Test O
Interactions O
Cephalosporins B-group
, O
including O
cefotaxime B-drug
sodium I-drug
, O
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

OBJECTIVES O
. O

Metoclopramide B-drug
: O
Bioavailability O
is O
mildly O
reduced O
( O
approximately O
10 O
% O
) O
when O
zalcitabine B-drug
and O
metoclopramide B-drug
are O
coadministered O
. O

In O
our O
laboratory O
, O
preliminary O
whole-cell O
, O
tight O
seal O
recordings O
of O
rat O
spinal O
substantia O
gelatinosa O
neurons O
including O
biocytin O
in O
the O
patch O
pipette O
yielded O
a O
significantly O
smaller O
proportion O
of O
neurons O
hyperpolarized O
by O
selective B-group
opioid I-group
agonists I-group
compared O
with O
recordings O
without O
biocytin O
. O

Nonetheless O
, O
the O
range O
of O
individual O
Simulect B-brand
clearance O
values O
in O
the O
presence O
of O
azathioprine B-drug
( O
12-57 O
mL/h O
) O
or O
mycophenolate B-drug
mofetil I-drug
( O
7-54 O
mL/h O
) O
did O
not O
extend O
outside O
the O
range O
observed O
with O
dual O
therapy O
( O
10-78 O
mL/h O
) O
. O

In O
vivo O
interaction O
studies O
in O
humans O
have O
demonstrated O
that O
digoxin B-drug
and O
warfarin B-drug
do O
not O
affect O
the O
PK O
properties O
of O
anagrelide B-drug
, O
nor O
does O
anagrelide B-drug
affect O
the O
PK O
properties O
of O
digoxin B-drug
or O
warfarin B-drug
. O

Diltiazem B-drug
plasma O
levels O
were O
not O
significantly O
affected O
by O
lovastatin B-drug
or O
pravastatin B-drug
. O

Metabolism O
of O
dasatinib B-drug
is O
mainly O
hepatic O
. O

Cimetidine B-drug
, O
Ranitidine B-drug
: O
In O
normal O
volunteers O
( O
n=9 O
) O
, O
pretreatment O
with O
cimetidine B-drug
or O
ranitidine B-drug
did O
not O
affect O
flurbiprofen B-drug
pharmacokinetics O
except O
that O
a O
small O
( O
13 O
% O
) O
but O
statistically O
significant O
increase O
in O
the O
area O
under O
the O
serum O
concentration O
curve O
of O
flurbiprofen B-drug
resulted O
with O
cimetidine B-drug
. O

Using O
in O
situ O
hybridization O
, O
we O
observed O
that O
METH B-drug
caused O
a O
rapid O
and O
transient O
dose-dependent O
increase O
in O
arc O
mRNA O
level O
in O
the O
striatum O
and O
cortex O
that O
was O
abolished O
by O
pretreatment O
with O
the O
specific O
dopamine O
D1 O
receptor O
antagonist O
SCH-23390 B-drug_n
but O
not O
by O
an O
atypical B-group
neuroleptic I-group
clozapine B-drug
. O

Consider O
additive O
sedative O
effects O
and O
confusional O
states O
to O
emerge O
, O
if O
chlorprothixene B-drug
is O
given O
with O
benzodiazepines B-group
or O
barbituates B-group
. O

Aminophylline B-drug
Etomidate I-drug
antagonism O

Coumarin B-group
Anticoagulants O
: O
In O
a O
small O
clinical O
trial O
in O
which O
lovastatin B-drug
was O
administered O
to O
warfarin B-drug
treated O
patients O
, O
no O
effect O
on O
prothrombin O
time O
was O
detected O
. O

Coadministration O
of O
single O
, O
oral O
doses O
of O
zaleplon B-drug
with O
erythromycin B-drug
( O
10 O
mg O
and O
800 O
mg O
, O
respectively O
) O
, O
a O
strong O
, O
selective O
CYP3A4 O
inhibitor O
produced O
a O
34 O
% O
increase O
in O
zaleplons B-drug
maximal O
plasma O
concentrations O
and O
a O
20 O
% O
increase O
in O
the O
area O
under O
the O
plasma O
concentration-time O
curve O
. O

Other O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
( O
e.g. O
, O
aspirin B-brand
) O
may O
also O
have O
this O
effect O
. O

iii O
. O

The O
clinical O
relevance O
is O
unclear O
. O

alcohol* B-drug
; O

In O
vitro O
studies O
have O
shown O
that O
fenoprofen B-drug
, O
because O
of O
its O
affinity O
for O
albumin O
, O
may O
displace O
from O
their O
binding O
sites O
other O
drugs O
that O
are O
also O
albumin O
bound O
, O
and O
this O
may O
lead O
to O
drug O
interaction O
. O

[ O
A O
pharmacological O
analysis O
of O
the O
effect O
of O
angiotensin B-drug_n
on O
stimulated O
gastric O
secretion O
] O
Chronic O
experiments O
on O
dogs O
with O
gastric O
fistulas O
were O
carried O
out O
to O
study O
the O
influence O
of O
angiotensin B-drug_n
1 I-drug_n
and O
angiotensin B-drug_n
2 I-drug_n
on O
pentagastrin- B-drug
and O
histamine-induced B-drug
gastric O
acid O
secretion O
. O

changes O
in O
cervical O
mucus O
, O
the O
endometrium O
, O
and O
the O
fallopian O
tubes O
; O

Anticoagulants B-group
including O
coumarin O
derivatives O
, O
indandione O
derivatives O
, O
and O
platelet B-group
aggregation I-group
inhibitors I-group
such O
as O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
( O
NSAIDs B-group
) O
, O
and O
aspirin B-brand
may O
increase O
the O
risk O
of O
bleeding O
when O
administered O
concomitantly O
with O
ardeparin B-drug
. O

Coadministration O
of O
valdecoxib B-drug
( O
10 O
mg O
BID O
for O
7 O
days O
) O
with O
glyburide B-drug
( O
5 O
mg O
QD O
or O
10 O
mg O
BID O
) O
did O
not O
affect O
the O
pharmacokinetics O
( O
exposure O
) O
of O
glyburide B-drug
. O

Protein O
Binding O
In O
vitro O
, O
diclofenac B-drug
interferes O
minimally O
or O
not O
at O
all O
with O
the O
protein O
binding O
of O
salicylic B-drug
acid I-drug
( O
20 O
% O
decrease O
in O
binding O
) O
, O
tolbutamide B-drug
, O
prednisolone B-drug
( O
10 O
% O
decrease O
in O
binding O
) O
, O
or O
warfarin B-drug
. O

injection O
of O
phencyclidine B-drug_n
( O
PCP B-drug_n
) O
were O
observed O
by O
measuring O
locomotor O
activity O
and O
stereotyped O
behavior O
. O

Thus O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
EQUETROTM B-brand
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
adjustment O
may O
be O
necessary O
. O

Repeated O
injection O
of O
PCP B-drug_n
for O
20 O
days O
into O
mice O
induced O
lower O
locomotor O
activity O
than O
that O
in O
acutely O
injected O
mice O
. O

Ibogaine B-drug_n
, O
but O
not O
18-MC B-drug_n
, O
decreases O
heart O
rate O
at O
high O
doses O
. O

Similar O
effects O
would O
be O
expected O
with O
other O
potent O
CYP2D6 O
inhibitors O
( O
e.g. O
, O
fluoxetine B-drug
, O
quinidine B-drug
) O
. O

The O
following O
medications O
have O
been O
administered O
in O
clinical O
trials O
with O
Simulect B-brand
with O
no O
increase O
in O
adverse O
reactions O
: O
ATG/ALG O
, O
azathioprine B-drug
, O
corticosteroids B-group
, O
cyclosporine B-drug
, O
mycophenolate B-drug
mofetil I-drug
, O
and O
muromonab-CD3 B-drug
. O

Therefore O
, O
it O
is O
recommended O
that O
Fluvoxamine B-drug
Tablets O
not O
be O
used O
in O
combination O
with O
MAOIs B-group
, O
or O
within O
14 O
days O
of O
discontinuing O
treatment O
with O
a O
MAOI B-group
. O

Midazolam B-drug
used O
at O
doses O
of O
1.25 O
mg/kg O
and O
2.5 O
mg/kg O
decreased O
the O
antinociceptive O
effect O
of O
morphine B-drug
, O
metamizol B-drug
( O
only O
in O
the O
tail-flick O
test O
) O
and O
indomethacin B-drug
. O

Oral O
Contraceptives B-group
Rofecoxib B-drug
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
ethinyl B-drug
estradiol I-drug
and O
norethindrone B-drug
. O

The O
continued O
need O
for O
the O
other O
antiarrhythmic B-drug
agent O
should O
be O
reviewed O
after O
the O
effects O
of O
amiodarone B-drug
have O
been O
established O
, O
and O
discontinuation O
ordinarily O
should O
be O
attempted O
. O

Drug-lab O
interactions O
: O
implications O
for O
nutrition O
support O
. O

However O
, O
careful O
attention O
must O
be O
directed O
to B-group
cross O
toxicity O
and O
possible O
pharmacokinetic O
interactions O
between O
antiretroviral O
and O
antineoplastic B-group
drugs I-group
. O

Effect O
of O
other O
agents O
on O
the O
pharmacokinefics O
of O
aprepitant B-drug

Patients O
who O
require O
the O
use O
of O
one O
of O
these O
drugs O
with O
HIVID B-drug
should O
have O
frequent O
clinical O
and O
laboratory O
monitoring O
with O
dosage O
adjustment O
for O
any O
significant O
change O
in O
renal O
function O
. O

however O
, O
150 O
mg O
of O
ranitidine B-drug
q12h O
for O
3 O
days O
increased O
the O
ceftibuten B-drug
C O
max O
by O
23 O
% O
and O
ceftibuten B-drug
AUC O
by O
16 O
% O
. O

Antacid B-group
( O
Maalox B-brand
) O
: O
Maalox B-brand
reduced O
the O
bioavailability O
of O
gabapentin B-drug
( O
N=16 O
) O
by O
about O
20 O
% O
. O

The O
intensity O
, O
uniformity O
and O
time O
course O
of O
anticoagulant B-group
interference O
by O
phenobarbital B-drug
, O
secobarbital B-drug
, O
glutethimide B-drug
, O
chloral B-drug
hydrate I-drug
and O
methaqualone B-drug
were O
systematically O
investigated O
in O
16 O
patients O
receiving O
coumarin B-group
therapy O
. O

Warfarin-Vitamin B-drug
K B-group
can O
antagonize O
the O
effect O
of O
warfarin B-drug

If O
a O
patient O
has O
been O
treated O
with O
cyclophosphamide B-drug
within O
10 O
days O
of O
general O
anesthesia O
, O
the O
anesthesiologist O
should O
be O
alerted O
. O

The O
effect O
of O
alosetron B-drug
on O
monoamine O
oxidases O
and O
on O
intestinal O
first O
pass O
secondary O
to O
high O
intraluminal O
concentrations O
have O
not O
been O
examined O
. O

2 O
. O

Clinical O
implications O
of O
warfarin B-drug
interactions O
with O
five O
sedatives B-group
. O

Table O
5a O
: O
Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
SUSTIVA B-brand

Clonidine B-drug
: O
Concomitant O
administration O
of O
clonidine B-drug
with O
agents B-group
with I-group
b-blocking I-group
properties I-group
may O
potentiate O
blood-pressure- O
and O
heart-rate-lowering O
effects O
. O

Steady O
state O
plasma O
digitoxin B-drug
concentrations O
did O
not O
appear O
to O
change O
. O

CFUs O
were O
maintained O
at O
low O
levels O
( O
10 O
( O
3 O
) O
CFU O
mL O
( O
-1 O
) O
) O
for O
24 O
h O
by O
vancomycin/flavone B-drug
combinations O
. O

Appropriate O
doses O
for O
this O
combination O
are O
not O
established O
. O

Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
cotherapy O
, O
an O
increased O
dose O
of O
tricyclic B-group
antidepressant I-group
may O
be O
required O
. O

Olanzapine B-drug
treatment O
improves O
quality O
of O
life O
in O
patients O
with O
schizophrenia O
and O
related O
psychoses O
to O
a O
greater O
extent O
than O
haloperidol B-drug
, O
and O
to O
broadly O
the O
same O
extent O
as O
risperidone B-drug
. O

Since O
PLETAL B-brand
is O
extensively O
metabolized O
by O
cytochrome O
P-450 O
isoenzymes O
, O
caution O
should O
be O
exercised O
when O
PLETAL B-brand
is O
coadministered O
with O
inhibitors O
of O
C.P.A O
. O
such O
as O
ketoconazole B-drug
and O
erythromycin B-drug
or O
inhibitors O
of O
CYP2C19 O
such O
as O
omeprazole B-drug
. O

On O
the O
average O
for O
the O
group O
, O
the O
dose O
of O
cyclosporine B-drug
was O
reduced O
about O
20 O
% O
in O
these O
patients O
. O

In O
vitro O
studies O
evaluating O
the O
minimum O
inhibitory O
concentration O
( O
MIC O
) O
of O
vancomycin B-drug
, O
cefazolin B-drug
, O
ampicillin B-drug
, O
ampicillin/flucoxacillin B-drug
, O
ceftazidime B-drug
, O
gentamicin B-drug
, O
and O
amphotericin B-drug
demonstrated O
no O
evidence O
of O
incompatibility O
of O
these O
antibiotics B-group
with O
EXTRANEAL B-brand
. O

Fulminant O
rhabdomyolysis O
has O
been O
seen O
as O
early O
as O
three O
weeks O
after O
initiation O
of O
combined O
therapy O
with O
another O
fibrate B-group
and O
lovastatin B-drug
but O
may O
be O
seen O
after O
several O
months O
. O

Although O
it O
has O
not O
been O
definitively O
demonstrated O
that O
fluvoxamine B-drug
is O
a O
potent O
IIIA4 O
inhibitor O
, O
it O
is O
likely O
to O
be O
, O
given O
the O
substantial O
interaction O
of O
fluvoxamine B-drug
with O
alprazolam B-drug
. O

Although O
the O
clinical O
significance O
is O
not O
known O
, O
it O
is O
not O
recommended O
that O
cefditoren B-drug
pivoxil I-drug
be O
taken O
concomitantly O
with O
H2 B-group
receptor I-group
antagonists I-group
. O

The O
administration O
of O
guanfacine B-drug
concomitantly O
with O
known O
microsomal O
enzyme O
inducer O
( O
phenobarbital B-drug
or O
phenytoin B-drug
) O
to O
two O
patients O
with O
renal O
impairment O
reportedly O
resulted O
in O
significant O
reductions O
in O
elimination O
half-life O
and O
plasma O
concentration O
. O

These O
antibiotics B-group
should O
be O
used O
in O
the O
myasthenic O
patient O
only O
where O
definitely O
indicated O
, O
and O
then O
careful O
adjustment O
should O
be O
made O
of O
adjunctive O
anticholinesterase B-group
dosage O
. O

Both O
18-MC B-drug_n
and O
ibogaine B-drug_n
are O
sequestered O
in O
fat O
and O
, O
like O
ibogaine B-drug_n
, O
18-MC B-drug_n
probably O
has O
an O
active O
metabolite O
. O

Theophylline B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
40 O
mg/day O
for O
21 O
days O
) O
and O
the O
CYP1A2 O
substrate O
theophylline B-drug
( O
single O
dose O
of O
300 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
theophylline B-drug
. O

Digitalis B-group
Glycosides I-group
: O
Therapeutic O
effects O
of O
digitalis B-group
glycosides I-group
may O
be O
reduced O
. O

However O
, O
other O
published O
reports O
describe O
modest O
elevations O
( O
less O
than O
two-fold O
) O
of O
clozapine B-drug
and O
metabolite O
concentrations O
when O
clozapine B-drug
was O
taken O
with O
paroxetine B-drug
, O
fluoxetine B-drug
, O
and O
sertraline B-drug
. O

These O
results O
suggest O
that O
D1 O
receptors O
are O
coupled O
to O
activation O
of O
arc O
gene O
, O
which O
may O
be O
involved O
in O
functional O
or O
structural O
alterations O
underlying O
neural O
plasticity O
triggered O
by O
METH B-drug
. O

. O

Close O
monitoring O
allows O
physicians O
to O
minimize O
risks O
, O
maximize O
benefits O
, O
and O
get O
the O
most O
out O
of O
what O
modern O
medications O
can O
do O
to O
help O
older O
patients O
. O

Because O
ritonavir B-drug
is O
coadministered O
, O
prescribers O
should O
also O
refer O
to O
the O
prescribing O
information O
for O
ritonavir B-drug
regarding O
drug O
interactions O
associated O
with O
this O
agent O
. O

Exogenous O
estradiol B-drug
also O
appeared O
to O
influence O
the O
percentage O
of O
endotoxin-induced B-drug_n
deaths O
in O
a O
dose-dependent O
manner O
. O

Therefore O
, O
caution O
should O
be O
used O
when O
administering O
MEPRON B-brand
concurrently O
with O
other O
highly O
plasma O
protein- O
bound O
drugs O
with O
narrow O
therapeutic O
indices O
, O
as O
competition O
for O
binding O
sites O
may O
occur O
. O

Therefore O
, O
the O
potential O
for O
such O
drug O
interaction O
should O
be O
considered O
in O
patients O
receiving O
AZOPT B-brand
( O
brinzolamide B-drug
ophthalmic O
suspension O
) O
1 O
% O
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
adrenal B-group
corticosteroids I-group
. O

forms O
of O
memory O
. O

Warfarin B-drug
, O
Digoxin B-drug
, O
Salicylate B-group
, O
and O
Heparin B-drug
The O
in O
vitro O
binding O
of O
warfarin B-drug
to O
plasma O
proteins O
is O
only O
slightly O
reduced O
by O
ketorolac B-drug
tromethamine I-drug
( O
99.5 O
% O
control O
vs O
99.3 O
% O
) O
when O
ketorolac B-drug
plasma O
concentrations O
reach O
5 O
to10 O
m O
g/mL O
. O

Conversely O
, O
at O
exposure O
levels O
close O
to O
the O
" O
limit O
values O
" O

Reduced O
response O
to O
metyrapone O
test O
. O

Subjects O
treated O
with O
200 O
mg O
of O
dideoxyinosine B-drug
twice O
daily O
for O
21 O
days O
received O
1200 O
mg O
of O
azithromycin B-drug
or O
an O
equivalent O
amount O
of O
placebo/day O
for O
Days O
8 O
to O
21 O
. O

Therefore O
, O
caution O
should O
be O
used O
in O
concomitant O
administration O
. O

Use O
of O
barrier O
form O
of O
contraception O
is O
suggested O
while O
on O
griseofulvin B-drug
therapy O
. O

With O
drugs O
inhibiting O
CYP3A O
to O
a O
lesser O
, O
but O
still O
significant O
degree O
, O
estazolam B-drug
should O
be O
used O
only O
with O
caution O
and O
consideration O
of O
appropriate O
dosage O
reduction O
. O

However O
, O
because O
some O
quinolones B-group
have O
been O
reported O
to O
enhance O
the O
anticoagulant O
effects O
of O
warfarin B-drug
or O
its O
derivatives O
in O
patients O
, O
the O
prothrombin O
time O
or O
other O
suitable O
coagulation O
test O
should O
be O
closely O
monitored O
if O
a O
quinolone B-group
antimicrobial I-group
is O
administered O
concomitantly O
with O
warfarin B-drug
or O
its O
derivatives O
. O

Clinically O
meaningful O
drug O
interactions O
have O
occurred O
with O
concomitant O
medications O
and O
include O
, O
but O
are O
not O
limited O
to O
the O
following O
: O
Agents O
Highly O
Bound O
to O
Plasma O
Protein O
Carbamazepine B-drug
is O
not O
highly O
bound O
to O
plasma O
proteins O
; O

Clinical O
Laboratory O

Geriatric O
Use O
When O
tumor O
response O
was O
considered O
by O
age O
, O
objective O
responses O
were O
seen O
in O
24 O
% O
and O
22 O
% O
of O
patients O
under O
65 O
years O
of O
age O
and O
in O
16 O
% O
and O
11 O
% O
of O
patients O
65 O
years O
of O
age O
and O
older O
, O
who O
were O
treated O
with O
FASLODEX B-brand
in O
the O
European O
and O
North O
American O
trials O
, O
respectively O
. O

Therefore O
, O
etodolac B-drug
can O
generally O
be O
given O
without O
the O
need O
for O
dosage O
modifications O
in O
special O
populations O
such O
as O
uncompromised O
elderly O
patients O
, O
those O
with O
moderate O
renal O
impairment O
, O
and O
patients O
with O
stable O
hepatic O
disease O
. O

Studies O
of O
the O
effect O
of O
food O
on O
the O
pharmacokinetics O
of O
fluvastatin B-drug
have O
demonstrated O
marked O
reductions O
in O
the O
rate O
of O
bioavailability O
-- O
from O
40 O
% O
to O
60 O
% O
; O

In O
a O
patient O
with O
a O
nonfunctioning O
thyroid O
gland O
who O
is O
receiving O
thyroid O
replacement O
therapy O
, O
free O
levothyroxine B-drug
may O
be O
decreased O
when O
estrogens B-group
are O
started O
thus O
increasing O
thyroid B-group
requirements O
. O

In O
patients O
receiving O
Nalfon B-brand
and O
a O
steroid B-group
concomitantly O
, O
any O
reduction O
in O
steroid B-group
dosage O
should O
be O
gradual O
in O
order O
to O
avoid O
the O
possible O
complications O
of O
sudden O
steroid B-group
withdrawal O
. O

The O
effect O
of O
foods O
highly O
fortified O
with O
elemental O
iron B-drug_n
( O
primarily O
iron-fortified B-drug_n
breakfast O
cereals O
) O
on O
cefdinir B-drug
absorption O
has O
not O
been O
studied O
. O

As O
plasma O
protein O
binding O
of O
decitabine B-drug
is O
negligible O
( O
1 O
% O
) O
, O
interactions O
due O
to O
displacement O
of O
more O
highly O
protein O
bound O
drugs O
from O
plasma O
proteins O
are O
not O
expected O
. O

Although O
specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ALPHAGAN B-brand
P I-brand
, O
the O
possibility O
of O
an O
additive O
or O
potentiating O
effect O
with O
CNS B-group
depressants I-group
( O
alcohol B-drug
, O
barbiturates B-group
, O
opiates B-group
, O
sedatives B-group
, O
or O
anesthetics B-group
) O
should O
be O
considered O
. O

Gabapentin B-drug
pharmacokinetic O
parameters O
without O
and O
with O
probenecid B-drug
were O
comparable O
. O

and O
, O
rarely O
, O
dry O
mouth O
, O
anorexia O
, O
taste O
disorder O
, O
abdominal O
pain O
, O
vomiting O
, O
diarrhea O
, O
and O
positive O
test O
for O
occult O
blood O
in O
stool O
. O

Plasma O
levels O
of O
anticonvulsant B-group
agents I-group
may O
become O
subtherapeutic O
during O
cisplatin B-drug
therapy O
. O

Cardiovascular O
agents O
( O
e.g. O
, O
atenolol B-drug
, O
hydrochlorothiazide B-drug
, O
propranolol B-drug
) O
. O

+164 O
% O

vi O
. O

A O
possible O
interaction O
between O
glyburide B-drug
and O
ciprofloxacin B-drug
, O
a O
fluoroquinolone B-group
antibiotic I-group
, O
has O
been O
reported O
, O
resulting O
in O
a O
potentiation O
of O
the O
hypoglycemic O
action O
of O
glyburide B-drug
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

These O
above O
findings O
are O
summarized O
in O
TABLE O
1 O
. O

In O
vitro O
studies O
have O
shown O
that O
, O
because O
of O
its O
affinity O
for O
protein O
, O
6MNA B-drug_n
may O
displace O
other O
protein-bound O
drugs O
from O
their O
binding O
site O
. O

The O
effects O
of O
PEGASYS B-brand
on O
male O
fertility O
have O
not O
been O
studied O
. O

The O
pressor O
effects O
of O
catecholamines B-group
such O
as O
dopamine B-drug
or O
norepinephrine B-drug
are O
enhanced O
by O
Bretylium B-drug
Tosylate I-drug
. O

Because O
dexfenfluramine B-drug
is O
a O
serotonin O
releaser O
and O
reuptake O
inhibitor O
, O
dexfenfluramine B-drug
should O
not O
be O
used O
concomitantly O
with O
a O
MAO B-group
inhibitor I-group
. O

CONCLUSIONS/INTERPRETATION O
: O
Glucose B-drug
and O
insulin B-drug
can O
exert O
additive O
vasodilator O
properties O
on O
renal O
and O
ocular O
circulation O
. O

Dexamethasone B-drug
at O
10 O
( O
-10 O
) O
M O
or O
retinyl B-drug
acetate I-drug
at O
about O
3 O
X O
10 O
( O
-9 O
) O
M O
inhibits O
proliferation O
stimulated O
by O
EGF B-drug_n
. O

Therefore O
, O
concurrent O
administration O
of O
drugs O
that O
induce O
or O
inhibit O
this O
enzyme O
may O
affect O
quetiapine B-drug
pharmacokinetics O
. O

Our O
results O
indicate O
important O
relationships O
among O
ras O
, O
nucleophosmin/B23 O
, O
activation O
of O
caspase-3 O
, O
and O
induction O
of O
apoptosis O
. O

Plasma O
concentrations O
increased O
by O
SUSTIVA B-brand
( O
efavirenz B-drug
) O
; O

Coadministration O
of O
terfenadine B-drug
with O
Itraconazole B-drug
has O
led O
to O
elevated O
plasma O
concentrations O
of O
terfenadine B-drug
, O
resulting O
in O
rare O
instances O
of O
life- O
threatening O
cardiac O
dysrhythmias O
and O
one O
death O
. O

Agents O
that O
are O
CYP O
inducers O
that O
have O
been O
found O
, O
or O
are O
expected O
, O
to O
decrease O
plasma O
levels O
of O
EQUETROTM B-brand
are O
the O
following O
: O
Cisplatin B-drug
, O
doxorubicin B-drug
HCL I-drug
, O
felbamate B-drug
, O
rifampin B-drug
, O
phenobarbital B-drug
, O
Phenytoin B-drug
( O
2 O
) O
, O
primidone B-drug
, O
methsuximide B-drug
, O
and O
theophylline B-drug
Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
EQUETROTM B-brand
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
one O
of O
these O
CYP3A4 O
inducers O
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
increase O
for O
EQUETROTM B-brand
may O
be O
necessary O
. O

The O
Cmax O
of O
norethindrone B-drug
was O
13 O
% O
higher O
when O
it O
was O
coadministered O
with O
gabapentin B-drug
; O

The O
effectiveness O
of O
norepinephrine B-drug
in O
increasing O
the O
force O
of O
contraction O
was O
decreased O
in O
relation O
to O
the O
degree O
of O
heart O
failure O
. O

Cholestyramine B-drug
resin B-group
may O
delay O
or O
reduce O
the O
absorption O
of O
concomitant O
oral O
medication O
such O
as O
phenylbutazone B-group
, O
warfarin B-drug
, O
thiazide B-group
diuretics I-group
( O
acidic O
) O
or O
propranolol B-drug
( O
basic O
) O
, O
as O
well O
as O
tetracycline B-drug
penicillin I-drug
G I-drug
, O
phenobarbital B-drug
, O
thyroid O
and O
thyroxine B-drug
preparations O
, O
estrogens B-group
and O
progestins B-group
, O
and O
digitalis B-group
. O

- O
Changes O
in O
TBg O
concentration O
should O
be O
taken O
into O
consideration O
in O
the O
interpretation O
of O
T4 O
and O
T3 O
values O
. O

14-OH O
metabolite O
concentration O

No O
data O
from O
prospective O
clinical O
trials O
currently O
exist O
comparing O
the O
3 O
approved O
agents O
( O
efavirenz B-drug
, O
nevirapine B-drug
or O
delavirdine B-drug
) O
. O

A O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O

Intracellular O
and O
extracellular O
application O
of O
RR B-drug_n
reduced O
ADP-induced O
increases O
in O
[ O
Ca O
( O
2+ O
) O
] O
( O
i O
) O
. O

Imipramine B-drug
: O
Coadministration O
of O
single O
doses O
of O
Sonata B-brand
20 O
mg O
and O
imipramine B-drug
75 O
mg O
produced O
additive O
effects O
on O
decreased O
alertness O
and O
impaired O
psychomotor O
performance O
for O
2 O
to O
4 O
hours O
after O
administration O
. O

Total O
body O
clearance O
of O
Simulect B-brand
was O
reduced O
by O
an O
average O
22 O
% O
and O
51 O
% O
when O
azathioprine B-drug
and O
mycophenolate B-drug
mofetil I-drug
, O
respectively O
, O
were O
added O
to O
a O
regimen O
consisting O
of O
cyclosporine B-drug
, O
USP O
( O
MODIFIED O
) O
and O
corticosteroids B-group
. O

Of O
the O
1357 O
patients O
who O
received O
AMEVIVE B-brand
in O
clinical O
trials O
, O
a O
total O
of O
100 O
patients O
were O

Ibandronate B-drug
should O
be O
taken O
at O
least O
60 O
minutes O
before O
any O
oral O
medications O
containing O
multivalent O
cations O
( O
including O
antacids B-group
, O
supplements O
or O
vitamins B-group
) O
. O

Frequent O
prothrombin O
determinations O
are O
advisable O
until O
it O
has O
been O
determined O
definitely O
that O
the O
prothrombin O
level O
has O
been O
stabilized O
. O

The O
risk O
of O
a O
potential O
interaction O
between O
NovoSeven B-brand
and O
coagulation B-group
factor I-group
concentrates O
has O
not O
been O
adequately O
evaluated O
in O
preclinical O
or O
clinical O
studies O
. O

Probenecid B-drug
: O
Probenecid B-drug
slows O
the O
renal O
elimination O
of O
lome-floxacin O
. O

Among O
the O
polyene B-group
antibiotics I-group
, O
many O
, O
like O
filipin B-drug_n
, O
can O
not O
be O
used O
clinically O
because O
they O
are O
toxic O
; O

Patients O
' O
mean O
age O
was O
69.1 O
( O
95 O
% O
CI O
, O
+/- O
1.2 O
) O
. O

Plasma O
valproate B-drug
concentration O
should O
be O
monitored O
when O
isoniazid B-drug
and O
valproate B-drug
are O
co O
administered O
, O
and O
appropriate O
dosage O
adjustments O
of O
valproate B-drug
should O
be O
made O
. O

Effective O
use O
of O
drugs O
in O
therapy O
depends O
not O
only O
on O
clinical O
acumen O
but O
also O
on O
the O
availability O
of O
relevant O
pharmacokinetic O
and O
pharmacodynamic O
data O
. O

Drug O
Interactions O
. O

salicylates B-group
; O
sulfinpyrazone B-drug
; O

No O
adverse O
effects O
on O
female O
fertility O
and O
embryonic O
survival O
were O
evident O
in O
female O
animals O
dosed O
at O
0.001 O
mg/kg/day O
( O
approximately O
one-thousandth O
of O
the O
human O
dose O
based O
on O
BSA O
) O
. O

These O
agents O
have O
also O
been O
shown O
to O
decrease O
platelet O
nucleotide O
release O
and O
thromboxane O
A2 O
generation O
. O

Do O
not O
start O
or O
stop O
any O
medicine O
without O
doctor O
or O
pharmacist O
approval O
. O

Psychoactive B-group
Drugs I-group
: O
Hallucinations O
have O
been O
reported O
when O
TORADOL B-brand
was O
used O
in O
patients O
taking O
psychoactive B-group
drugs I-group
( O
fluoxetine B-drug
, O
thiothixene B-drug
, O
alprazolam B-drug
) O
. O

Use O
caution O
when O
giving O
these O
drugs O
together O
, O
especially O
in O
patients O
with O
hepatic O
or O
cardiac O
disease O
. O

In O
addition O
, O
Fondaparinux B-drug
neither O
influenced O
the O
pharmacodynamics O
of O
warfarin B-drug
, O
acetylsalicylic B-drug
acid I-drug
, O
piroxicam B-drug
, O
and O
digoxin B-drug
, O
nor O
the O
pharmacokinetics O
of O
digoxin B-drug
at O
steady O
state O
. O

Cypermethrin-induced B-drug
oxidative O
stress O
in O
rat O
brain O
and O
liver O
is O
prevented O
by O
vitamin B-drug
E I-drug
or O
allopurinol B-drug
. O

In O
patients O
taking O
diclofenac B-drug
and O
lithium B-drug
concomitantly O
, O
lithium B-drug
toxicity O
may O
develop O
. O

In O
the O
present O
study O
, O
the O
atypical B-group
antipsychotic I-group
clozapine B-drug
was O
tested O
in O
combination O
with O
an O
active O
dose O
of O
PCP B-drug_n
in O
two-lever O
drug O
discrimination O
and O
mixed O
signalled-unsignalled O
differential-reinforcement-of-low-rates O
( O
DRL O
) O
procedures O
. O

The O
vasodilating O
effects O
of O
isosorbide B-drug
mononitrate I-drug
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-group
. O

In O
vitro O
, O
buspirone B-drug
does O
not O
displace O
tightly O
bound O
drugs O
like O
phenytoin B-drug
, O
propranolol B-drug
, O
and O
warfarin B-drug
from O
serum O
proteins O
. O

No O
evidence O
of O
fetal O
toxicity O
including O
adverse O
effects O
on O
immune O
system O
development O
was O
observed O
in O
any O
of O
these O
animals O
. O

Efavirenz B-drug
has O
demonstrated O
superiority O
over O
nelfinavir B-drug
in O
nucleoside-experienced O
patients O
, O
although O
combining O
these O
2 O
agents O
may O
represent O
the O
best O
approach O
in O
these O
circumstances O
. O

Gold B-group
is O
excreted O
slowly O
from O
the O
body O
. O

When O
ertapenem B-drug
is O
co-administered O
with O
probenecid B-drug
( O
500 O
mg O
p.o O
. O
every O
6 O
hours O
) O
, O
probenecid B-drug
competes O
for O
active O
tubular O
secretion O
and O
reduces O
the O
renal O
clearance O
of O
ertapenem B-drug
. O

METHODS O
: O
All O
patients O
were O
enrolled O
in O
two O
sequential O
trials O
performed O
at O
the O
Aviano O
Cancer O
Center O
, O
Italy O
, O
from O
April O
1988 O
to O
December O
1998 O
. O

There O
was O
no O
effect O
on O
bleeding O
time O
, O
PT O
or O
aPTT O
. O

The O
potential O
for O
drug O
interactions O
with O
EMTRIVA B-brand
has O
been O
studied O
in O
combination O
with O
indinavir B-drug
, O
stavudine B-drug
, O
famciclovir B-drug
, O
and O
tenofovir B-drug
disoproxil I-drug
fumarate I-drug
. O

therefore O
, O
administration O
of O
these O
agents O
should O
precede O
lomefloxacin B-drug
dosing O
by O
4 O
hours O
or O
follow O
lomefloxacin B-drug
dosing O
by O
at O
least O
2 O
hours O
. O

As O
a O
moderate O
inhibitor O
of O
CYP3A4 O
, O
aprepitant B-drug
can O
increase O
plasma O
concentrations O
of O
coadministered O
medicinal O
products O
that O
are O
metabolized O
through O
CYP3A4 O
. O

Medications O
can O
interfere O
with O
folate O
utilization O
, O
including O
: O
anticonvulsant B-group
medications I-group
( O
such O
as O
phenytoin B-drug
, O
and O
primidone B-drug
) O
metformin B-drug
( O
sometimes O
prescribed O
to O
control O
blood O
sugar O
in O
type O
2 O
diabetes O
) O
sulfasalazine B-drug
( O
used O
to O
control O
inflammation O
associated O
with O
Crohns O
disease O
and O
ulcerative O
colitis O
) O
triamterene B-drug
( O
a O
diuretic B-group
) O
Methotrexate B-drug
There O
has O
been O
concern O
about O
the O
interaction O
between O
vitamin B-drug
B12 I-drug
and O
folic B-drug
acid I-drug
. O

Digoxin B-drug
: O
Some O
calcium B-group
blockers I-group
may O
increase O
the O
concentration O
of O
digitalis B-group
preparations I-group
in O
the O
blood O
. O

The O
mechanism O
of O
the O
action O
of O
PTX B-drug_n
was O
discussed O
in O
the O
relation O
with O
Na O
, O
K-ATPase O
. O

Pregnancy O
estrogens B-group
and O
estrogen-containing B-group
oral O
contraceptives B-group
increase O
TBg O
concentrations O
. O

Reformed O
microtubules O
appeared O
to O
function O
normally O
with O
respect O
to O
their O
possible O
role O
in O
the O
transport O
of O
noradrenaline O
storage O
vesicles O
along O
the O
axons O
. O

Free O
hormone O
concentrations O
may O
be O
decreased O
. O

Exposed O
histidines O
on O
toxin B-drug_n
A I-drug_n
are O
available O
for O
zinc B-drug
chelation O
, O
and O
these O
have O
been O
exploited O
in O
the O
development O
of O
a O
novel O
purification O
protocol O
for O
toxin B-drug_n
A I-drug_n
using O
zinc-chelating B-drug
chromatography O
. O

However O
, O
it O
was O
observed O
that O
the O
pharmacokinetics O
of O
ENBREL B-brand
was O
unaltered O
by O
concomitant O
methotrexate B-drug
in O
rheumatoid O
arthritis O
patients O
. O

Ketamine B-drug
: O
When O
administered O
to O
patients O
on O
a O
thyroid B-group
preparation I-group
, O
this O
parenteral O
anesthetic B-group
may O
cause O
hypertension O
and O
tachycardia O
. O

Acetaminophen B-drug
, O
lidocaine B-drug
, O
phenobarbital B-drug
, O
quinidine B-drug
, O
theophylline B-drug
, O
and O
valproic B-drug
acid I-drug
were O
added O
to O
pooled O
human O
serum O
at O
therapeutic O
concentrations O
. O

Metformin B-drug
: O
In O
healthy O
subjects O
given O
single O
500 O
mg O
doses O
of O
cephalexin B-drug
and O
metformin B-drug
, O
plasma O
metformin B-drug
mean O
cmax O
and O
AUC O
increased O
by O
an O
average O
of O
34 O
% O
and O
24 O
% O
, O
respectively O
, O
and O
metformin B-drug
mean O
renal O
clearance O
decreased O
by O
14 O
% O
. O

Therefore O
, O
a O
possible O
lack O
of O
desired O
effect O
of O
treatment O
should O
be O
taken O
into O
consideration O
before O
such O
drugs O
are O
given O
concomitantly O
with O
lactulose B-drug
. O

Nevertheless O
, O
clinical O
studies O
, O
as O
well O
as O
postmarketing O
observations O
have O
shown O
that O
Lodine B-brand
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

MAO B-group
inhibitors I-group
, O
narcotic B-group
analgesics I-group
( O
e.g. O
, O
meperidine B-drug
) O
, O
nitrates B-group
and O
nitrites B-group
, O
sympathomimetic B-group
agents I-group
, O
tricyclic B-group
antidepressants I-group
, O
and O
other O
drugs O
having O
anticholinergic O
activity O
. O

consequently O
, O
caution O
is O
advised O
if O
dexfenfluramine B-drug
and O
such O
drugs O
are O
prescribed O
concurrently O
. O

( O
Effects O
may O
be O
potentiated O
when O
used O
concurrently O
with O
thiazide B-group
diuretics I-group
; O

The O
effectiveness O
of O
progestin-only B-group
pills O
is O
reduced O
by O
hepatic O
enzyme-inducing O
drugs O
such O
as O
the O
anticonvulsants B-group
phenytoin B-drug
, O
carbamazepine B-drug
, O
and O
barbiturates B-group
, O
and O
the O
antituberculosis B-group
drug I-group
rifampin B-drug
. O

Concurrent O
administration O
of O
indinavir B-drug
and O
didanosine B-drug
significantly O
reduces O
the O
level O
of O
exposure O
to O
indinavir B-drug
, O
but O
it O
is O
unclear O
how O
soon O
after O
didanosine B-drug
administration O
indinavir B-drug
may O
be O
given O
safely O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
control O
. O

Drug O
interaction O
studies O
with O
Xigris B-brand
have O
not O
been O
performed O
in O
patients O
with O
severe O
sepsis O
. O

Phenytoin B-drug
, O
nicotine B-drug
, O
and O
rifampin B-drug
may O
decrease O
Clozapine B-drug
plasma O
levels O
, O
resulting O
in O
a O
decrease O
in O
effectiveness O
of O
a O
previously O
effective O
Clozapine B-drug
dose O
. O

Concomitant O
treatment O
of O
four O
patients O
in O
the O
United O
Kingdom O
with O
FOSCAVIR B-brand
and O
intravenous O
pentamidine B-drug
may O
have O
caused O
hypocalcemia O
; O

Tablets O
Simultaneous O
administration O
of O
sucralfate B-drug
and O
furosemide B-drug
tablets O
may O
reduce O
the O
natriuretic O
and O
antihypertensive O
effects O
of O
furosemide B-drug
. O

Coadministration O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
( O
day O
1 O
) O
and O
40 O
mg O
QD O
( O
days O
2-7 O
) O
) O
with O
glyburide B-drug
( O
5 O
mg O
QD O
) O
did O
not O
affect O
either O
the O
pharmacokinetics O
( O
exposure O
) O
or O
the O
pharmacodynamics O
( O
blood O
glucose O
and O
insulin O
levels O
) O
of O
glyburide B-drug
. O

No O
significant O
effects O
on O
cisapride B-drug
metabolism O
or O
QT O
interval O
were O
noted O
. O

This O
study O
demonstrates O
that O
concurrent O
administration O
of O
thiosulfate B-drug
permits O
at O
least O
a O
twofold O
increase O
in O
dose O
and O
total O
exposure O
to O
cisplatin B-drug
. O

Therefore O
, O
such O
combined O
treatment O
should O
be O
approached O
with O
caution O
and O
patients O
should O
be O
monitored O
closely O
when O
Clozapine B-drug
is O
combined O
with O
these O
drugs O
, O
particularly O
with O
fluvoxamine B-drug
. O

In O
the O
long-term O
safety O
studies O
, O
guanfacine B-drug
was O
given O
concomitantly O
with O
many O
drugs O
without O
evidence O
of O
any O
interactions O
. O

The O
concurrent O
use O
of O
Robinul B-brand
Injection O
with O
other O
anticholinergics B-group
or O
medications O
with O
anticholinergic O
activity O
, O
such O
as O
phenothiazines B-group
, O
antiparkinson B-group
drugs I-group
, O
or O
tricyclic B-group
antidepressants I-group
, O
may O
intensify O
the O
antimuscarinic O
effects O
and O
may O
result O
in O
an O
increase O
in O
anticholinergic O
side O
effects O
. O

They O
are O
weak O
inhibitors O
of O
CYP2C19 O
and O
CYP2A6 O
, O
and O
mild-to-moderate O
inhibitors O
of O
CYP2C9 O
at O
therapeutic O
concentrations O
. O

Because O
fluvoxamine B-drug
reduces O
the O
clearance O
of O
both O
diazepam B-drug
and O
its O
active O
metabolite O
, O
N-desmethyldiazepam B-drug_n
, O
there O
is O
a O
strong O
likelihood O
of O
substantial O
accumulation O
of O
both O
species O
during O
chronic O
co-administration O
. O

Antibiotics B-group
: O
No O
human O
drug O
interaction O
studies O
with O
antibiotics B-group
were O
conducted O
. O

There O
have O
been O
greater O
than O
two-fold O
increases O
of O
previously O
stable O
plasma O
levels O
of O
tricyclic B-group
antidepressants I-group
when O
fluoxetine B-drug
has O
been O
administered O
in O
combination O
with O
these O
agents O
. O

No O
formal O
drug/laboratory O
test O
interaction O
studies O
have O
been O
conducted O
with O
CLOLAR B-brand
. O

In O
patients O
where O
rifampin B-drug
or O
other O
CYP3A4 O
inducers O
are O
indicated O
, O
alternative O
therapeutic O
agents O
with O
less O
enzyme O
induction O
potential O
should O
be O
considered O
. O

As O
with O
all O
drugs O
, O
the O
potential O
exists O
for O
interaction O
with O
other O
drugs O
by O
a O
variety O
of O
mechanisms O
. O

The O
amount O
of O
metformin B-drug
absorbed O
while O
taking O
Acarbose B-drug
was O
bioequivalent O
to O
the O
amount O
absorbed O
when O
taking O
placebo O
, O
as O
indicated O
by O
the O
plasma O
AUC O
values O
. O

All O
the O
animals O
were O
killed O
at O
the O
end O
of O
the O
9th O
week O
of O
the O
experiment O
. O

The O
pharmacokinetics O
of O
etodolac B-drug
in O
healthy O
normal O
volunteers O
has O
been O
extensively O
studied O
and O
is O
well O
described O
. O

Patients O
on O
lithium B-drug
treatment O
should O
be O
closely O
monitored O
when O
CELEBREX B-brand
is O
introduced O
or O
withdrawn O
. O

In O
addition O
, O
administration O
to O
a O
patient O
population O
with O
hepatic O
insufficiency O
resulted O
in O
a O
2.5-fold O
increase O
in O
both O
the O
rate O
and O
extent O
of O
bioavailability O
relative O
to O
controls O
. O

Hydrocodone B-drug
increases O
gabapentin B-drug
AUC O
values O
by O
14 O
% O
. O

Therefore O
, O
Clozapine B-drug
should O
not O
be O
used O
with O
other O
agents O
having O
a O
well-known O
potential O
to O
suppress O
bone O
marrow O
function O
. O

We O
could O
observe O
that O
ginsenosides B-drug_n
inhibited O
high O
threshold O
voltage-dependent O
Ca O
( O
2+ O
) O
currents O
in O
a O
dose-dependent O
manner O
. O

Selegiline B-drug
- O
L-phenylalanine B-drug
and O
the O
selective B-group
MAO I-group
inhibitor I-group
selegiline B-drug
may O
have O
synergistic O
antidepressant O
activity O
if O
used O
concomitantly O
. O

As O
the O
primary O
effect O
of O
adenosine B-drug
is O
to O
decrease O
conduction O
through O
the O
A-V O
node O
, O
higher O
degrees O
of O
heart O
block O
may O
be O
produced O
in O
the O
presence O
of O
carbamazepine B-drug
. O

The O
effect O
of O
these O
interactions O
on O
mean O
AUCs O
and O
Cmin O
are O
summarized O
in O
Table O
2 O
: O
Table O
2 O
: O
Summary O
of O
AED O
interactions O
with O
Trileptal B-brand

Drugs O
and O
other O
substances O
demonstrated O
to O
be O
CYP O
3A O
inhibitors O
on O
the O
basis O
of O
clinical O
studies O
involving O
benzodiazepines B-group
metabolized O
similarly O
to O
alprazolam B-drug
or O
on O
the O
basis O
of O
in O
vitro O
studies O
with O
alprazolam B-drug
or O
other O
benzodiazepines B-group
( O
caution O
is O
recommended O
during O
coadministration O
with O
alprazolam B-drug
) O
: O
Available O
data O
from O
clinical O
studies O
of O
benzodiazepines B-group
other O
than O
alprazolam B-drug
suggest O
a O
possible O
drug O
interaction O
with O
alprazolam B-drug
for O
the O
following O
: O
diltiazem B-drug
, O
isoniazid B-drug
, O
macrolide B-group
antibiotics I-group
such O
as O
erythromycin B-drug
and O
clarithromycin B-drug
, O
and O
grapefruit O
juice O
. O

Ketorolac B-drug
does O
not O
alter O
digoxin B-drug
protein O
binding O
. O

Tricyclic B-group
antidepressants I-group
may O
enhance O
the O
seizure O
risk O
in O
patients O
taking O
tramadol B-drug

Since O
the O
therapeutic O
range O
of O
theophylline B-drug
is O
narrow O
theophylline B-drug
serum O
levels O
should O
be O
monitored O
closely O
, O
and O
appropriate O
dosage O
adjustments O
of O
theophylline B-drug
should O
be O
made O
. O

Combination O
was O
associated O
with O
a O
higher O
frequency O
of O
adverse O
clinical O
experiences O
( O
eg O
, O
dizziness O
, O
nausea O
, O
paresthesia O
) O
and O
laboratory O
abnormalities O
( O
elevated O
liver O
enzymes O
) O
. O

Cimetidine B-drug
: O
Cimetidine B-drug
has O
been O
demonstrated O
to O
interfere O
with O
the O
elimination O
of O
other O
quinolones B-group
. O

Antipyrine B-drug
: O
Because O
atorvastatin B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
antipyrine B-drug
, O
interactions O
with O
other O
drugs B-drug
metabolized O
via O
the O
same O
cytochrome O
isozymes O
are O
not O
expected O
. O

Because O
a O
similar O
interaction O
is O
likely O
, O
VIRACEPT B-brand
should O
also O
not O
be O
administered O
concurrently O
with O
astemizole B-drug
. O

Calcium B-group
channel I-group
blocking I-group
agents I-group
: O
Coadministration O
of O
calcium B-group
channel I-group
blockers I-group
did O
not O
have O
any O
effect O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-drug
in O
the O
clinical O
trials O
. O

Anticoagulants B-drug
: O
Potentiation O
of O
warfarin-type B-drug
( O
CYP2C9 B-drug
and O
CYP3A4 B-drug
substrate O
) O
anticoagulant B-drug
response O
is O
almost O
always O
seen O
in O
patients O
receiving O
amiodarone B-drug
and O
can O
result O
in O
serious O
or O
fatal O
bleeding O
. O

The O
use O
of O
MAO B-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
with O
hydrocodone B-drug
preparations O
may O
increase O
the O
effect O
of O
either O
the O
antidepressant B-group
or O
hydrocodone B-drug
. O

It O
has O
recently O
been O
demonstrated O
that O
toxin B-drug_n
A I-drug_n
exerts O
its O
cytotoxic O
effect O
by O
the O
glucosylation O
of O
the O
small O
GTP-binding O
proteins O
of O
the O
Rho O
family O
. O

Potentiation O
occurs O
with O
ganglionic B-group
peripheral I-group
adrenergic I-group
blocking I-group
drugs I-group
. O

Also O
, O
in O
vitro O
experiments O
demonstrated O
a O
lack O
of O
interaction O
between O
dirithromycin B-drug
and O
terfenadine B-drug
. O

The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O

The O
main O
indications O
are O
eclampsia O
, O
some O
dysrhythmias O
( O
torsades O
de O
pointe O
particularly O
) O
and O
myocardial O
ischaemias O
. O

Also O
, O
there O
were O
no O
clinically O
significant O
differences O
in O
adverse O
events O
when O
loratadine B-drug
was O
administered O
with O
or O
without O
ketoconazole B-drug
. O

To O
determine O
whether O
injection O
of O
thiosulfate B-drug
would O
permit O
larger O
doses O
of O
cisplatin B-drug
to O
be O
administered O
, O
a O
fixed O
9.9-g/m2 O
dose O
of O
thiosulfate B-drug
was O
given O
intravenously O
over O
three O
hours O
concurrently O
with O
escalating O
doses O
of O
cisplatin B-drug
. O

Cytochalasin B-drug_n
D I-drug_n
at O
10 O
microM O
preferentially O
blocked O
the O
secretory O
effect O
of O
carbachol B-drug
and O
its O
synergism O
with O
cAMP O
, O
whereas O
it O
had O
no O
effect O
on O
histamine- O
or O
cAMP-stimulated O
acid O
secretion O
within O
15 O
min O
. O

Omeprazole B-drug
: O
No O
clinically O
significant O
changes O
in O
lomefloxacin B-drug
pharmacokinetics O
( O
AUC O
, O
C O
max O
, O
or O
T O
max O
) O
were O
observed O
when O
a O
single O
dose O
of O
lomefloxacin B-drug
400 O
mg O
was O
given O
after O
multiple O
doses O
of O
omeprazole B-drug
( O
20 O
mg O
qd O
) O
in O
13 O
healthy O
volunteers O
. O

Caution O
is O
indicated O
when O
piperacillin B-drug
is O
used O
perioperatively O
. O

In O
the O
presence O
of O
phentolamine B-drug
( O
10 O
( O
-6 O
) O
M O
) O
, O
the O
second O
contraction O
was O
inhibited O
selectively O
. O

Heparin B-drug
Sodium I-drug
Injection O
should O
not O
be O
mixed O
with O
doxorubicin B-drug
, O
droperidol B-drug
, O
ciprofloxacin B-drug
, O
or O
mitoxantrone B-drug
, O
since O
it O
has O
been O
reported O
that O
these O
drugs O
are O
incompatible O
with O
heparin B-drug
and O
a O
precipitate O
may O
form O
. O

The O
intestinal O
absorption O
of O
arsenate B-drug_n
( O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
) I-drug_n
has O
been O
investigated O
in O
the O
chick O
by O
means O
of O
the O
in O
situ O
ligated O
duodenal O
loop O
technique O
. O

If O
leprosy-associated O
inflammatory O
reactions O
develop O
in O
patients O
being O
treated O
with O
dapsone B-drug
and O
clofazimine B-drug
, O
it O
is O
still O
advisable O
to O
continue O
treatment O
with O
both O
drugs O
. O

Fexofenadine B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
either O
erythromycin B-drug
or O
ketoconazole B-drug
. O

Dofetilide B-drug
is O
metabolized O
to O
a O
small O
extent O
by O
the O
CYP3A4 O
isoenzyme O
of O
the O
cytochrome O
P450 O
system O
. O

Because O
the O
risk O
to O
the O
development O
of O
the O
fetal O
immune O
system O
and O
postnatal O
immune O
function O
in O
humans O
is O
unknown O
, O
AMEVIVE B-brand
should O
be O
used O
during O
pregnancy O
only O
if O
clearly O
needed O
. O

Significant O
pharmacokinetic O
interactions O
mediated O
by O
inhibition O
of O
CYP O
isoenzymes O
therefore O
appear O
unlikely O
. O

Tiagabine B-drug
has O
shown O
no O
clinically O
important O
potentiation O
of O
the O
pharmacodynamic O
effects O
of O
triazo O
lam O
or O
alcohol B-drug
. O

metabolizers O
. O

Population O
pharmacokinetic O
analyses O
were O
conducted O
on O
plasma O
concentration O
data O
from O
1445 O
patients O
in O
clinical O
trials O
to O
examine O
the O
effects O
of O
concomitant O
medications O
on O
clearance O
or O
volume O
of O
distribution O
of O
dofetilide B-drug
. O

Isoproterenol B-drug
hydrochloride I-drug
injection O
and O
epinephrine B-drug
should O
not O
be O
administered O
simultaneously O
because O
both O
drugs O
are O
direct O
cardiac O
stimulants O
and O
their O
combined O
effects O
may O
induce O
serious O
arrhythmias O
. O

Compared O
with O
lean O
rats O
, O
arteries O
from O
dietary-obese O
rats O
showed O
significant O
( O
P O
< O
0.001 O
) O
endothelial O
dysfunction O
, O
as O
indicated O
by O
a O
decrease O
( O
> O
20 O
% O
) O
in O
maximal O
acetylcholine-induced O
vasorelaxation O
. O

Suppression O
by O
verapamil B-drug
of O
bombesin-enhanced B-drug_n
peritoneal O
metastasis O
of O
intestinal O
adenocarcinomas O
induced O
by O
azoxymethane B-drug_n
in O
wistar O
rats O
. O

Glyburide B-drug
: O
In O
a O
randomized O
, O
multiple-dose O
crossover O
study O
, O
patients O
with O
Type O
2 O
diabetes O
were O
administered O
120 O
mg O
Starlix B-brand
three O
times O
a O
day O
before O
meals O
for O
1 O
day O
in O
combination O
with O
glyburide B-drug
10 O
mg O
daily O
. O

This O
might O
increase O
the O
risk O
of O
methotrexate B-drug
toxic O
reactions O
. O

Since O
the O
arrival O
of O
oral O
erection-supporting B-group
medication I-group
, O
patients O
want O
to O
know O
how O
safe O
sexual O
activity O
is O
in O
cardiovascular O
disease O
in O
general O
and O
during O
use O
of O
erection-supporting B-group
medication I-group
in O
particular O
. O

Bile B-group
acid I-group
sequestrants I-group
have O
been O
shown O
to O
bind O
other O
drugs O
given O
concurrently O
. O

Allopurinol B-drug
: O
In O
a O
study O
of O
healthy O
male O
volunteers O
no O
significant O
pharmacokinetic O
interaction O
occurred O
when O
captopril B-drug
and O
allopurinol B-drug
were O
administered O
concomitantly O
for O
6 O
days O
. O

See O
CLINICAL O
PHARMACOLOGY O
. O

Inhibitory O
effects O
of O
ruthenium B-drug_n
red I-drug_n
on O
inositol O
1,4 O
, O
5-trisphosphate-induced O
responses O
in O
rat O
megakaryocytes O
. O

Drugs O
That O
Inhibit O
Both O
Aldehyde O
Oxidase O
and O
CYP3A4 O
Cimetidine B-drug
: O
Cimetidine B-drug
inhibits O
both O
aldehyde O
oxidase O
( O
in O
vitro O
) O
and O
CYP3A4 O
( O
in O
vitro O
and O
in O
vivo O
) O
, O
the O
primary O
and O
secondary O
enzymes O
, O
respectively O
, O
responsible O
for O
zaleplon B-drug
metabolism O
. O

Drug/Laboratory O
Test O
Interactions O
No O
laboratory O
test O
abnormalities O
related O
to O
the O
use O
of O
guanfacine B-drug
have O
been O
identified O
. O

These O
increases O
in O
concentration O
may O
lead O
to O
increased O
effects O
, O
( O
lower O
blood O
pressure O
and O
increased O
heart O
rate O
) O
. O

There O
have O
been O
postmarketing O
reports O
of O
drug O
interactions O
when O
erythromycin B-drug
is O
coadministered O
with O
cisapride B-drug
, O
resulting O
in O
QT O
prolongation O
, O
cardiac O
arrythmias O
, O
ventricular O
tachycardia O
, O
ventricular O
fibrulation O
, O
and O
torsades O
de O
pointes O
, O
most O
like O
due O
to O
inhibition O
of O
hepatic O
metabolism O
of O
cisapride B-drug
by O
erythromycin B-drug
. O

There O
are O
3 O
types O
of O
indications O
: O
specific O
( O
for O
the O
treatment O
of O
some O
forms O
of O
magnesium B-drug
deficit O
i.e O
. O
acute O
) O
, O
pharmacological O
( O
i.e O
. O
without O
alterations O
of O
magnesium B-drug
status O
) O
and O
mixed O
-- O
pharmacological O
and O
aetiopathogenic O
-- O
( O
for O
example O
complications O
of O
chronic O
alcoholism O
) O
. O

decreased O
antithrombin O
3 O
; O

Two O
percent O
of O
patients O
treated O
concurrently O
with O
ENBREL B-brand
and O
anakinra B-drug
developed O
neutropenia O
( O
ANC O
1 O
x O
109/L O
) O
. O

Reported O
examples O
of O
this O
interaction O
include O
the O
following O
: O
Antibiotics B-drug
: O
Rifampin B-drug
is O
a O
potent O
inducer O
of O
CYP3A4 B-drug
. O

The O
resulting O
increase O
in O
free O
drug O
concentration O
may O
lead O
to O
enhanced O
drug O
effect O
in O
vivo O
. O

The O
results O
raise O
the O
possibility O
that O
the O
ethanolysis O
reaction O
may O
occur O
in O
the O
stomach O
of O
people O
who O
consume O
alcohol B-drug
and O
3-hydroxy-1,4-benzodiazepine B-group
on O
a O
regular O
basis O
. O

Patients O
should O
be O
warned O
of O
the O
potential O
danger O
of O
the O
intravenous O
self-administration O
of O
benzodiazepines B-group
while O
under O
treatment O
with O
SUBOXONE B-brand
or O
SUBUTEX B-brand
. O

In O
vitro O
studies O
also O
indicate O
that O
celecoxib B-drug
, O
although O
not O
a O
substrate O
, O
is O
an O
inhibitor O
of O
cytochrome O
P450 O
2D6 O
. O

Acute O
symptoms O
should O
be O
treated O
with O
a O
short-acting O
, O
inhaled O
beta2-agonist B-group
such O
as O
salbutamol B-drug
( O
the O
physician O
should O
provide O
the O
patient O
with O
such O
medication O
and O
instruct O
the O
patient O
in O
how O
it O
should O
be O
used O
) O
. O

Drug O
interaction O
studies O
of O
mefenamic B-drug
acid I-drug
and O
these O
compounds O
have O
not O
been O
conducted O
. O

Cimetidine B-drug
is O
reported O
to O
reduce O
hepatic O
metabolism O
of O
certain O
tricyclic B-drug
antidepressants I-drug
, O
thereby O
delaying O
elimination O
and O
increasing O
steady-state O
concentrations O
of O
these O
drugs B-drug
. O

This O
indicates O
that O
gabapentin B-drug
does O
not O
undergo O
renal O
tubular O
secretion O
by O
the O
pathway O
that O
is O
blocked O
by O
probenecid B-drug
. O

Induction O
of O
such O
tumors O
is O
consistent O
with O
the O
pharmacology-related O
endocrine O
feedback O
alterations O
in O
gonadotropin O
levels O
caused O
by O
an O
antiestrogen B-group
. O

Acid-catalyzed O
ethanolysis O
of O
temazepam B-drug
in O
anhydrous O
and O
aqueous O
ethanol B-drug
solutions O
. O

Concomitant O
use O
of O
calcium B-drug
supplements O
and O
L-lysine B-drug
may O
increase O
calcium B-drug
absorption O

Monitor O
serum O
potassium O
levels O
; O

Digoxin B-drug
: O
In O
a O
study O
in O
12 O
patients O
with O
congestive O
heart O
failure O
where O
ketoprofen B-drug
and O
digoxin B-drug
were O
concomitantly O
administered O
, O
ketoprofen B-drug
did O
not O
alter O
the O
serum O
levels O
of O
digoxin B-drug
. O

Valproate B-drug
Keppra B-brand
( O
1500 O
mg O
twice O
daily O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
valproate B-drug
in O
healthy O
volunteers O
. O

If O
you O
are O
50 O
years O
of O
age O
or O
older O
, O
ask O
your O
physician O
to O
check O
your O
B12 O
status O
before O
you O
take O
a O
supplement O
that O
contains O
folic B-drug
acid I-drug
. O

Vancomycin O
resistance O
reversal O
in O
enterococci O
by O
flavonoids O
. O

route O
. O

Jacalin B-drug_n
is O
a O
D-Gal O
binding O
lectin O
and O
should O
be O
a O
useful O
tool O
for O
studying O
of O
serum O
and O
secretory O
IgA O
. O

The O
increase O
of O
phenobarbital B-drug
level O
, O
however O
, O
is O
small O
( O
15 O
% O
) O
when O
given O
with O
Trileptal B-brand
. O

therefore O
, O
periodic O
liver O
function O
testing O
( O
transaminases O
, O
bilirubin O
, O
and O
alkaline O
phosphatase O
) O
should O
be O
considered O
. O

Until O
specific O
compatibility O
data O
are O
available O
, O
it O
is O
not O
recommended O
that O
DOXIL B-brand
be O
mixed O
with O
other O
drugs O
. O

Anticonvulsants B-group

Pharmacokinetic-related O
Interactions O
: O
Clozapine B-drug
is O
a O
substrate O
for O
many O
CYP O
450 O
isozymes O
, O
in O
particular O
1A2 O
, O
2D6 O
, O
and O
3A4 O
. O

Concomitant O
use O
of O
Isocarboxazid B-drug
and O
other O
psychotropic B-group
agents I-group
is O
generally O
not O
recommended O
because O
of O
possible O
potentiating O
effects O
. O

Methadone B-drug

Table O
9 O

The O
majority O
of O
adverse O
events O
with O
NNRTIs B-group
occur O
within O
the O
first O
month O
, O
and O
are O
predictable O
and O
manageable O
without O
therapy O
interruption O
. O

administration O
1 O
hour O
before O
or O
4 O
hours O
after O
colestipol B-drug
is O
recommended O
. O
) O

Failure O
of O
neomycin B-drug
to O
modify O
ACTH B-group
induced O
hypertension O
in O
sheep O
. O

PATIENTS O
: O
Random O
sample O
of O
626 O
MAC O
out O
of O
a O
total O
of O
1306 O
. O

Monitor O
for O
symptoms O
of O
hyperglycemia O
; O

At O
higher O
than O
recommended O
doses O
, O
VIOXX B-brand
75 O
mg O
administered O
once O
daily O
for O
10 O
days O
increased O
plasma O
concentrations O
by O
23 O
% O
as O
measured O
by O
AUC0-24hr O
in O
patients O
receiving O
methotrexate B-drug
7.5 O
to O
15 O
mg/week O
for O
rheumatoid O
arthritis O
. O

Acitretin B-drug
: O
Interferes O
with O
the O
contraceptive O
effect O
of O
microdosed O
progestin-containing B-group
minipill O
preparations O
. O

Co-administration O
of O
CYP3A4 O
inhibitors O
( O
eg O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
grapefruit O
juice O
, O
cimetidine B-drug
) O
with O
felodipine B-drug
may O
lead O
to O
several- O
fold O
increases O
in O
the O
plasma O
levels O
of O
felodipine B-drug
, O
either O
due O
to O
an O
increase O
in O
bioavailability O
or O
due O
to O
a O
decrease O
in O
metabolism O
. O

Differences O
can O
occur O
in O
therapeutic O
effect O
and O
in O
adverse O
events O
. O

Conversely O
, O
adverse O
effects O
may O
result O
from O
displacement O
of O
protein-bound O
Anafranil B-brand
by O
other O
highly O
bound O
drugs O
. O

The O
recommended O
dosage O
( O
one O
or O
two O
capsules O
twice O
daily O
, O
morning O
and O
evening O
) O
should O
not O
be O
exceeded O
. O

Increases O
in O
sertraline B-drug
dose O
should O
be O
guided O
by O
clinical O
response O
. O

Pharmacokinetic O
studies O
have O
demonstrated O
that O
omeprazole B-drug
and O
erythromycin B-drug
significantly O
increased O
the O
systemic O
exposure O
of O
cilostazol B-drug
and/or O
its O
major O
metabolites O
. O

Brain O
hemorrhage O
and O
optic O
nerve O
vacuolation O
were O
seen O
in O
another O
female O
dog O
that O
was O
sacrificed O
in O
moribund O
condition O
after O
11 O
weeks O
of O
escalating O
doses O
up O
to O
280 O
mg/kg/day O
. O

Warning O
signs O
, O
irrespective O
of O
cause O
, O
are O
: O
dryness O
of O
mouth O
, O
thirst O
, O
weakness O
, O
lethargy O
, O
drowsiness O
, O
restlessness O
, O
muscle O
pains O
or O
cramps O
, O
muscular O
fatigue O
, O
hypotension O
, O
oliguria O
, O
tachycardia O
, O
and O
gastrointestinal O
disturbances O
such O
as O
nausea O
and O
vomiting O
. O

In O
studies O
in O
normal O
volunteers O
, O
there O
was O
no O
pharmacodynamic O
interaction O
between O
intravenous O
iloprost B-drug
and O
either O
nifedipine B-drug
, O
diltiazem B-drug
, O
or O
captopril B-drug
. O

Expected O
to O
substantially O
decrease O
plasma O
levels O
of O
efavirenz B-drug
; O
has O
not O
been O
studied O
in O
combination O
with O
SUSTIVA B-brand
. O

As O
with O
some O
other O
nondepolarizing B-group
neuromuscular I-group
blocking I-group
agents I-group
, O
the O
time O
of O
onset O
of O
neuromuscular O
block O
induced O
by O
NUROMAX B-brand
is O
lengthened O
and O
the O
duration O
of O
block O
is O
shortened O
in O
patients O
receiving O
phenytoin B-drug
or O
carbamazepine B-drug
. O

Uricosuric B-group
drugs I-group
, O
such O
as O
probenecid B-drug
and O
sulfinpyrazone B-drug
, O
can O
inhibit O
renal O
tubular O
secretion O
of O
nitrofurantoin B-drug
. O

Potential O
for O
ABILIFY B-brand
to O
Affect O
Other O
Drugs O
Aripiprazole B-drug
is O
unlikely O
to O
cause O
clinically O
important O
pharmacokinetic O
interactions O
with O
drugs O
metabolized O
by O
cytochrome O
P450 O
enzymes O
. O

Antifungals B-group
: O
In O
vitro O
and/or O
in O
vivo O
data O
indicate O
that O
fluconazole B-drug
, O
itraconazole B-drug
, O
and O
oral O
ketoconazole B-drug
markedly O
inhibit O
the O
metabolism O
of O
cisapride B-drug
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

This O
medicine O
should O
not O
be O
taken O
with O
MAO B-group
inhibitors I-group
. O

Drugs O
that O
inhibit O
cytochrome O
P450IID6 O
, O
such O
as O
quinidine B-drug
, O
might O
increase O
the O
plasma O
concentrations O
of O
flecainide B-drug
in O
patients O
that O
are O
on O
chronic O
flecainide B-drug
therapy O
; O

Methotrexate B-drug
VIOXX B-brand
12.5 O
, O
25 O
, O
and O
50 O
mg O
, O
each O
dose O
administered O
once O
daily O
for O
7 O
days O
, O
had O
no O
effect O
on O
the O
plasma O
concentration O
of O
methotrexate B-drug
as O
measured O
by O
AUC0-24hr O
in O
patients O
receiving O
single O
weekly O
methotrexate B-drug
doses O
of O
7.5 O
to O
20 O
mg O
for O
rheumatoid O
arthritis O
. O

Antacids I-group
: O
Administration O
of O
flurbiprofen B-drug
to O
volunteers O
under O
fasting O
conditions O
, O
or O
with O
antacid B-group
suspension O
yielded O
similar O
serum O
flurbiprofen B-drug
time O
profiles O
in O
young O
subjects O
( O
n=12 O
) O
. O

Effects O
on O
the O
absorption O
of O
other O
beta-blockers B-group
have O
not O
been O
determined O
. O

Therefore O
, O
EXTREME O
CAUTION O
should O
be O
exercised O
when O
administering O
dopamine B-drug
HCl I-drug
to O
patients O
receiving O
cyclopropane B-drug
or O
halogenated B-group
hydrocarbon I-group
anesthetics I-group
. O

Another O
investigator O
found O
no O
increase O
in O
digoxin B-drug
levels O
in O
12 O
patients O
with O
coronary O
artery O
disease O
. O

PEGASYS B-brand
is O
to O
be O
used O
during O
pregnancy O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
to O
the O
fetus O
. O

In O
hematologic O
studies O
or O
in O
transfusion O
cross-matching O
procedures O
when O
anti-globulin O
tests O
are O
performed O
on O
the O
minor O
side O
or O
in O
Coombs O
testing O
of O
newborns O
whose O
mothers O
have O
received O
cephalosporin B-group
antibiotics I-group
before O
parturition O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
may O
be O
due O
to O
the O
drug O
. O

Anticoagulants B-group
. O

Tolbutamide B-drug
: O
In O
diabetic O
patients O
receiving O
diflunisal B-drug
and O
tolbutamide B-drug
, O
no O
significant O
effects O
were O
seen O
on O
tolbutamide B-drug
plasma O
levels O
or O
fasting O
blood O
glucose O
. O

There O
is O
limited O
experience O
with O
concomitant O
antihypertensive B-group
agents I-group
such O
as O
alpha-blockers B-group
, O
calcium B-group
channel-blockers I-group
, O
ACE B-group
inhibitors I-group
, O
and O
diuretics B-group
( O
both O
thiazide-like B-group
and O
loop O
) O
. O

No O
drug O
, O
nutritional O
supplement O
, O
food O
or O
herb O
interactions O
have O
yet O
been O
reported O
. O

Note O
: O
dissolution O
of O
aerosol O
particles O
of O
budesonide B-drug
in O
Survanta B-brand
, O
a O
model O
lung B-group
surfactant I-group
. O

If O
TYKERB B-brand
is O
administered O
with O
drugs O
that O
are O
substrates O
of O
Pgp O
, O
increased O
concentrations O
of O
the O
substrate O
drug O
are O
likely O
, O
and O
caution O
should O
be O
exercised O
. O

ETHANOL B-drug
/ O
NUTRITION O
/ O
HERB O
INTERACTIONS O
: O
Food O
: O
CNS O
effects O
of O
caffeine B-drug
may O
be O
enhanced O
if O
combination B-group
hormonal I-group
contraceptives I-group
are O
used O
concurrently O
with O
caffeine B-drug
. O

If O
antacids B-group
are O
required O
during O
OMNICEF B-brand
therapy O
, O
OMNICEF B-brand
should O
be O
taken O
at O
least O
2 O
hours O
before O
or O
after O
the O
antacid B-group
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCA O
treatment O
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

It O
is O
not O
known O
if O
the O
effects O
of O
butorphanol B-drug
are O
altered O
by O
concomitant O
medications O
that O
affect O
hepatic O
metabolism O
of O
drugs O
( O
erythromycin B-drug
, O
etc O
. O
) O
, O
but O
physicians O
should O
be O
alert O
to O
the O
possibility O
that O
a O
smaller O
initial O
dose O
and O
longer O
intervals O
between O
doses O
may O
be O
needed O
. O

The O
mean O
C O
max O
, O
T O
max O
, O
and O
AUC O
of O
the O
acid O
metabolite O
of O
terfenadine B-drug
were O
not O
significantly O
changed O
. O

Beta-blocking B-group
Agents I-group
: O
The O
concomitant O
use O
of O
Bepridil B-drug
and O
beta-blocking B-group
agents I-group
has O
been O
well O
tolerated O
in O
patients O
with O
stable O
angina O
. O

The O
possibility O
of O
increased O
interaction O
should O
be O
kept O
in O
mind O
when O
Orudis B-brand
doses O
greater O
than O
50 O
mg O
as O
a O
single O
dose O
or O
200 O
mg O
of O
ketoprofen B-drug
per O
day O
are O
used O
concomitantly O
with O
highly O
bound O
drugs O
. O

Results O
showed O
that O
, O
depending O
on O
the O
task O
considered O
, O
the O
same O
pharmacological O
treatment O
produced O
either O
a O
facilitation O
or O
an O
impairment O
of O
acquisition O
. O

Co-administration O
of O
nelfinavir B-drug
at O
steady-state O
with O
a O
single O
dose O
of O
azithromycin B-drug
. O

TABLE O
1 O
Effects O
on O
Plasma O
Concentrations O
( O
AUC O
0-24 O
hrs O
) O
of O
Loratadine B-drug
and O
Descarboethoxyloratadine B-drug
After O
10 O
Days O
of O
Coadministration O
( O
Loratadine B-drug
10 O
mg O
) O
in O
Normal O
Volunteers O

Serum O
infliximab B-drug
concentrations O
appeared O
to O
be O
unaffected O
by O
baseline O
use O
of O
medications O
for O
the O
treatment O
of O
Crohn O
s O
disease O
including O
corticosteroids B-group
, O
antibiotics B-group
( O
metronidazole B-drug
or O
ciprofloxacin B-drug
) O
and O
aminosalicylates O
. O

Erythromycin B-drug
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam B-drug
and O
midazolam B-drug
and O
thus O
may O
increase O
the O
pharmacologic O
effect O
of O
these O
benzodiazepines B-group
. O

Drugs O
Associated O
With O
Peripheral O
Neuropathy O
: O
The O
concomitant O
use O
of O
HIVID B-drug
with O
drugs O
that O
have O
the O
potential O
to O
cause O
peripheral O
neuropathy O
should O
be O
avoided O
where O
possible O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
. O

Elevated O
plasma O
levels O
of O
theophylline B-drug
have O
been O
reported O
with O
concomitant O
quinolone B-group
use O
. O

HAART O
was O
included O
with O
combination O
therapy O
from O
January O
1997 O
. O

Consequently O
, O
estazolam B-drug
should O
be O
avoided O
in O
patients O
receiving O
ketoconazole B-drug
and O
itraconazole B-drug
, O
which O
are O
very O
potent O
inhibitors O
of O
CYP3A O
. O

trimethoprim/sulfamethoxazole B-drug
; O

We O
conclude O
that O
an O
ability O
of O
some O
P O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

Drug O
interactions O
caused O
by O
inhibition O
of O
P-glycoprotein-mediated O
drug O
clearance O
or O
CYP-mediated O
drug O
clearance O
with O
the O
listed O
isoforms O
are O
unlikely O
. O

Drugs O
other O
than O
those O
listed O
here O
may O
also O
interact O
with O
glimepiride B-drug
or O
affect O
your O
condition O
. O

In O
a O
clinical O
trial O
of O
217 O
pediatric O
patients O
( O
12 O
to O
17 O
years O
) O
with O
severe O
recalcitrant O
nodular O
acne O
, O
transient O
elevations O
in O
CPK O
were O
observed O
in O
12 O
% O
of O
patients O
, O
including O
those O
undergoing O
strenuous O
physical O
activity O
in O
association O
with O
reported O
musculoskeletal O
adverse O
events O
such O
as O
back O
pain O
, O
arthralgia O
, O
limb O
injury O
, O
or O
muscle O
sprain O
. O

Recent O
, O
better O
designed O
studies O
have O
not O
reported O
these O
adverse O
effects O
. O

Administration O
of O
doxapram B-drug
to O
patients O
who O
are O
receiving O
sympathomimetic B-group
or O
monoamine B-group
oxidase I-group
inhibiting I-group
drugs I-group
may O
result O
in O
an O
additive O
pressor O
effect O
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reactions O
. O

Therefore O
, O
proton B-group
pump I-group
inhibitors I-group
should O
be O
taken O
at O
least O
30 O
minutes O
prior O
to O
sucralfate B-drug
. O

Potential O
for O
Interaction O
with O
Drugs O
that O
Affect O
Gastric O
Acidity O
: O
Duloxetine B-drug
has O
an O
enteric O
coating O
that O
resists O
dissolution O
until O
reaching O
a O
segment O
of O
the O
gastrointestinal O
tract O
where O
the O
pH O
exceeds O
5.5 O
. O

Non-steroidal B-group
Anti-inflammatory I-group
Drugs I-group
: O
In O
some O
patients O
, O
the O
administration O
of O
a O
non-steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium-sparing O
and O
thiazide B-group
diuretics I-group
. O

In O
vitro O
studies O
indicate O
that O
bupropion B-drug
is O
primarily O
metabolized O
to O
hydroxybupropion B-drug_n
by O
the O
CYP2B6 O
isoenzyme O
. O

In O
vitro O
, O
the O
UDP-glucuronyl O
transferase O
level O
was O
increased O
, O
indicating O
induction O
of O
this O
enzyme O
. O

In O
Study O
1 O
, O
patients O
with O
colorectal O
cancer O
were O
given O
irinotecan/5-FU/leucovorin B-drug
( O
bolus-IFL O
) O
with O
or O
without O
AVASTIN B-brand
. O

Avoid O
saw O
palmetto O
, O
red O
clover O
, O
ginseng O
. O

. O

phase O
2 O
( O
days O
14-44 O
) O
: O
fluoxetine B-drug
20 O
mg/day O
; O

In O
study O
one O
, O
hyperglycaemic O
clamps O
( O
5.6 O
mmol/l O
, O
11.1 O
mmol/ O
1 O
, O
16.7 O
mmol/l O
) O
were O
carried O
out O
during O
placebo O
or O
insulin B-drug
( O
dose O
1 O
: O
1 O
mU/kg/min O
; O
dose O
2 O
: O
2 O
mU/kg/min O
) O
infusion O
. O

Omniscan B-brand
interferes O
with O
serum O
calcium O
measurements O
with O
some O
colorimetric O
( O
complexometric O
) O
methods O
commonly O
used O
in O
hospitals O
, O
resulting O
in O
serum O
calcium O
concentrations O
lower O
than O
the O
true O
values O
. O

Appropriate O
dosage O
adjustments O
may O
be O
necessary O
. O

Drug/ O
Laboratory O
Tests O
Interactions O
Hyperaminotransferasemia O
: O
Significant O
elevations O
of O
aminotransferase O
( O
SGOT O
[ O
S-AST O
] O
and O
SGPT O
[ O
S-ALT O
] O
) O
levels O
have O
occurred O
in O
a O
high O
percentage O
of O
patients O
( O
and O
healthy O
subjects O
) O
who O
have O
received O
heparin B-drug
sodium I-drug
. O

The O
effect O
of O
clofarabine B-drug
on O
the O
metabolism O
of O
cytochrome O
p450 O
substrates O
has O
not O
been O
studied O
. O

The O
effect O
of O
natural O
and O
synthetic O
galloyl O
esters O
on O
glucocorticoid-induced O
gene O
expression O
was O
evaluated O
by O
using O
rat O
fibroblast O
3Y1 O
cells O
stably O
transfected O
with O
a O
luciferase O
reporter O
gene O
under O
the O
transcriptional O
regulation O
of O
the O
mouse O
mammary O
tumor O
virus O
promoter B-drug
. O

The O
ECG O
changes O
and/or O
hypokalemia O
that O
may O
result O
from O
the O
administration O
of O
non-potassium B-group
sparing I-group
diuretics I-group
( O
such O
as O
loop O
or O
thiazide B-group
diuretics I-group
) O
can O
be O
acutely O
worsened O
by O
beta-agonists B-group
, O
especially O
when O
the O
recommended O
dose O
of O
the O
beta-agonist B-group
is O
exceeded O
. O

Corticotropin B-drug
may O
accentuate O
the O
electrolyte O
loss O
associated O
with O
diuretic B-group
therapy O
. O

Given O
the O
anticonvulsant O
properties O
of O
carbamazepine B-drug
, O
EQUETROTM B-brand
may O
reduce O
the O
thyroid O
function O
as O
has O
been O
reported O
with O
other O
anticonvulsants B-group
. O

Concomitant O
single O
dose O
administration O
of O
valdecoxib B-drug
20 O
mg O
with O
multiple O
doses O
of O
ketoconazole B-drug
and O
fluconazole B-drug
produced O
a O
significant O
increase O
in O
exposure O
of O
valdecoxib B-drug
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
enhance O
the O
locomotor O
and/or O
stereotypic O
effects O
of O
stimulants O
. O

Protease B-group
inhibitor I-group
: O
atazanavir B-drug

T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
. O

Therefore O
, O
patients O
with O
COPD O
should O
not O
normally O
be O
treated O
with O
beta-blockers B-group
. O

The O
interaction O
of O
intramuscularly O
injected O
ketamine B-drug
and O
its O
N-demethylated O
metabolite O
( O
metabolite O
I O
) O
with O
halothane B-drug
was O
evaluated O
in O
rats O
. O

It O
is O
recommended O
that O
the O
dose O
of O
rifabutin B-drug
be O
reduced O
to O
one-half O
the O
usual O
dose O
when O
administered O
with O
VIRACEPT B-brand
. O

however O
, O
patients O
receiving O
such O
combined O
therapy O
should O
be O
monitored O
closely O
for O
early O
evidence O
of O
neurological O
toxicity O
and O
treatment O
discontinued O
promptly O
if O
such O
signs O
appear O
. O

During O
phenytoin B-drug
and O
fluvoxamine O
treatment O
, O
ataxia O
, O
a O
typical O
side O
effect O
of O
phenytoin B-drug
, O
was O
observed O
. O

1 O
. O

The O
increased O
plasma O
concentration O
of O
terfenadine B-drug
or O
its O
metabolite O
may O
result O
in O
prolonged O
QT O
intervals O
. O

Phenytoin O
intoxication O
induced O
by O
fluvoxamine B-drug
. O

Clinically O
significant O
interactions O
would O
not O
be O
expected O
since O
the O
NRTIs B-group
are O
metabolized O
via O
a O
different O
route O
than O
efavirenz B-drug
and O
would O
be O
unlikely O
to O
compete O
for O
the O
same O
metabolic O
enzymes O
and O
elimination O
pathways O
. O

In O
a O
pharmacokinetic O
interaction O
study O
with O
warfarin B-drug
, O
bioavailability O
parameters O
, O
the O
degree O
of O
protein O
binding O
, O
and O
the O
anticoagulant O
effect O
( O
measured O
by O
prothrombin O
time O
) O
of O
warfarin B-drug
were O
not O
significantly O
changed O
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O

A O
method O
to O
maximize O
the O
therapeutic O
benefit O
of O
gentamicin B-drug
while O
minimizing O
the O
risk O
of O
nephrotoxicity O
and O
the O
appearance O
of O
a O
hot O
kidney O
on O
scintigraphy O
is O
desirable O
. O

Drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
TRACRIUM B-brand
include O
: O
enflurane B-drug
; O

Patients O
stabilized O
on O
oral O
anticoagulants B-group
who O
are O
found O
to O
require O
thyroid B-group
replacement O
therapy O
should O
be O
watched O
very O
closely O
when O
thyroid O
is O
started O
. O

The O
second O
study O
was O
identical O
but O
endogenous O
insulin O
secretion O
was O
blocked O
with O
somatostatin B-drug
. O

If O
other O
muscle B-group
relaxants I-group
are O
used O
during O
the O
same O
procedure O
, O
the O
possibility O
of O
a O
synergistic O
or O
antagonist O
effect O
should O
be O
considered O
. O

Magnesium- B-drug
and/or O
aluminum-containing B-drug
antacids B-group
, O
products O
containing O
ferrous B-drug
sulfate I-drug
( O
iron B-drug
) O
, O
multivitamin B-group
preparations I-group
containing O
zinc B-drug
or O
other O
metal O
cations O
, O
or O
Videx B-brand
( O
didanosine B-drug
) O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
should O
not O
be O
taken O
within O
3 O
hours O
before O
or O
2 O
hours O
after O
FACTIVE B-brand
. O

The O
concomitant O
administration O
of O
either O
cocaine B-drug
or O
amphetamine B-drug
, O
compounds O
which O
inhibit O
neuronal O
reuptake O
of O
norepinephrine O
, O
disrupts O
the O
behavioral O
response O
of O
the O
genetically O
nervous O
E-strain O
subjects O
to O
a O
far O
greater O
extent O
than O
the O
stable O
A-strain O
subjects O
. O

If O
TYKERB B-brand
is O
administered O
with O
drugs O
that O
inhibit O
Pgp O
, O
increased O
concentrations O
of O
lapatinib B-drug
are O
likely O
, O
and O
caution O
should O
be O
exercised O
. O

Because O
changes O
in O
glucose O
concentrations O
with O
valdecoxib B-drug
coadministration O
were O
within O
the O
normal O
variability O
and O
individual O
glucose O
concentrations O
were O
above O
or O
near O
70 O
mg/dL O
, O
dose O
adjustment O
for O
glyburide B-drug
( O
5 O
mg O
QD O
and O
10 O
mg O
BID O
) O
with O
valdecoxib B-drug
coadministration O
( O
up O
to O
40 O
mg O
QD O
) O
is O
not O
indicated O
. O

False-positive O
direct O
Coombs O
tests O
have O
been O
reported O
during O
treatment O
with O
other O
cephalosporins B-group
. O

Impaired O
glucose O
tolerance O
. O

Ketoconazole B-drug
: O
When O
a O
single O
125-mg O
dose O
of O
Aprepitant B-drug
was O
administered O
on O
Day5 O
of O
a O

In O
four O
subjects O
with O
epilepsy O
ingesting O
valproate B-drug
, O
the O
steady-state O
trough O
( O
Cmin O
) O
valproate B-drug
plasma O
concentration O
was O
63 O
16 O
micrograms/mL O
. O

Anti-HIV B-group
Reverse I-group
Transcriptase I-group
Inhibitors I-group

Clofibric B-drug_n
acid I-drug_n
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
the O
clearance O
of O
clofibric B-drug_n
acid I-drug_n
. O

No O
specific O
studies O
have O
been O
performed O
and O
caution O
is O
recommended O
. O

rash O

Frequent O
determination O
of O
prothrombin O
time O
and O
close O
monitoring O
of O
the O
patient O
is O
essential O
to O
ascertain O
when O
adjustment O
of O
dosage O
of O
anticoagulant B-group
may O
be O
needed O
. O

A O
21 O
( O
17 O
) O
% O
decrease O
in O
the O
steady-state O
AUC O
of O
ganciclovir B-drug
was O
observed O
when O
VIDEX B-brand
was O
administered O
2 O
hours O
prior O
to O
ganciclovir B-drug
, O
but O
not O
when O
the O
two O
drugs O
were O
administered O
simultaneously O
( O
n O
= O
12 O
) O
. O

Cevimeline B-drug
might O
interfere O
with O
desirable O
antimuscarinic O
effects O
of O
drugs O
used O
concomitantly O
. O

Statistical O
analysis O
: O
Mantel-Haenszel O
( O
alpha O
= O
0.05 O
) O
. O

Cyclosporine B-drug
doses O
, O
trough O
concentrations O
, O
and O
AUC O
exhibited O
similar O
temporal O
patterns O
during O
the O
course O
of O
the O
study O
regardless O
of O
the O
co-administered O
everolimus B-drug
dose O
level O
( O
P O
= O
.13 O
, O
.82 O
, O
and O
.76 O
, O
respectively O
) O
. O

No O
drug O
interactions O
have O
been O
observed O
with O
the O
Vitrasert B-brand
Implant O
. O

No O
interactions O
were O
observed O
. O

An O
interaction O
study O
with O
warfarin B-drug
showed O
no O
clinically O
significant O
effect O
of O
anastrozole B-drug
on O
warfarin B-drug
pharmacokinetics O
or O
anticoagulant O
activity O
. O

Drug/Laboratory O
Test O
Interactions O
Naproxen B-drug
may O
decrease O
platelet O
aggregation O
and O
prolong O
bleeding O
time O
. O

Intestinal O
absorption O
of O
arsenate B-drug_n
in O
the O
chick O
. O

Ethanol B-drug
depressed O
the O
amplitudes O
of O
most O
evoked O
potential O
components O
in O
comparison O
to O
saline O
administration O
. O

alcohol B-drug
, O
barbiturates B-drug
and O
other O
CNS B-drug
depressants I-drug
; O

An O
immune O
response O
to O
Campath B-brand
may O
interfere O
with O
subsequent O
diagnostic O
serum O
tests O
that O
utilize O
antibodies B-group

After O
one O
day O
, O
fecal O
as O
well O
as O
urinary O
excretion O
of O
both O
elements O
had O
already O
responded O
to O
the O
dietary O
treatments O
, O
with O
constant O
values O
being O
reached O
after O
approximately O
three O
days O
. O

Epinephrine B-drug
also O
should O
be O
used O
cautiously O
with O
other O
drugs O
( O
e.g. O
, O
digitalis B-group
, O
glycosides B-group
) O
that O
sensitize O
the O
myocardium O
to O
the O
actions O
of O
sympathomimetic B-group
drugs I-group
. O

Significant O
increases O
In O
AUC O
( O
27 O
% O
) O
and O
Cmax O
( O
58 O
% O
) O
and O
decreases O
in O
tmax O
( O
23 O
% O
) O
of O
propranolol B-drug
were O
noted O
in O
this O
study O
. O

Treatment O
with O
PEGASYS B-brand
once O
weekly O
for O
4 O
weeks O
in O
healthy O
subjects O
was O
associated O
with O
an O
inhibition O
of O
P450 O
1A2 O
and O
a O
25 O
% O
increase O
in O
theophylline B-drug
AUC O
. O

Itraconazole B-drug

Clinical O
Comment O

The O
risks O
of O
using O
Anafranil B-brand
in O
combination O
with O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

- O
Quinidine B-drug
( O
e.g. O
, O
Quinidex B-brand
) O
or O

Drug/Laboratory O
Test O
Interactions O
Increases O
in O
lymphocyte O
counts O
related O
to O
the O
pharmacologic O
mechanism O
of O
action O
are O
frequently O
observed O
during O
RAPTIVA B-brand
treatment O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
and O
because O
there O
exists O
the O
potential O
for O
serious O
adverse O
reactions O
in O
nursing O
infants O
from O
AMEVIVE B-brand
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
while O
taking O
the O
drug O
or O
to O
discontinue O
the O
use O
of O
the O
drug O
, O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

Both O
efavirenz B-drug
and O
nevirapine B-drug
have O
been O
compared O
to O
triple O
therapy O
with O
the O
PI B-group
indinavir B-drug
over O
48 O
weeks O
as O
initial O
therapy O
, O
with O
similar O
responses O
being O
observed O
with O
nevirapine B-drug
regimens O
and O
superiority O
observed O
with O
efavirenz B-drug
. O

Several O
drug O
interaction O
studies O
have O
been O
completed O
with O
both O
INVIRASE B-brand
and O
FORTOVASE B-brand
. O

Bexarotene B-drug
oxidative O
metabolites O
appear O
to O
be O
formed O
by O
cytochrome O
P450 O
3A4 O
. O

If O
you O
think O
you O
are O
taking O
an O
MAO B-group
inhibitor I-group
talk O
to O
your O
doctor O
or O
pharmacist O
. O

The O
effect O
of O
a O
pulmonary B-group
surfactant I-group
extract O
from O
bovine O
lung O
, O
Survanta B-brand
, O
on O
the O
dissolution O
rate O
of O
aerosol O
particles O
of O
budesonide B-drug
was O
determined O
. O

In O
a O
single O
study O
, O
rats O
given O
high O
intraperitoneal O
doses O
of O
an O
MAO B-group
inhibitor I-group
plus O
disulfiram B-drug
experienced O
severe O
toxicity O
, O
including O
convulsions O
and O
death O
. O

FACTIVE B-brand
had O
no O
significant O
effect O
on O
the O
anticoagulant O
effect O
of O
warfarin B-drug
in O
healthy O
subjects O
on O
stable O
warfarin B-drug
therapy O
. O

The O
interindividual O
pharmacokinetic O
variability O
for O
AUC O
was O
85.4 O
% O
and O
intraindividual O
, O
interoccasion O
variability O
was O
40.8 O
% O
. O

Excretion O
of O
thioethers O
in O
urine O
after O
exposure O
to O
electrophilic O
chemicals O
. O

Expected O
changes O
in O
laboratory O
assessments O
of O
PT O
and O
INR O
were O
observed O
after O
warfarin B-drug
administration O
, O
but O
these O
changes O
were O
not O
affected O
by O
concomitant O
lenalidomide B-drug
administration O
. O

Propoxyphene B-drug
: O
In O
cases O
of O
propoxyphene B-drug
overdosage O
, O
amphetamine B-drug
CNS O
stimulation O
is O
potentiated O
and O
fatal O
convulsions O
can O
occur O
. O

Quinolones B-group
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

Caution O
should O
be O
exercised O
with O
these O
drugs O
when O
treating O
patients O
receiving O
TAXOTERE B-brand
as O
there O
is O
a O
potential O
for O
a O
significant O
interaction O
. O

Except O
for O
clindamycin-sensitive B-drug
isolates O
, O
synergy O
was O
usually O
observed O
only O
at O
concentrations O
of O
one O
or O
both O
drugs O
which O
are O
not O
readily O
obtainable O
in O
vivo O
. O

- O
Cholestyramine B-drug
and O
colestipol B-drug
resins B-group
: O
Cholestytamine B-drug
and O
colestipol B-drug
resins B-group
have O
the O
potential O
of O
binding O
thiazide B-group
diuretics I-group
and O
reducing O
diuretic B-group
absorption O
from O
the O
gastrointestinal O
tract O

This O
medicine O
should O
not O
be O
taken O
with O
MAO B-group
inhibitors I-group
. O

Patients O
with O
a O
very O
low O
cardiac O
capacity O
should O
be O
advised O
to O
refrain O
from O
treatment O
of O
the O
erection O
disorder O
. O

As O
binding O
of O
MHD B-drug_n
to O
plasma O
proteins O
is O
low O
( O
40 O
% O
) O
, O
clinically O
significant O
interactions O
with O
other O
drugs O
through O
competition O
for O
protein O
binding O
sites O
are O
unlikely O
. O

Adverse O
reactions O
related O
to O
alpha B-drug
interferons O
, O
such O
as O
CNS O
, O
cardiac O
, O
and O
systemic O
( O
eg O
, O
flu-like O
) O
effects O
may O
be O
more O
severe O
in O
the O
elderly O
and O
caution O
should O
be O
exercised O
in O
the O
use O
of O
PEGASYS B-brand
in O
this O
population O
. O

In O
opioid-dependent B-group
patients O
, O
mixed B-group
agonist/antagonist I-group
analgesics I-group
may O
precipitate O
withdrawal O
symptoms O
. O

Chirocaine B-brand
should O
be O
used O
with O
caution O
in O
patients O
receiving O
other O
local O
anesthetics B-group
or O
agents O
structurally O
related O
to O
amide-type O
local O
anesthetics O
since O
the O
toxic O
effects O
of O
these O
drugs O
could O
be O
additive O
. O

Misonidazole B-drug_n
reduced O
the O
antitumour O
activity O
of O
oral O
CCNU B-drug
by O
dose O
modifying O
factors O
( O
DMF O
) O
of O
0.58-0.71 O
. O

An O
association O
between O
prilocaine B-drug
and O
an O
increased O
risk O
of O
methaemoglobinaemia O
, O
particularly O
in O
infants O
, O
has O
specifically O
been O
described O
in O
a O
literature O
case O
report O
. O

Fenfluramine B-drug
may O
increase O
slightly O
the O
effect O
of O
antihypertensive B-group
drugs I-group
, O
e.g. O
, O
guanethidine B-drug
, O
methyldopa B-drug
, O
reserpine B-drug
. O

Cytochrome O
P450 O
1A2 O
( O
CYP1A2 O
) O
is O
known O
to O
be O
the O
major O
enzyme O
involved O
in O
the O
metabolism O
of O
caffeine B-drug
. O

Exposure O
of O
the O
muscle O
to O
ouabain B-drug
( O
10 O
( O
-5 O
) O
M O
) O
markedly O
increased O
the O
PTX-induced B-drug_n
release O
. O

The O
possibility O
of O
hypotensive O
effects O
with O
enalapril B-drug
or O
enalaprilat B-drug
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-drug
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
enalapril B-drug
or O
enalaprilat B-drug
. O

+15 O
% O
+0 O
% O
+17 O
% O
+13 O
% O

When O
phenobarbital B-drug
is O
added O
to O
or O
withdrawn O
from O
treatment O
, O
dosage O
adjustment O
of O
Nalfon B-brand
may O
be O
required O
. O

Digitalis B-group
: O
Immediate O
Release O
Capsules O
: O
Since O
there O
have O
been O
isolated O
reports O
of O
patients O
with O
elevated O
digoxin B-drug
levels O
, O
and O
there O
is O
a O
possible O
interaction O
between O
digoxin B-drug
and O
nifedipine B-drug
, O
it O
is O
recommended O
that O
digoxin B-drug
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
nifedipine B-drug
to O
avoid O
possible O
over- O
or O
under-digitalization O
. O

Cyclosporin B-drug
, O
tacrolimus B-drug
, O
sirolimus B-drug

Thus O
, O
the O
selective O
regulation O
of O
voltage-dependent O
Ca O
( O
2+ O
) O
subtypes O
by O
ginsenosides B-drug_n
in O
bovine O
chromaffin O
cell O
could O
be O
the O
cellular O
basis O
of O
antistress O
effects O
induced O
by O
ginseng B-drug
. O

It O
has O
been O
reported O
that O
the O
addition O
of O
triamterene B-drug
to O
a O
maintenance O
schedule O
of O
INDOCIN B-brand
resulted O
in O
reversible O
acute O
renal O
failure O
in O
two O
of O
four O
healthy O
volunteers O
. O

As O
with O
other O
drugs O
primarily O
being O
metabolized O
through O
CYP3A4 O
, O
ingestion O
of O
grapefruit O
or O
grapefruit O
juice O
should O
be O
avoided O
in O
connection O
with O
budesonide B-drug
administration O
. O

. O

Dexamethasone B-drug
had O
a O
similar O
effect O
in O
the O
presence O
of O
insulin B-drug
. O

There O
is O
limited O
experience O
with O
use O
of O
retinal O
tamponades O
in O
conjunction O
with O
the O
Vitrasert B-brand
Implant O
. O

Drugs O
which O
inhibit O
CYP2D6 O
and O
CYP3A3/4 O
also O
inhibit O
the O
metabolism O
of O
cevimeline B-drug
. O

Tubocurarine B-drug

Benzyl B-drug_n
alcohol I-drug_n
has O
been O
reported O
to O
be O
associated O
with O
an O
increased O
incidence O
of O
neurological O
and O
other O
complications O
in O
neonates O
and O
infants O
, O
which O
are O
sometimes O
fatal O
. O

+135 O
% O

these O
may O
also O
occur O
in O
neonates O
whose O
mothers O
received O
cephalosporins B-group
before O
delivery O
. O

Blood O
glucose O
concentrations O
should O
be O
carefully O
monitored O
when O
Itraconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
are O
coadministered O
. O

Prednisolone B-drug
: O
Ethinyl B-drug
estradiol I-drug
may O
inhibit O
the O
metabolism O
of O
prednisolone B-drug
, O
leading O
to O
increased O
plasma O
concentrations O
. O

Coadministration O
of O
Aprepitant B-drug
with O
drugs O
that O
induce O
CYP3A4 O
activity O
may O
result O
in O
reduced O
plasma O
concentrations O
and O
decreased O
efficacy O
of O
Aprepitant B-drug
. O

Diagnostic O
dip-stick O
methodology O
, O
used O
to O
detect O
ketone O
bodies O
in O
urine O
, O
has O
resulted O
in O
false-positive O
findings O
in O
some O
patients O
treated O
with O
Lodine B-brand
. O

Concomitant O
Administration O
with O
Racemic O
Citalopram B-drug
Citalopram I-drug
- O
Since O
escitalopram B-drug
is O
the O
active O
isomer O
of O
racemic O
citalopram B-drug
( O
Celexa B-brand
) O
, O
the O
two O
agents O
should O
not O
be O
coadministered O
. O

Calcium B-group
channel I-group
blockers I-group

Antihypertensive B-group
medications I-group
, O
other O
, O
especially O
diazoxide B-drug
, O
or O
preanesthetic B-group
and O
anesthetic O
agents O
used O
in O
surgery O
or O
skeletal-muscle B-group
relaxants I-group
, O
nondepolarizing O
, O
used O
in O
surgery O

Clinical O
Comment O

Glyburide B-drug
: O
The O
concomitant O
administration O
of O
ciprofloxacin B-drug
with O
the O
sulfonylurea B-group
glyburide B-drug
has O
, O
on O
rare O
occasions O
, O
resulted O
in O
severe O
hypoglycemia O
. O

However O
, O
theophylline B-drug
plasma O
concentrations O
should O
be O
monitored O
, O
with O
dosage O
adjustment O
as O
appropriate O
, O
in O
patients O
whose O
pulmonary O
disease O
requires O
maintaining O
a O
given O
theophylline B-drug
plasma O
concentration O
for O
optimal O
pulmonary O
function O
or O
in O
patients O
with O
theophylline B-drug
concentrations O
at O
the O
higher O
end O
of O
the O
therapeutic O
range O
. O

Chronic O
administration O
of O
phenobarbital B-drug
, O
a O
known O
enzyme O
inducer O
, O
may O
be O
associated O
with O
a O
decrease O
in O
the O
plasma O
half-life O
of O
fenoprofen B-drug
. O

Similarly O
dialyzed O
were O
phenobarbital B-drug
, O
quinidine B-drug
, O
and O
theophylline B-drug
, O
both O
alone O
at O
therapeutic O
concentrations O
in O
serum O
and O
with O
ethanol B-drug
at O
three O
different O
concentrations O
in O
serum O
. O

Do O
not O
take O
this O
medicine O
with O
St. O
Johns O
Wort O
because O
of O
the O
additive O
effects O
of O
sertonin O
. O

ATROVENT B-brand
Inhalation O
Aerosol O
has O
been O
used O
concomitantly O
with O
other O
drugs O
, O
including O
sympathomimetic B-group
bronchodilators I-group
, O
methylxanthines B-group
, O
and O
steroids B-group
, O
commonly O
used O
in O
the O
treatment O
of O
chronic O
obstructive O
pulmonary O
disease O
. O

This O
drug O
may O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-drug
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-drug
) O
. O

This O
could O
lead O
to O
decreased O
salicylate B-group
serum O
levels O
or O
increase O
the O
risk O
of O
salicylate B-group
toxicity O
when O
corticosteroid B-drug
is O
withdrawn O
. O

Oral O
Hypoglycemics B-group
: O
Diclofenac B-drug
does O
not O
alter O
glucose O
metabolism O
in O
normal O
subjects O
nor O
does O
it O
alter O
the O
effects O
of O
oral O
hypoglycemic B-group
agents I-group
. O

After O
extensive O
intake O
of O
grapefruit O
juice O
( O
which O
inhibits O
CYP3A4 O
activity O
predominantly O
in O
the O
intestinal O
mucosa O
) O
, O
the O
systemic O
exposure O
for O
oral O
budesonide B-drug
increased O
about O
two O
times O
. O

Drug/Laboratory O
Test O
Interactions O
Blood O
Glucose O
Blood O
glucose O
measurement O
must O
be O
done O
with O
a O
glucose-specific O
method O
to O
prevent O
maltose O
interference O
with O
test O
results O
. O

Interaction O
with O
phenytoin B-drug
, O
lidocaine B-drug
and O
theophylline B-drug
has O
also O
been O
reported O
to O
produce O
adverse O
clinical O
effects O
. O

Carbamazepine B-drug
: O
Elevated O
carbamazepine B-drug
levels O
have O
been O
reported O
in O
postmarketing O
experience O
when O
SUPRAX B-brand
is O
administered O
concomitantly O
. O

Aspirin B-brand
increased O
ulcerogenic O
effect O
; O

Concurrent O
use O
of O
tetracycline B-drug
may O
render O
oral O
contraceptives B-group
less O
effective O
. O

These O
results O
suggest O
that O
KRM-1648 B-drug_n
has O
a O
great O
potential O
in O
the O
treatment O
of O
M O
. O

Two O
different O
types O
of O
therapy O
with O
magnesium B-drug
are O
used O
: O
physiological O
oral O
magnesium B-drug
supplementation O
which O
is O
totally O
atoxic O
since O
it O
palliates O
magnesium B-drug
deficiencies O
by O
simply O
normalizing O
the O
magnesium B-drug
intake O
and O
pharmacological O
magnesium B-drug
therapy O
which O
may O
induce O
toxicity O
since O
it O
creates O
iatrogenic O
magnesium B-drug
overload O
. O

No O
data O
are O
available O
on O
potential O
interactions O
in O
individuals O
who O
consume O
greater O
than O
200 O
mg O
of O
caffeine B-drug
per O
day O
or O
in O
those O
, O
such O
as O
the O
geriatric O
population O
, O
who O
are O
generally O
believed O
to O
be O
more O
susceptible O
to O
the O
development O
of O
drug-induced O
CNS-related O
adverse O
effects O
. O

Theophylline B-drug
: O
Twelve O
healthy O
male O
volunteers O
were O
administered O
one O
200-mg O
ceftibuten B-drug
capsule O
twice O
daily O
for O
6 O
days O
. O

No O
significant O
interactions O
were O
found O
between O
nisoldipine B-drug
and O
warfarin B-drug
or O
digoxin B-drug
. O

It O
was O
concluded O
that O
oral O
oxycodone B-drug
and O
levofloxacin B-drug
can O
be O
administered O
concomitantly O
without O
a O
significant O
decrease O
in O
AUC O
, O
Cmax O
, O
or O
tmax O
. O

The O
cause O
of O
the O
reported O
association O
has O
not O
been O
established O
. O

Phosphate-Binding O
Agents O
: O
Since O
vitamin B-group
D I-group
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate-binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O

vasculitis O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

Antacids B-group
: O
Nonclinical O
data O
demonstrate O
that O
the O
solubility O
of O
dasatinib B-drug
is O
pH O
dependent O
. O

It O
is O
not O
known O
which O
drug O
clearance O
mechanism O
involved O
in O
caspofungin B-drug
disposition O
may O
be O
inducible O
. O

Laboratory O
Tests O
Response O
to O
Plenaxis B-brand
should O
be O
monitored O
by O
measuring O
serum O
total O
testosterone B-drug
concentrations O
just O
prior O
to O
administration O
on O
Day O
29 O
and O
every O
8 O
weeks O
thereafter O
. O

In O
the O
present O
study O
we O
evaluated O
the O
interference O
of O
antidepressants B-group
with O
blood O
glucose O
levels O
of O
diabetic O
and O
non-diabetic O
rats O
. O

In O
two O
clinical O
studies O
, O
cyclosporine B-drug
( O
one O
4 O
mg/kg O
dose O
or O
two O
3 O
mg/kg O
doses O
) O
increased O
the O
AUC O
of O
caspofungin B-drug
by O
approximately O
35 O
% O
. O

dietary O
deficiencies O
; O

Women O
should O
practice O
additional O
methods O
of O
contraception O
and O
not O
rely O
on O
hormonal O
contraception O
alone O
when O
taking O
TRACLEER B-brand
. O

Concomitant O
use O
of O
barbiturates B-group
usually O
depresses O
griseofulvin B-drug
activity O
and O
may O
necessitate O
raising O
the O
dosage O
. O

Tetracycline B-drug
, O
a O
bacteriostatic B-group
antibiotic I-group
, O
may O
antagonize O
the O
bactericidal O
effect O
of O
penicillin B-drug
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

There O
have O
been O
no O
formal O
clinical O
studies O
to O
evaluate O
the O
drug O
interactions O
of O
TAXOTERE B-brand
with O
other O
medications O
. O

Amphetamines B-group
may O
enhance O
the O
effects O
of O
tricyclic B-group
antidepressants I-group
. O

Immunologic O

In O
clinical O
trials O
, O
the O
concomitant O
administration O
of O
sulfadoxine B-drug
and O
pyrimethamine B-drug
did O
not O
alter O
the O
adverse O
reaction O
profile O
. O

Coadministration O
of O
VIRACEPT B-brand
and O
drugs O
that O
induce O
CYP3A O
may O
decrease O
nelfinavir B-drug
plasma O
concentrations O
and O
reduce O
its O
therapeutic O
effect O
. O

CYP3A4 O
inhibitors O
: O
May O
increase O
the O
levels/effects O
of O
chlorpheniramine B-drug
. O

Results O
from O
human O
in O
vitro O
metabolism O
studies O
and O
nonclinical O
studies O
show O
that O
REVLIMID B-brand
( O
lenalidomide B-drug
) O
is O
neither O
metabolized O
by O
nor O
inhibits O
or O
induces O
the O
cytochrome O
P450 O
pathway O
suggesting O
that O
lenalidomide B-drug
is O
not O
likely O
to O
cause O
or O
be O
subject O
to O
P450-based O
metabolic O
drug O
interactions O
in O
man O
. O

The O
effects O
of O
ketamine B-drug
and O
of O
Innovar B-brand
anesthesia O
on O
digitalis B-group
tolerance O
in O
dogs O
. O

The O
potential O
effects O
of O
fulvestrant B-drug
on O
the O
fertility O
of O
male O
animals O
were O
not O
studied O
but O
in O
a O
6-month O
toxicology O
study O
, O
male O
rats O
treated O
with O
intramuscular O
doses O
of O
15 O
mg/kg/30 O
days O
, O
10 O
mg/rat/30 O
days O
, O
or O
10 O
mg/rat/15 O
days O
fulvestrant B-drug
showed O
a O
loss O
of O
spermatozoa O
from O
the O
seminiferous O
tubules O
, O
seminiferous O
tubular O
atrophy O
, O
and O
degenerative O
changes O
in O
the O
epididymides O
. O

Talk O
to O
your O
doctor O
and O
pharmacist O
before O
taking O
any O
prescription O
or O
over-the-counter O
medicines O
, O
including O
herbal O
products O
. O

If O
you O
are O
taking O
medications O
for O
migraines O
such O
as O
Imitrex B-brand
, O
talk O
to O
your O
doctor O
before O
starting O
this O
medicine O
. O

Consequently O
, O
it O
is O
recommended O
that O
fluvoxamine B-drug
not O
be O
used O
in O
combination O
with O
either O
terbinafine B-drug
, O
astemizole B-drug
, O
or O
cisapride B-drug
. O

In O
a O
similar O
study O
with O
tamsulosin B-drug
in O
healthy O
volunteers O
, O
1 O
of O
24 O
subjects O
dosed O
with O
Vardenafil B-drug
20 O
mg O
and O
tamsulosin B-drug
0.4 O
mg O
separated O
by O
6 O
hours O
experienced O
a O
standing O
systolic O
blood O
pressure O
below O
85 O
mm O
Hg O
. O

Doses O
of O
these O
and O
perhaps O
other O
medications O
may O
need O
to O
be O
adjusted O
in O
patients O
who O
successfully O
quit O
smoking O
. O

However O
, O
no O
related O
changes O
were O
noted O
in O
the O
QT0 O
on O
ECG O
taken O
at O
2 O
, O
6 O
, O
and O
24 O
hours O
after O
the O
coadministration O
. O

The O
effect O
of O
gabapentin B-drug
on O
cimetidine B-drug
was O
not O
evaluated O
. O

However O
, O
in O
clinical O
studies O
the O
consequences O
of O
concomitant O
irbesartan B-drug
on O
the O
pharmacodynamics O
of O
warfarin B-drug
were O
negligible O
. O

When O
patients O
have O
received O
such O
drugs O
, O
the O
dose O
of O
INAPSINE B-brand
required O
will O
be O
less O
than O
usual O
. O

Pyrantel B-drug
( O
e.g. O
, O
Antiminth B-drug
) O
- O
Taking O
piperazine B-drug
and O
pyrantel B-drug
together O
may O
decrease O
the O
effects O
of O
piperazine B-drug
. O

The O
clinical O
significance O
of O
this O
observation O
is O
unknown O
. O

The O
administrative O
arrangements O
in O
an O
area O
of O
Scotland O
were O
accompanied O
by O
a O
300 O
% O
increase O
in O
the O
frequency O
of O
admissions O
for O
mania O
, O
whereas O
in O
an O
area O
of O
the O
West O
Midlands O
, O
a O
large O
decrease O
was O
achieved O
. O

However O
, O
it O
should O
be O
noted O
that O
both O
products O
are O
capable O
of O
producing O
transient O
increases O
in O
blood O
pressure O
. O

Probenecid B-drug
given O
concurrently O
increases O
naproxen B-drug
anion O
plasma O
levels O
and O
extends O
its O
plasma O
half-life O
significantly O
. O

Concomitant O
administration O
of O
ketoconazole B-drug
tablets O
with O
phenytoin B-drug
may O
alter O
the O
metabolism O
of O
one O
or O
both O
of O
the O
drugs O
. O

Adrenergic B-group
blockers I-group
Adrenergic I-group
blockers I-group
are O
inhibited O
by O
amphetamines B-group
. O

Since O
there O
have O
been O
conflicting O
results O
regarding O
the O
effect O
of O
digoxin B-drug
levels O
, O
it O
is O
recommended O
that O
digoxin B-drug
levels O
be O
monitored O
when O
initiating O
, O
adjusting O
, O
and O
discontinuing O
diltiazem B-drug
hydrochloride I-drug
therapy O
to O
avoid O
possible O
over- O
or O
under-digitalization O
. O

However O
, O
caution O
must O
be O
exercised O
in O
extrapolating O
these O
findings O
to O
the O
clinical O
situation O
and O
in O
the O
use O
of O
glipizide B-drug
with O
these O
drugs O
. O

The O
daily O
dose O
of O
dexamethasone B-drug
administered O
in O
clinical O
studies O
with O
Aprepitant B-drug
reflects O
an O
approximate O
50 O
% O
reduction O
of O
the O
dose O
of O
dexamethasone B-drug
. O

During O
controlled O
hypotensive O
anesthesia O
using O
labetalol B-drug
HCl I-drug
in O
association O
with O
halothane B-drug
, O
high O
concentrations O
( O
3 O
% O
or O
above O
) O
of O
halothane B-drug
should O
not O
be O
used O
because O
the O
degree O
of O
hypotension O
will O
be O
increased O
and O
because O
of O
the O
possibility O
of O
a O
large O
reduction O
in O
cardiac O
output O
and O
an O
increase O
in O
central O
venous O
pressure O
. O

It O
is O
desirable O
to O
monitor O
TCA B-group
plasma O
levels O
whenever O
a O
TCA B-group
is O
going O
to O
be O
co-administered O
with O
another O
drug O
known O
to O
be O
an O
inhibitor O
of O
P450 O
2D6 O
. O

Formal O
drug O
interaction O
studies O
with O
Abciximab B-drug
have O
not O
been O
conducted O
. O

Bosentan B-drug
had O
no O
relevant O
inhibitory O
effect O
on O
any O
CYP O
isoenzymes O
tested O
( O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP3A4 O
) O
. O

Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
frequently O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

indinavir I-drug
concentration O

- O
Lofexidine B-drug
may O
enhance O
the O
CNS O
depressive O
effects O
of O
alcohol B-drug
, O
barbiturates B-group
and O
other O
sedatives B-group

When O
s.c O
. O

Population O
pharmacokinetic O
analyses O
revealed O
that O
MTX B-drug
, O
NSAIDs B-group
, O
corticosteroids B-group
, O
and O
TNF B-group
blocking I-group
agents I-group
did O
not O
influence O
abatacept B-drug
clearance O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Carcinogenesis O
PEGASYS B-brand
has O
not O
been O
tested O
for O
its O
carcinogenic O
potential O
. O

Alosetron B-drug
also O
does O
not O
appear O
to O
induce O
CYP O
enzymes O
2E1 O
or O
2C19 O
. O

There O
is O
now O
strong O
evidence O
that O
intensive O
control O
of O
blood O
glucose O
can O
significantly O
reduce O
and O
retard O
the O
microvascular O
complications O
of O
retinopathy O
, O
nephropathy O
, O
and O
neuropathy O
. O

20 O
mg O
result O
in O
incomplete O
depletion O
which O
becomes O
complete O
after O
a O
second O
additional O
dose O
. O

Excessive O
widening O
of O
the O
QRS O
complex O
and/or O
prolongation O
of O
the O
Q-T O
interval O
may O
occur O
in O
these O
situations O
. O

These O
effects O
of O
calcium B-group
blockers I-group
on O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
could O
contribute O
in O
part O
to O
their O
efficacy O
in O
patients O
with O
ischemic O
heart O
disease O
. O

Antithrombotics B-group

pruritus O

Lovastatin B-drug

Palytoxin B-drug_n
( O
PTX B-drug_n
) O
, O
C129H223N3O54 O
, O
isolated O
from O
marine O
coelenterates O
of O
Palythoa O
tuberculosa O
, O
caused O
a O
first O
rapid O
contraction O
followed O
by O
the O
slow O
phasic O
contraction O
of O
guinea-pig O
vas O
deferens O
. O

If O
TRANXENE B-brand
tablets O
are O
used O
to O
treat O
anxiety O
associated O
with O
somatic O
disease O
states O
, O
careful O
attention O
must O
be O
paid O
to O
possible O
drug O
interaction O
with O
concomitant O
medication O
. O

Cancer O
chemotherapy O

Drugs O
Within O
Class O
Not O
To O
Be O
Coadministered O
With O
SUSTIVA B-brand

Every O
other O
day O
dosing O
with O
100m O
g/kg O
( O
1200m O
g/m2 O
) O
PEGASYS B-brand
( O
equivalent O
to O
approximately O
30 O
times O
the O
recommended O
human O
dose O
) O
had O
no O
effects O
on O
cycle O
duration O
or O
reproductive O
hormone O
status O
. O

Symptoms O
resolved O
when O
clonidine B-drug
was O
withdrawn O
and O
recurred O
when O
the O
patient O
was O
rechallenged O
with O
clonidine B-drug
. O

Rearrangements O
of O
genomes O
have O
been O
found O
to O
accompany O
cellular O
aging O
. O

Anagrelide B-drug
demonstrates O
some O
limited O
inhibitory O
activity O
towards O
CYP1A2 O
which O
may O
present O
a O
theoretical O
potential O
for O
interaction O
with O
other O
coadministered O
medicinal O
products O
sharing O
that O
clearance O
mechanism O
e.g O
. O
theophylline B-drug
. O

Cefuroxime B-drug
does O
not O
interfere O
with O
the O
assay O
of O
serum O
and O
urine O
creatinine O
by O
the O
alkaline O
picrate O
method O
. O

Because O
of O
the O
danger O
of O
a O
potentially O
fatal O
prolongation O
of O
the O
QTc O
interval O
, O
halofantrine B-drug
must O
not O
be O
given O
simultaneously O
with O
or O
subsequent O
to O
Mefloquine B-drug
. O

He O
was O
treated O
aggressively O
with O
intravenous O
hydration O
, O
sodium B-drug
bicarbonate I-drug
, O
and O
hemodialysis O
. O

Alcohol B-drug
, O
in O
particular O
, O
has O
been O
found O
to O
exhibit O
additive O
effects O
of O
this O
variety O
. O

indinavir I-drug
concentration O

Since O
the O
pharmacokinetics O
of O
BUSULFEX B-brand
were O
studied O
in O
patients O
treated O
with O
phenytoin B-drug
, O
the O
clearance O
of O
BUSULFEX B-brand
at O
the O
recommended O
dose O
may O
be O
lower O
and O
exposure O
( O
AUC O
) O
higher O
in O
patients O
not O
treated O
with O
phenytoin B-drug
. O

Effects O
of O
Other O
Antiepileptic B-group
Drugs I-group
on O
Felbatol B-brand
Phenytoin B-drug
: O
Phenytoin B-drug
causes O
an O
approximate O
doubling O
of O
the O
clearance O
of O
Felbatol B-brand
( O
felbamate B-drug
) O
at O
steady O
state O
and O
, O
therefore O
, O
the O
addition O
of O
phenytoin B-drug
causes O
an O
approximate O
45 O
% O
decrease O
in O
the O
steady-state O
trough O
concentrations O
of O
Felbatol B-brand
as O
compared O
to O
the O
same O
dose O
of O
Felbatol B-brand
given O
as O
monotherapy O
. O

[ O
Pharmacologic O
interactions O
in O
chronic O
treatments O
: O
corrective O
measures O
for O
its O
prevention O
in O
a O
basic O
area O
of O
rural O
health O
] O
OBJECTIVES O
: O
To O
identify O
the O
pharmacological O
interactions O
of O
clinical O
relevance O
( O
PICR O
) O
in O
the O
medication O
authorization O
cards O
( O
MAC O
) O
of O
the O
chronically O
ill O
and O
to O
establish O
strategies O
to O
minimise O
their O
appearance O
. O

As O
a O
result O
, O
drugs O
that O
are O
metabolized O
by O
these O
enzyme O
systems O
may O
have O
lower O
than O
expected O
plasma O
levels O
when O
coadministered O
with O
nevirapine B-drug
. O

General O
: O
In O
humans O
, O
valdecoxib B-drug
metabolism O
is O
predominantly O
mediated O
via O
CYP O
3A4 O
and O
2C9 O
with O
glucuronidation O
being O
a O
further O
( O
20 O
% O
) O
route O
of O
metabolism O
. O

International O
Normalized O
Ratio O
( O
INR O
) O
elevations O
and/or O
bleeding O
events O
have O
been O
reported O
in O
some O
patients O
taking O
warfarin B-drug
while O
on O
IRESSA B-brand
therapy O
. O

There O
have O
been O
case O
reports O
of O
increased O
steady-state O
levels O
of O
quinidine B-drug
, O
procainamide B-drug
, O
and O
phenytoin B-drug
during O
concomitant O
therapy O
with O
amiodarone B-drug
. O

Since O
1988 O
, O
it O
has O
been O
noted O
that O
incidence O
of O
melarsoprol B-drug
reaction O
had O
increased O
systematically O
between O
June O
and O
October O
of O
each O
year O
, O
indicating O
strong O
seasonal O
variation O
. O

Treatment O
plans O
for O
patients O
taking O
anticoagulants B-group
can O
become O
complicated O
. O

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
CLINISTIX O
or O
TES-TAPE O
) O
be O
used O
. O

Saquinavir I-drug

There O
is O
no O
evidence O
in O
animal O
or O
human O
studies O
that O
TORADOL B-brand
induces O
or O
inhibits O
hepatic O
enzymes O
capable O
of O
metabolizing O
itself O
or O
other O
drugs O

Coadministration O
of O
propoxyphene B-drug
decreased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-drug
by O
6 O
% O
, O
decreased O
clearance O
by O
38 O
% O
, O
and O
increased O
half-life O
by O
58 O
% O
. O

No O
formal O
interaction O
studies O
have O
been O
performed O
. O

A O
similar O
association O
, O
though O
less O
marked O
, O
has O
been O
suggested O
with O
barbiturates B-group
, O
phenyl-butazone O
, O
phenytoin B-drug
sodium I-drug
, O
carbamazepine B-drug
and O
possibly O
with O
griseofulvin B-drug
, O
ampicillin B-drug
, O
and O
tetracyclines B-group
( O
72 O
) O

Pharmacokinetic O
interaction O
between O
single O
oral O
doses O
of O
diltiazem B-drug
and O
sirolimus B-drug
in O
healthy O
volunteers O
. O

Resveratrol B-drug_n
( O
5-35 O
micromol/l O
) O
induced O
concentration-dependent O
relaxation O
of O
mesenteric O
arteries O
preconstricted O
with O
noradrenaline B-drug
( O
8 O
micromol/l O
) O
or O
KCl B-drug
( O
125 O
mmol/l O
) O
from O
both O
lean O
and O
dietary-obese O
rats O
. O

When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
significantly O
reduced O
. O

Clinical O
studies O
have O
shown O
that O
atorvastatin B-drug
does O
not O
reduce O
basal O
plasma O
cortisol O
concentration O
or O
impair O
adrenal O
reserve O
. O

CNS-Active O
Drugs O
Ethanol B-drug
An O
additive O
effect O
on O
psychomotor O
performance O
was O
seen O
with O
coadministration O
of O
eszopiclone B-drug
and O
ethanol B-drug
0.70 O
g/kg O
for O
up O
to O
4 O
hours O
after O
ethanol B-drug
administration O
. O

In O
response O
to O
cocaine B-drug
, O
the O
locomotor O
activities O
of O
the O
SST O
were O
not O
significantly O
different O
from O
the O
RBC O
group O
. O

In O
previous O
reports O
we O
have O
shown O
that O
ginsenosides B-drug_n
inhibit O
high O
threshold O
voltage-dependent O
Ca O
( O
2+ O
) O
channels O
in O
neuronal O
cells O
. O

oxyphenbutazone B-drug
; O

The O
plasma O
concentrations O
of O
bosentan B-drug
were O
not O
affected O
. O

Hypoglycemics B-group
and O
endocrine O
drugs O
. O

Antiarrhythmics B-group
: O
Amiodarone B-drug
, O
bepridil B-drug
, O
flecainide B-drug
, O
propafenone B-drug
, O
quinidine B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
. O

H2-Receptor B-group
Antagonists I-group
: O
Co-administration O
of O
a O
single O
dose O
of O
intravenously O
administered O
famotidine B-drug
( O
20 O
mg O
) O
reduced O
the O
oral O
absorption O
of O
a O
single O
400 O
mg O
dose O
of O
cefditoren B-drug
pivoxil I-drug
administered O
following O
a O
meal O
, O
as O
evidenced O
by O
a O
27 O
% O
decrease O
in O
mean O
Cmax O
and O
a O
22 O
% O
decrease O
in O
mean O
AUC O
. O

Everolimus B-drug
exposure-response O
relationships O
between O
area O
under O
the O
blood O
concentration-time O
curve O
( O
AUC O
) O
and O
changes O
in O
platelets O
, O
leukocytes O
, O
and O
lipids O
were O
explored O
with O
the O
median-effect O
model O
. O

Thus O
, O
patients O
should O
be O
cautioned O
about O
the O
use O
of O
such O
drugs O
concurrently O
with O
LEXAPRO B-brand
. O

Oils O
may O
enhance O
absorption O
. O

Drugs O
Highly O
Bound O
To O
Plasma O
Protein O
Eszopiclone B-drug
is O
not O
highly O
bound O
to O
plasma O
proteins O
( O
52-59 O
% O
bound O
) O
; O

however O
, O
a O
comparison O
of O
fluvastatin B-drug
administration O
with O
the O
evening O
meal O
or O
at O
bedtime O
has O
revealed O
no O
significant O
differences O
in O
the O
extent O
of O
bioavailability O
( O
area O
under O
the O
curve O
) O
of O
these O
two O
regimens O
. O

Patients O
receiving O
catecholamine-depleting O
drugs O
, O
such O
as O
reserpine B-drug
or O
guanethidine B-drug
, O
should O
be O
closely O
monitored O
, O
because O
the O
added O
beta-adrenergic O
blocking O
action O
of O
ZEBETA B-brand
may O
produce O
excessive O
reduction O
of O
sympathetic O
activity O
. O

The O
benefits O
and O
risks O
of O
using O
TRICOR B-brand
with O
immunosuppressants B-group
and O
other O
potentially O
nephrotoxic O
agents O
should O
be O
carefully O
considered O
, O
and O
the O
lowest O
effective O
dose O
employed O

The O
16,16-dimethylprostaglandin B-drug_n
E2 I-drug_n
( O
dmPGE2 B-drug_n
) O
-induced O
diarrhea O
was O
analyzed O
in O
cecectomized O
rats O
prepared O
by O
resecting O
the O
cecum O
and O
its O
vasculature O
without O
disturbing O
the O
ileocecal O
junction O
. O

In O
vitro O
studies O
in O
human O
liver O
microsomes O
suggest O
that O
decitabine B-drug
is O
unlikely O
to O
inhibit O
or O
induce O
cytochrome O
P450 O
enzymes O
. O

In O
one O
controlled O
study O
of O
175 O
patients O
, O
transient O
drowsiness O
was O
observed O
in O
63 O
% O
of O
those O
receiving O
baclofen B-drug
tablets O
compared O
to O
36 O
% O
of O
those O
in O
the O
placebo O
group O
. O

HMG-CoA B-drug
Reductase I-drug
Inhibitors I-drug
: O
Simvastatin B-drug
( O
CYP3A4 B-drug
substrate O
) O
in O
combination O
with O
amiodarone B-drug
has O
been O
associated O
with O
reports O
of O
myopathy/rhabdomyolysis O
. O

The O
majority O
of O
patients O
in O
rheumatoid O
arthritis O
or O
Crohn O
s O
disease O
clinical O
studies O
received O
one O
or O
more O
concomitant O
medications O
. O

Danazol B-drug
: O
The O
risk O
of O
myopathy/rhabdomyolysis O
is O
increased O
by O
concomitant O
administration O
of O
danazol B-drug
particularly O
with O
higher O
doses O
of O
lovastatin B-drug
( O
see O
WARNINGS O
, O
Myopathy/Rhabdomyolysis O
) O
. O

one-half O
the O
human O
dose O
on O
BSA O
) O
when O
administered O
during O
the O
period O
of O
organogenesis O
. O

Close O
observation O
of O
the O
patient O
is O
recommended O
when O
a O
beta-blocker B-group
is O
administered O
to O
patients O
receiving O
catecholamine-depleting O
drugs O
such O
as O
reserpine B-drug
, O
because O
of O
possible O
additive O
effects O
and O
the O
production O
of O
hypotension O
and/or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

These O
findings O
suggest O
that O
the O
phenotype O
of O
a O
tumor O
that O
results O
from O
a O
pulse O
of O
a O
chemical O
carcinogen O
may O
depend O
upon O
the O
target O
cell O
. O

Ergot B-group
Derivatives I-group
: O
Dihydroergotamine B-drug
, O
ergonovine B-drug
, O
ergotamine B-drug
, O
methylergonovine B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and O
life-threatening O
reactions O
such O
as O
acute O
ergot B-group
toxicity O
characterized O
by O
peripheral O
vasospasm O
and O
ischemia O
of O
the O
extremities O
and O
other O
tissues O
. O

Measurement O
of O
nociception O
was O
performed O
within O
2 O
h O
after O
benzodiazepine B-group
administration O
. O

Epirubicin B-drug
is O
extensively O
metabolized O
by O
the O
liver O
. O

After O
consumption O
of O
alcohol B-drug
, O
at O
least O
36 O
hours O
should O
elapse O
before O
these O
determinations O
are O
made O
. O

If O
it O
is O
necessary O
to O
continue O
the O
diuretic B-group
, O
provide O
close O
medical O
supervision O
after O
the O
initial O
dose O
for O
at O
least O
two O
hours O
and O
until O
blood O
pressure O
has O
stabilized O
for O
at O
least O
an O
additional O
hour.. O

The O
magnitude O
of O
these O
effects O
may O
depend O
on O
the O
duration O
of O
administration O
of O
the O
volatile O
agents O
. O

Phenytoin B-drug
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-drug
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
phenytoin B-drug
with O
or O
without O
other O
enzyme- O
inducing O
AEDs B-group
. O

In O
addition O
, O
we O
have O
shown O
that O
RR B-drug_n
is O
a O
useful O
pharmacological O
tool O
with O
which O
to O
examine O
the O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
-mediated O
responses O
of O
megakaryocytes O
. O

Conversely O
, O
the O
administration O
of O
STADOL B-brand
NS I-brand
( O
1 O
mg O
butorphanol B-drug
QID O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
a O
300-mg O
dose O
of O
cimetidine B-drug
. O

Rifabutin B-drug

The O
clinical O
effects O
of O
this O
combination O
have O
not O
been O
studied O
. O

No O
drug O
interactions O
have O
been O
reported O
. O

The O
next O
chapter O
presents O
information O
on O
efficacy O
and O
pregnancy O
outcomes O
in O
terms O
of O
pregnancy O
rates O
, O
compliance O
and O
efficacy O
, O
ectopic O
pregnancies O
, O
the O
outcome O
of O
pregnancies O
conceived O
while O
using O
POCs B-group
, O
and O
fertility O
following O
discontinuation O
. O

Interactions O
between O
Betaseron B-brand
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O

There O
have O
been O
no O
reported O
cases O
from O
spontaneous O
reports O
of O
drug O
interaction O
between O
SSRIs B-group
and O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
. O

increased O
bilirubin O

A O
small O
number O
of O
patients O
received O
epirubicin-based B-drug
chemotherapy O
concomitantly O
with O
radiation O
therapy O
but O
had O
chemotherapy O
interrupted O
in O
order O
to O
avoid O
potential O
overlapping O
toxicities O
. O

Laboratory O
Test O
In O
clinical O
trials O
, O
no O
clinically O
relevant O
laboratory O
test O
abnormalities O
were O
identified O
as O
causally O
related O
to O
drug O
during O
short-term O
treatment O
with O
guanfacine B-drug
. O

These O
reactions O
consisted O
of O
erythema O
, O
pruritus O
, O
and O
hypotension O
and O
occurred O
within O
hours O
of O
administration O
of O
chemotherapy O
. O

Although O
much O
statistical O
work O
has O
focused O
on O
developing O
mathematical O
functions O
to O
model O
the O
joint O
dose-response O
curves O
, O
relatively O
little O
work O
exists O
in O
regard O
to O
designing O
experiments O
for O
assessing O
joint O
action O
. O

PEGASYS B-brand
is O
recommended O
for O
use O
in O
women O
of O
childbearing O
potential O
only O
when O
they O
are O
using O
effective O
contraception O
during O
therapy O
. O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

Lithium B-drug
carbonate I-drug
( O
450 O
mg O
BID O
for O
7 O
days O
) O
had O
no O
effect O
on O
valdecoxib B-drug
pharmacokinetics O
. O

Lithium B-drug
salts O

therefore O
, O
these O
combinations O
should O
be O
used O
with O
caution O
. O

Phenobarbital B-drug

Vasospastic O
reactions O
have O
been O
reported O
with O
therapeutic O
doses O
of O
ergotamine-containing B-drug
drugs O
when O
co-administered O
with O
these O
antibiotics B-group
. O

Apparent O
oral O
clearance O
and O
volume O
of O
distribution O
of O
sirolimus B-drug
decreased O
with O
38 O
% O
and O
45 O
% O
, O
respectively O
, O
when O
sirolimus B-drug
was O
given O
with O
diltiazem B-drug
. O

The O
interaction O
of O
prostaglandin B-drug
F2alpha I-drug
and O
synthetic O
oxytocin B-drug
on O
placental O
vessels O
was O
studied O
in O
vitro O
. O

Urinary O
alkalinizing O
agents O
increase O
blood O
levels O
and O
decrease O
excretion O
of O
amphetamines B-group
. O

( O
500 O
mg O
day O
1 O
, O
250 O
mg O
QD O
4 O
days O
) O

METHODS O
: O
Hydrocortisone B-drug
( O
100 O
mg O
) O
and O
d-amphetamine B-drug
( O
20 O
mg O
) O
were O
administered O
orally O
to O
16 O
healthy O
male O
and O
female O
volunteers O
in O
a O
four-session O
, O
placebo-controlled O
, O
within-subject O
, O
crossover O
design O
. O

The O
world O
medical O
literature O
contains O
43 O
reports O
of O
deaths O
associated O
with O
amphetamines B-drug
in O
a O
35-year O
period O
. O

Cardiovasculars O
: O
Cardiac B-drug
glycosides I-drug
: O
In O
patients O
receiving O
digoxin B-drug
therapy O
, O
administration O
of O
oral O
amiodarone B-drug
regularly O
results O
in O
an O
increase O
in O
serum O
digoxin B-drug
concentration O
that O
may O
reach O
toxic O
levels O
with O
resultant O
clinical O
toxicity O
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7 O
to O
10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O

New O
oral O
therapies O
for O
type O
2 O
diabetes O
mellitus O
: O
The O
glitazones B-group
or O
insulin O
sensitizers O
. O

CONCLUSIONS O
: O
In O
contrast O
to O
the O
effects O
of O
glucocorticoids B-group
in O
rodent O
studies O
, O
these O
results O
indicate O
that O
an O
acute O
increase O
in O
cortisol O
does O
not O
enhance O
the O
psychostimulant O
effects O
of O
d-amphetamine B-drug
in O
humans O
. O

In O
addition O
, O
ketoconazole B-drug
alone O
can O
inhibit O
adrenal O
corticosteroid B-drug
synthesis O
and O
may O
cause O
adrenal O
insufficiency O
during O
corticosteroid O
withdrawal O
. O

Aspirin B-brand
: O
Concomitant O
administration O
of O
diclofenac B-drug
and O
aspirin B-brand
is O
not O
recommended O
because O
diclofenac B-drug
is O
displaced O
from O
its O
binding O
sites O
during O
the O
concomitant O
administration O
of O
aspirin B-brand
, O
resulting O
in O
lower O
plasma O
concentrations O
, O
peak O
plasma O
levels O
, O
and O
AUC O
values O
. O

The O
clearance O
of O
benzodiazepines B-group
metabolized O
by O
glucuronidation O
( O
e. O
g. O
, O
lorazepam B-drug
, O
oxazepam B-drug
, O
temazepam B-drug
) O
is O
unlikely O
to O
be O
affected O
by O
fluvoxamine B-drug
. O

The O
pharmacokinetics O
of O
benzodiazepines B-group
are O
unaltered O
in O
the O
presence O
of O
flumazenil B-drug
and O
vice O
versa O
. O

however O
, O
the O
clinical O
significance O
is O
unknown O
. O

Other O
: O
Neither O
fosinopril B-drug
sodium I-drug
nor O
its O
metabolites O
have O
been O
found O
to O
interact O
with O
food O
. O

On O
the O
basis O
of O
this O
specificity O
we O
describe O
a O
simple O
and O
reliable O
affinity O
chromatography O
procedure O
for O
the O
purification O
of O
both O
human O
serum O
and O
colostrum O
IgA O
. O

and O
disulfiram B-drug
When O
amitriptyline B-drug
HCl I-drug
is O
given O
with O
anticholinergic B-drug
agents O
or O
sympathomimetic B-drug
drugs O
, O
including O
epinephrine B-drug
combined O
with O
local O
anesthetics B-drug
, O
close O
supervision O
and O
careful O
adjustment O
of O
dosages O
are O
required O
. O

Rifabutin B-drug
: O
Coadministration O
of O
rifabutin B-drug
and O
VIRACEPT B-brand
resulted O
in O
a O
32 O
% O
decrease O
in O
nelfinavir B-drug
plasma O
AUC O
and O
a O
207 O
% O
increase O
in O
rifabutin B-drug
plasma O
A.C O
. O

while O
no O
formal O
interaction O
studies O
have O
been O
conducted O
, O
no O
interactions O
were O
observed O
. O

Food O
has O
no O
clinically O
significant O
effect O
on O
the O
bioavailability O
of O
anagrelide B-drug
. O

Although O
no O
studies O
have O
been O
conducted O
, O
concomitant O
administration O
of O
Itraconazole B-drug
and O
phenytoin B-drug
may O
alter O
the O
metabolism O
of O
phenytoin B-drug
; O

Established O
Drug O
Interactions O
( O
continued O
) O

Potassium-sparing B-group
diuretics I-group
( O
e.g. O
, O
spironolactone B-drug
, O
triamterene B-drug
, O
or O
amiloride B-drug
) O
, O
potassium B-drug
supplements O
, O
or O
potassium-containing B-drug
salt O
substitutes O
may O
lead O
to O
significant O
increases O
in O
serum O
potassium O
. O

This O
observed O
increase O
in O
the O
bioavailability O
of O
fexofenadine B-drug
may O
be O
due O
to O
transport-related O
effects O
, O
such O
as O
p-glycoprotein O
. O
in O
vivo O
animal O
studies O
also O
suggest O
that O
in O
addition O
to O
enhancing O
absorption O
, O
ketoconazole B-drug
decreases O
fexofenadine B-drug
gastrointestinal O
secretion O
, O
while O
erythromycin B-drug
may O
also O
decrease O
biliary O
excretion O
. O

No O
pharmacokinetic O
drug-drug O
interaction O
studies O
were O
conducted O
with O
PERSANTINE B-brand
( O
dipyridamole B-drug
USP O
) O
Tablets O
. O

There O
is O
no O
experience O
with O
co-administration O
of O
Angiomax B-brand
and O
plasma O
expanders O
such O
as O
dextran B-drug
. O

On O
the O
ninth O
day O
, O
the O
rats O
were O
sacrificed O
and O
aortic O
rings O
, O
with O
or O
without O
endothelium O
, O
were O
used O
to O
generate O
concentration-response O
curves O
to O
noradrenaline B-drug
. O

At O
stable O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
concentrations O
greater O
than O
1 O
mM O
, O
fractional O
mucosal O
cell O
accumulation O
of O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
remains O
constant O
, O
while O
fractional O
transfer O
to O
the O
body O
declines O
. O

Although O
there O
is O
little O
published O
information O
on O
concomitant O
administration O
of O
lidocaine B-drug
and O
Bretylium B-drug
Tosylate I-drug
, O
these O
drugs O
are O
often O
administered O
concurrently O
without O
any O
evidence O
of O
interactions O
resulting O
in O
adverse O
effects O
or O
diminished O
efficacy O
. O

Plenaxis B-brand
is O
highly O
bound O
to O
plasma O
proteins O
( O
96 O
to O
99 O
% O
) O
. O

The O
concurrent O
use O
of O
tetracycline B-drug
and O
Penthrane B-brand
( O
methoxyflurane B-drug
) O
has O
been O
reported O
to O
result O
in O
fatal O
renal O
toxicity O
. O

Increased O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-group
and O
aminoglycoside B-group
antibiotics I-group
. O

with O
divalent O
or O
trivalent O
cations O
such O
as O
iron B-drug
; O

Patients O
response O
to O
oral O
anticoagulants B-group
may O
be O
affected O
by O
his/her O
thyroid O
and O
metabolic O
status O
. O

However O
, O
the O
relationship O
to O
nifedipine B-drug
therapy O
is O
uncertain O
. O

Cimetidine B-drug
increased O
AUC O
by O
about O
30 O
% O
but O
caused O
no O
change O
in O
Cmax O
. O

Clinically O
significant O
QTc O
prolongation O
has O
not O
been O
found O
with O
Mefloquineuine O
alone O
. O

Acute O
effect O
of O
different O
antidepressants B-group
on O
glycemia O
in O
diabetic O
and O
non-diabetic O
rats O
. O

In O
a O
separate O
study O
, O
baboons O
given O
3 O
doses O
of O
alefacept B-drug
at O
1 O
mg/kg O
every O
8 O
weeks O
were O
found O
to O
have O
centroblast O
proliferation O
in O
B-cell O
dependent O
areas O
in O
the O
germinal O
centers O
of O
the O
spleen O
following O
a O
116-day O
washout O
period O
. O

Nevirapine I-drug

Although O
there O
was O
no O
effect O
of O
Aprepitant B-drug
on O
the O
plasma O
AUC O
of O
R O
( O
+ O
) O
or O
S B-drug
( I-drug
- I-drug
) I-drug
warfarin I-drug
determined O
on O
Day B-drug
3 I-drug
, I-drug
there O
was O
a O
34 O
% O
decrease O
in O
S B-drug
( I-drug
- I-drug
) I-drug
warfarin I-drug
( O
a O
CYP2C9 O
substrate O
) O
trough O
concentration O
accompanied O
by O
a O
14 O
% O
decrease O
in O
the O
prothrombin O
time O
( O
reported O
as O
International O
Normalized O
Ratio O
or O
INR O
) O
5 O
days O
after O
completion O
of O
dosing O
with O
Aprepitant B-drug
. O

influenza B-group
virus I-group
vaccine I-group
; O

This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-drug
and O
a O
prolongation O
of O
its O
plasma O
half-life O
. O

Naproxen B-drug
and O
other O
NSAIDs B-group
can O
reduce O
the O
antihypertensive O
effect O
of O
propranolol B-drug
and O
other O
beta-blockers B-group
. O

Routine O
monitoring O
should O
be O
performed O
when O
therapy O
with O
BEXTRA B-brand
is O
either O
initiated O
or O
discontinued O
in O
patients O
on O
anticonvulsant O
therapy O
. O

These O
cephalosporins B-group
are O
inhibitors O
of O
hepatic O
vitamin O
K O
epoxide O
reductase O
. O

CONCLUSION O
: O
Fluvoxamine B-drug
is O
a O
moderate O
inhibitor O
of O
CYP2C9 O
in O
vivo O
. O

Calcium B-drug
, O
particularly O
if O
administered O
rapidly O
by O
the O
intravenous O
route O
, O
may O
produce O
serious O
arrhythmias O
in O
digitalized O
patients O
. O

Dextromethorphan B-drug
: O
Dextromethorphan B-drug
is O
primarily O
metabolized O
by O
CYP O
2D6 O
and O
to O
a O
lesser O
extent O
by O
3A4 O
. O

Didanosine B-drug

However O
, O
preliminary O
results O
from O
an O
8-week O
trial O
showed O
comparable O
cognitive O
enhancing O
effects O
of O
olanzapine B-drug
and O
risperidone B-drug
treatment O
in O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
. O

The O
physician O
should O
be O
alert O
for O
possible O
combined O
drug O
actions O
, O
desirable O
or O
undesirable O
, O
involving O
ifosfamide B-drug
even O
though O
ifosfamide B-drug
has O
been O
used O
successfully O
concurrently O
with O
other O
drugs O
, O
including O
other O
cytotoxic O
drugs O
. O

Population O
pharmacokinetic O
studies O
showed O
higher O
concentrations O
of O
cilostazol B-drug
among O
patients O
concurrently O
treated O
with O
diltiazem B-drug
, O
an O
inhibitor O
of O
C.P.A.. O

Lithium B-drug
: O
generally O
should O
not O
be O
given O
with O
diuretics B-group
. O

Antihistamines B-group
: O
Benzodiazepines B-group
GI O
Motility O
Agents O
Anti-Migraine B-group
Antifungal I-group

Cimetidine B-drug
treatment O
should O
be O
stopped O
during O
treatment O
with O
ELLENCE B-brand
. O

Propoxyphene B-drug
: O
The O
concurrent O
administration O
of O
propoxyphene B-drug
hydrochloride I-drug
does O
not O
affect O
the O
bioavailability O
of O
meclofenamate B-drug
sodium I-drug
. O

Alcohol B-drug
, O
barbiturates B-group
, O
or O
narcotics B-group
: O
potentiation O
of O
orthostatic O
hypotension O
may O
occur O
. O

. O

The O
120 O
mg/kg O
dose O
resulted O
in O
a O
systemic O
exposure O
approximately O
16 O
times O
the O
human O
plasma O
area-under-the-curve O
( O
AUC O
, O
0-24 O
hours O
) O
based O
on O
the O
maximum O
human O
dose O
of O
80 O
mg/day O
. O

This O
should O
be O
considered O
whenever O
these O
agents O
are O
prescribed O
concomitantly O
. O

Effect O
of O
rofecoxib B-drug
on O
the O
pharmacokinetics O
of O
digoxin B-drug
in O
healthy O
volunteers O
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactam B-group
antibiotics I-group
, O
renal O
excretion O
of O
loracarbef B-drug
is O
inhibited O
by O
probenecid B-drug
and O
resulted O
in O
an O
approximate O
80 O
% O
increase O
in O
the O
AUC O
for O
loracarbef B-drug
. O

Plasma O
exposure O
( O
AUC O
) O
to O
valdecoxib B-drug
was O
increased O
62 O
% O
when O
coadministered O
with O
fluconazole B-drug
and O
38 O
% O
when O
coadministered O
with O
ketoconazole B-drug
. O

Cyclosporine B-drug

vardenafil I-drug
concentration O

Interaction O
with O
central B-group
nervous I-group
system I-group
depressants I-group
other O
than O
benzodiazepines B-group
has O
not O
been O
specifically O
studied O
; O

Ketoconazole B-drug
did O
not O
affect O
the O
conversion O
of O
losartan B-drug
to O
the O
active O
metabolite O
after O
intravenous O
administration O
of O
losartan B-drug
, O
and O
erythromycin B-drug
had O
no O
clinically O
significant O
effect O
after O
oral O
administration O
. O

Antidepressants B-group
, O
tricyclic B-group
: O
Amphetamines B-group
may O
enhance O
the O
activity O
of O
tricyclic B-group
or O
sympathomimetic B-group
agents I-group
; O

Anagrelide B-drug
alone O
had O
no O
effect O
on O
platelet O
aggregation O
, O
but O
did O
slightly O
enhance O
the O
inhibition O
of O
platelet O
aggregation O
by O
aspirin B-brand
. O

Substantial O
intercurrent O
ethanol B-drug
use O
was O
present O
in O
each O
of O
these O
cases O
, O
and O
this O
may O
have O
contributed O
to O
the O
abnormalities O
seen O
. O

Therefore O
, O
concurrent O
use O
of O
aspirin B-brand
and O
ketoprofen B-drug
is O
not O
recommended O
. O

Tablets O
: O
The O
benzodiazepines B-group
, O
including O
lorazepam B-drug
, O
produce O
CNS-depressant O
effects O
when O
administered O
with O
such O
medications O
as O
barbiturates B-group
or O
alcohol B-drug
. O

The O
first O
test O
is O
obtained O
by O
the O
prescriber O
when O
the O
decision O
is O
made O
to O
pursue O
qualification O
of O
the O
patient O
for O
Accutane B-brand
( O
a O
screening O
test O
) O
. O

High O
oral O
magnesium B-drug
doses O
besides O
their O
laxative O
action O
may O
bring O
latent O
complications O
which O
may O
reduce O
lifespan O
. O

phenylbutazone B-drug
; O

Drug/Laboratory O
Test O
Interaction O
Because O
Xigris B-brand
may O
affect O
the O
APTT O
assay O
, O
Xigris B-brand
present O
in O
plasma O
samples O
may O
interfere O
with O
one-stage O
coagulation O
assays O
based O
on O
the O
APTT O
( O
such O
as O
factor O
VIII O
, O
IX O
, O
and O
XI O
assays O
) O
. O

Methenamine B-drug
therapy O
: O
Urinary O
excretion O
of O
amphetamines B-group
is O
increased O
, O
and O
efficacy O
is O
reduced O
, O
by O
acidifying B-group
agents I-group
used O
in O
methenamine B-drug
therapy O
. O

Rifampin B-drug
: O
Rifampin B-drug
increases O
the O
metabolism O
of O
ethinyl B-drug
estradiol I-drug
and O
some O
progestins B-group
( O
norethindrone B-drug
) O
resulting O
in O
decreased O
contraceptive O
effectiveness O
and O
increased O
menstrual O
irregularities O
. O

Potentiation O
of O
coumarin-type B-group
anticoagulants I-group
has O
been O
observed O
with O
prolongation O
of O
the O
prothrombin O
time/INR O
. O

Further O
, O
misoprostol B-drug
is O
reported O
to O
have O
a O
synergistic O
effect O
with O
this O
combination O
in O
ameliorating O
intestinal O
permeability O
. O

Phenothiazines B-group
- O
Taking O
piperazine B-drug
and O
a O
phenothiazine B-group
together O
may O
increase O
the O
risk O
of O
convulsions O
( O
seizures O
) O
. O

However O
, O
cohort O
data O
and O
selected O
patient O
data O
from O
clinical O
trials O
suggest O
comparable O
activity O
to O
PI-based B-group
regimens O
in O
these O
patients O
. O

Dicumarol B-drug
: O
It O
has O
been O
reported O
that O
allopurinol B-drug
prolongs O
the O
half-life O
of O
the O
anticoagulant B-group
, O
dicumarol B-drug
. O

Aspirin B-brand
: O
Concomitant O
administration O
of O
aspirin B-brand
with O
valdecoxib B-drug
may O
result O
in O
an O
increased O
risk O
of O
GI O
ulceration O
and O
complications O
compared O
to O
valdecoxib B-drug
alone O
. O

as O
such O
it O
may O
impair O
intestinal O
absorption O
of O
any O
of O
vitamin B-group
D I-group
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
the O
changes O
in O
the O
Kd O
of O
D2 O
in O
the O
NAC O
and O
the O
Bmax O
of O
D2 O
in O
the O
STR O
may O
contribute O
to O
the O
differences O
in O
locomotor O
responses O
to O
cocaine B-drug
exposure O
in O
these O
mouse O
lines O
. O

Barbiturates B-group
may O
decrease O
the O
effectiveness O
of O
oral O
contraceptives B-group
, O
certain O
antibiotics B-group
, O
quinidine B-drug
, O
theophylline B-drug
, O
corticosteroids B-group
, O
anticoagulants B-group
, O
and O
beta B-group
blockers I-group
. O

Glucose B-drug
, O
alone O
and O
in O
the O
presence O
of O
theophylline B-drug
, O
caused O
subnormal O
insulin O
release O
and O
less O
suppression O
of O
glucagon O
release O
in O
the O
diabectics O
than O
in O
the O
normals O
. O

Nucleophosmin/B23 O
in O
serum-deprived O
( O
0 O
% O
serum O
) O
NIH-3T3 O
cells O
was O
found O
to O
be O
highly O
unstable O
with O
a O
half-life O
less O
than O
4 O
h O
. O

Although O
deferasirox B-drug
has O
a O
lower O
affinity O
for O
aluminum B-drug
than O
for O
iron B-drug
, O
Exjade B-brand
should O
not O
be O
taken O
with O
aluminum-containing B-drug
antacid B-group
preparations I-group
. O

However O
, O
under O
certain O
circumstances O
, O
e.g. O
, O
as O
prophylaxis O
after O
myocardial O
infarction O
, O
there O
may O
be O
no O
acceptable O
alternatives O
to O
the O
use O
of O
beta-blockers B-group
in O
patients O
with O
COPD O
. O

Concomitant O
use O
of O
clozapine B-drug
with O
other O
drugs O
metabolized O
by O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
clozapine B-drug
or O
the O
other O
drug O
. O

increased O
serum O
triglyceride O
and O
phospholipid O
concentration O
. O

Digoxin B-drug
: O
Digoxin B-drug
concentrations O
are O
increased O
by O
about O
15 O
% O
when O
digoxin B-drug
and O
carvedilol B-drug
are O
administered O
concomitantly O
. O

This O
drug O
may O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-group
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-group
) O
. O

Patients O
receiving O
both O
drugs O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic O
and/or O
antihypertensive O
effect O
of O
furosemide B-drug
is O
achieved O
. O

Patients O
should O
not O
be O
re-treated O
with O
subsequent O
cycles O
of O
TAXOL B-brand
until O
neutrophils O
recover O
to O
a O
level O
1500 O
cells/mm3 O
and O
platelets O
recover O
to O
a O
level O
100,000 O
cells/mm3 O
. O

Anabolic B-group
steroids I-group
( O
particularly O
C-17 O
alkylated O
androgens B-group
such O
as O
oxymetholone B-drug
, O
methandrostenolone B-drug
, O
norethandrolone B-drug
, O
and O
similar O
compounds O
) O
enhanced O
tendency O
toward O
edema O
. O

Physicians O
are O
provided O
this O
information O
to O
increase O
awareness O
of O
the O
potential O
for O
serious O
interactions O
when O
cinoxacin B-drug
and O
certain O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
are O
administered O
concomitantly O
. O

Furthermore O
, O
no O
significant O
difference O
in O
pharmacodynamic O
effect O
( O
reduction O
in O
low-density O
lipoprotein O
cholesterol O
levels O
) O
could O
be O
ascertained O
between O
mealtime O
dosing O
and O
bedtime O
dosing O
. O

5 O
. O

In O
diabetic O
patients O
, O
the O
metabolic O
effects O
of O
androgens B-group
may O
decrease O
blood O
glucose O
and O
therefore O
, O
insulin B-drug
requirements O
. O

The O
incidence O
of O
hypertriglyceridemia O
is O
1 O
patient O
in O
4 O
on O
Accutane B-brand
therapy O

Dexamethasone B-drug
and O
retinyl B-drug
acetate I-drug
similarly O
inhibit O
and O
stimulate O
EGF- B-drug_n
or O
insulin-induced B-drug
proliferation O
of O
prostatic O
epithelium O
. O

Cold O
and O
flu O
remedies O
. O

Diflunisal B-drug
decreased O
the O
hyperuricemic O
effect O
of O
furosemide B-drug
. O

No O
other O
pharmacokinetic O
parameters O
were O
changed O
. O

Use O
of O
Antithrombotics B-group
Aspirin B-brand
and O
heparin B-drug
have O
been O
administered O
concomitantly O
with O
and O
following O
infusions O
of O
Activase B-brand
in O
the O
management O
of O
acute O
myocardial O
infarction O
or O
pulmonary O
embolism O
. O

The O
results O
from O
a O
study O
in O
which O
eight O
HIV-infected O
individuals O
were O
treated O
with O
zidovudine B-drug
, O
8 O
+/- O
0.4 O
mg/kg/day O
, O
showed O
that O
the O
pharmacokinetics O
of O
zidovudine B-drug
were O
not O
affected O
during O
concomitant O
administration O
of O
Itraconazole B-drug
, O
100 O
mg O
b.i.d O
. O

The O
concomitant O
administration O
of O
quinolones B-group
including O
norfloxacin B-drug
with O
glyburide B-drug
( O
a O
sulfonylurea B-group
agent I-group
) O
has O
, O
on O
rare O
occasions O
, O
resulted O
in O
severe O
hypoglycemia O
. O

Phenytoin B-drug
may O
also O
cause O
increased O
serum O
concentrations O
of O
glucose O
, O
alkaline O
phosphatase O
, O
and O
gamma O
glutamyl O
transpeptidase O
( O
GGT O
) O
. O

The O
risk O
of O
metabolic O
interactions O
caused O
by O
an O
effect O
on O
an O
individual O
isoform O
is O
therefore O
minimized O
. O

" O
hippocampal-independent O
" O

Repeated O
doses O
of O
colestipol B-drug
hydrochloride I-drug
given O
prior O
to O
a O
single O
dose O
of O
propranolol B-drug
in O
human O
trials O
have O
been O
reported O
to O
decrease O
propranolol B-drug
absorption O
. O

Acetaminophen B-drug
and O
methotrexate B-drug
- O
L-methionine B-drug
may O
decrease O
hepatic O
toxicity O
in O
those O
with O
acetaminophen B-drug
overdosage O
or O
in O
those O
taking O
methotrexate B-drug
. O

Cholestyramine B-drug
and O
Charcoal B-drug
Administration O
of O
cholestyramine B-drug
or O
activated B-drug
charcoal I-drug
in O
patients O
( O
n=13 O
) O
and O
volunteers O
( O
n=96 O
) O
resulted O
in O
a O
rapid O
and O
significant O
decrease O
in O
plasma O
M1 O
( O
the O
active O
metabolite O
of O
leflunomide B-drug
) O
concentration O
. O

In O
some O
patients O
, O
combined O
use O
of O
INDOCIN B-brand
and O
diflunisal B-drug
has O
been O
associated O
with O
fatal O
gastrointestinal O
hemorrhage O
. O

- O
Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
may O
reduce O
the O
efficacy O
of O
lofexidine B-drug
. O

Furosemide B-drug
may O
add O
to O
or O
potentiate O
the O
therapeutic O
effect O
of O
other O
antihypertensive B-group
drugs I-group
. O

dosage O
adjustments O
may O
be O
necessary O
. O
) O

Synergism O
was O
observed O
when O
GL B-drug_n
was O
combined O
with O
cefazolin B-drug
against O
Bacillus O
subtilis O
and O
Klebsiella O
oxytoca O
. O

Etonogestrel B-drug
may O
interact O
with O
the O
following O
medications O
: O
acetaminophen B-drug
( O
Tylenol B-brand
) O
, O
antibiotics B-group
such O
as O
ampicillin B-drug
and O
tetracycline B-drug
, O
anticonvulsants B-group
( O
Dilantin B-brand
, O
Phenobarbital B-drug
, O
Tegretol B-brand
, O
Trileptal B-brand
, O
Topamax B-brand
, O
Felbatol B-brand
) O
, O
antifungals B-group
( O
Gris-PEG B-brand
, O
Nizoral B-brand
, O
Sporanox B-brand
) O
, O
atorvastatin B-drug
( O
Lipitor B-brand
) O
, O
clofibrate B-drug
( O
Atromid-S B-brand
) O
, O
cyclosporine B-drug
( O
Neoral B-brand
, O
Sandimmune B-brand
) O
, O
HIV O
drugs O
classified O
as O
protease B-group
inhibitors I-group
( O
Agenerase B-brand
, O
Crixivan B-brand
, O
Fortovase B-brand
, O
Invirase B-brand
, O
Kaletra B-brand
, O
Norvir B-brand
, O
Viracept B-brand
) O
, O
morphine B-drug
( O
Astramorph B-brand
, O
Kadian B-brand
, O
MS B-brand
Contin I-brand
) O
, O
phenylbutazone B-drug
, O
prednisolone B-drug
( O
Prelone B-brand
) O
, O
rifadin B-brand
( O
rifampin B-drug
) O
, O
St. O
Johns O
wort O
, O
temazepam B-drug
, O
theophylline B-drug
( O
Theo-Dur B-brand
) O
, O
and O
vitamin B-drug
C I-drug
. O

The O
three O
study O
periods O
were O
separated O
by O
a O
21-day O
washout O
phase O
. O

Nephrotoxic O
agents O
: O
Concomitant O
administration O
of O
VISTIDE B-brand
and O
agents O
with O
nephrotoxic O
potential O
[ O
e.g. O
, O
intravenous O
aminoglycosides B-group
( O
e.g. O
, O
tobramycin B-drug
, O
gentamicin B-drug
, O
and O
amikacin B-drug
) O
, O
amphotericin B-drug
B I-drug
, O
foscarnet B-drug
, O
intravenous O
pentamidine B-drug
, O
vancomycin B-drug
, O
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
] O
is O
contraindicated O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
aluminum O
and O
magnesium B-drug
hydroxides O
does O
not O
interfere O
with O
absorption B-drug
of O
meclofenamate B-drug
sodium I-drug
. O

Tell O
your O
doctor O
if O
you O
are O
taking O
any O
of O
the O
following O
drugs O
: O
blood B-group
thinners O
( O
Coumadin B-brand
) O
other O
antidepressants B-group
metoprolol B-drug
antihistamines B-group
carbamazepine B-drug
( O
Tegretol B-brand
) O
cimetidine B-drug
( O
Tagamet B-brand
) O
estrogens B-group
fluoxetine B-drug
( O
Prozac B-brand
) O
intraconazole O
( O
Sporanox B-brand
) O
ketoconazole B-drug
( O
Nizoral B-brand
) O
levodopa B-drug
lithium I-drug
muscle B-group
relaxants I-group
birth O
control O
pills O
sleeping O
pills O
thyroid O
medications O

and/or O
Drug/Laboratory O
Test O
Interactions O
See O
CLINICAL O
PHARMACOLOGY O
, O
Pharmacokinetics O
and O
Drug O
Interactions O
. O

Furosemide B-drug
should O
not O
be O
used O
concomitantly O
with O
ethacrynic B-drug
acid I-drug
because O
of O
the O
possibility O
of O
ototoxicity O
. O

Vitamin B-group
D I-group
: O
The O
coadministration O
of O
any O
of O
the O
vitamin B-group
D I-group
analogues I-group
should O
be O
avoided O
as O
this O
could O
create O
possible O
additive O
effects O
and O
hypercalcemia O
. O

A O
variety O
of O
neurological O
toxic O
effects O
and O
malignant O
hyperpyrexia O
can O
occur O
, O
sometimes O
with O
fatal O
results O
. O

No O
information O
is O
available O
about O
the O
interaction O
of O
cephalexin B-drug
and O
metformin B-drug
following O
multiple O
doses O
of O
either O
drug O
. O

The O
groups O
then O
took O
500 O
mg O
of O
tolbutamide B-drug
as O
a O
single O
dose O
( O
day O
0 O
) O
. O

Indinavir B-drug

When O
other O
potent O
parental O
antihypertensive B-group
drugs I-group
, O
such O
as O
diazoxide B-drug
, O
are O
used O
in O
combination O
with O
hydralazine B-drug
, O
patients O
should O
be O
continuously O
observed O
for O
several O
hours O
for O
any O
excessive O
fall O
in O
blood O
pressure O
. O

Agents O
Increasing O
Serum O
Potassium O
: O
PRINIVIL B-brand
attenuates O
potassium O
loss O
caused O
by O
thiazide-type B-group
diuretics I-group
. O

Effects O
were O
already O
seen O
with O
doses O
corresponding O
to O
relevant O
plasma O
levels O
in O
humans O
, O
and O
the O
intracellular O
phosphorylation O
of O
zalcitabine B-drug
to O
its O
three O
metabolites O
( O
including O
the O
active O
zalcitabine O
triphosphate O
metabolite O
) O
was O
significantly O
inhibited O
. O

In O
the O
large O
, O
placebo-controlled O
osteoporosis O
Treatment O
Study O
, O
aspirin B-brand
and O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
were O
taken O
by O
62 O
% O
of O
the O
2946 O
patients O
. O

Certain O
drugs O
including O
thiazides B-group
, O
corticosteroids B-group
, O
thyroid B-group
products I-group
, O
and O
sympathomimetics B-group
may O
reduce O
the O
hypoglycemic O
action O
of O
Starlix B-brand
and O
other O
oral O
antidiabetic B-group
drugs I-group
. O

Neuromuscular B-group
Blockers I-group
: O
In O
one O
study O
of O
10 O
healthy O
volunteers O
, O
administration O
of O
PRECEDEX B-brand
for O
45 O
minutes O
at O
a O
plasma O
concentration O
of O
1 O
( O
one O
) O
ng/mL O
resulted O
in O
no O
clinically O
meaningful O
increases O
in O
the O
magnitude O
or O
neuromuscular O
blockade O
associated O
with O
rocuronium B-drug
administration O
. O

A O
variety O
of O
parametric O
dose-response O
models O
based O
on O
either O
the O
normal O
or O
logistic O
probability O
distribution O
have O
been O
proposed O
in O
the O
literature O
. O

Drugs O
with O
parasympathomimetic O
effects O
administered O
concurrently O
with O
cevimeline B-drug
can O
be O
expected O
to O
have O
additive O
effects O
. O

Thus O
, O
concomitant O
therapy O
with O
warfarin B-drug
and O
Lodine B-brand
should O
not O
require O
dosage O
adjustment O
of O
either O
drug O
. O

A O
study O
in O
14 O
normal O
male O
and O
female O
volunteers O
suggests O
that O
coadministration O
of O
cisapride B-drug
and O
ketoconazole B-drug
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

The O
IC O
( O
50 O
) O
was O
about O
120 O
microgram/ml O
. O

- O
Phenothiazines B-group
( O
acetophenazine B-drug
[ O
e.g. O
, O
Tindal B-brand
] O
, O
chlorpromazine B-drug
[ O
e.g. O
, O
Thorazine B-brand
] O
, O
fluphenazine B-drug
[ O
e.g. O
, O
Prolixin B-brand
] O
, O
mesoridazine B-brand
[ O
e.g. O
, O
Serentil B-brand
] O
, O
perphenazine B-drug
[ O
e.g. O
, O
Trilafon B-brand
] O
, O
prochlorperazine B-drug
[ O
e.g. O
, O
Compazine B-brand
] O
, O
promazine B-drug
[ O
e.g. O
, O
Sparine B-brand
] O
, O
promethazine B-drug
[ O
e.g. O
, O
Phenergan B-brand
] O
, O
thioridazine B-drug
[ O
e.g. O
, O
Mellaril B-brand
] O
, O
trifluoperazine B-drug
[ O
e.g. O
, O
Stelazine B-brand
] O
, O
triflupromazine B-drug
[ O
e.g. O
, O
Vesprin B-brand
] O
, O
trimeprazine B-drug
[ O
e.g. O
, O
Temaril B-brand
] O
) O
or O

Drug/Laboratory O
Test O
Interactions O
Finasteride B-drug
had O
no O
effect O
on O
circulating O
levels O
of O
cortisol O
, O
thyroid-stimulating O
hormone O
, O
or O
thyroxine O
, O
nor O
did O
it O
affect O
the O
plasma O
lipid O
profile O
( O
e.g. O
, O
total O
cholesterol O
, O
low-density O
lipoproteins O
, O
high-density O
lipoproteins O
and O
triglycerides O
) O
or O
bone O
mineral O
density O
. O

Some O
quinolones B-group
, O
including O
ciprofloxacin B-drug
, O
have O
also O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

Simultaneous O
administration O
of O
SPRYCEL B-brand
with O
antacids B-group
should O
be O
avoided O
. O

procainamide B-drug
; O

Your O
doctor O
or O
pharmacist O
can O
give O
you O
more O
information O
on O
MAO B-group
inhibitors I-group
. O

Clonidine B-drug
hydrochloride I-drug
may O
enhance O
the O
CNS-depressive O
effects O
of O
alcohol B-drug
, O
barbiturates B-group
or O
other O
sedatives B-group
. O

Warfarin B-drug
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
no O
clinically O
relevant O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
between O
isradipine B-drug
and O
racemic O
warfarin B-drug
was O
seen O
when O
two O
single O
oral O
doses O
of O
warfarin B-drug
( O
0.7 O
mg/kg O
body O
weight O
) O
were O
administered O
during O
11 O
days O
of O
multipledose O
treatment O
with O
5 O
mg O
b.i.d O
. O
isradipine B-drug
. O

These O
events O
were O
also O
reported O
to O
occur O
when O
contrast O
media O
was O
given O
several O
months O
after O
interleukin-2 B-drug
treatment O
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

Established O
and O
Other O
Potentially O
Significant O
Drug O
Interactions O
: O
Alteration O
in O
Dose O
or O
Regimen O
May O
Be O
Recommended O
Based O
on O
Drug O
Interaction O
Studies O
or O
Predicted O
Interaction O

. O

In O
an O
in O
vivo O
metabolic O
probe O
study O
, O
alosetron B-drug
did O
not O
inhibit O
CYP2E1 O
but O
did O
produce O
30 O
% O
inhibition O
of O
both O
CYP1A2 O
and O
N-acetyltransferase O
. O

2 O
. O

Saquinavir B-drug
: O
The O
combination O
of O
HIVID B-drug
, O
saquinavir B-drug
, O
and O
ZDV B-drug
has O
been O
studied O
( O
as O
triple O
combination O
) O
in O
adults O
. O

Serotonergic B-group
Agents I-group
: O
Co-administration O
of O
linezolid B-drug
and O
serotonergic B-group
agents I-group
was O
not O
associated O
with O
serotonin O
syndrome O
in O
Phase O
1 O
, O
2 O
or O
3 O
studies O
. O

In O
an O
analysis O
of O
the O
supraventricular O
arrhythmia O
and O
DIAMOND O
patient O
populations O
, O
the O
concomitant O
administration O
of O
verapamil B-drug
with O
dofetilide B-drug
was O
associated O
with O
a O
higher O
occurrence O
of O
torsade O
de O
pointes O
. O

Digoxin B-drug
, O
Nimodipine B-drug
and O
Losartan B-drug
: O
Bosentan B-drug
has O
no O
significant O
pharmacokinetic O
interactions O
with O
digoxin B-drug
and O
nimodipine B-drug
, O
and O
losartan B-drug
has O
no O
significant O
effect O
on O
plasma O
levels O
of O
bosentan B-drug
. O

In O
general O
, O
if O
a O
patient O
shows O
no O
signs O
of O
sedation O
within O
2 O
hours O
after O
a O
1-mg O
dose O
of O
flumazenil B-drug
, O
serious O
resedation O
at O
a O
later O
time O
is O
unlikely O
. O

Mice O
from O
the O
20th O
generation O
of O
three O
lines O
divergently O
selected O
for O
response O
to O
pentobarbital-induced B-drug
sedation O
times O
[ O
long-sedation O
time O
( O
LST O
) O
, O
short O
sedation O
time O
( O
SST O
) O
, O
and O
randomly O
bred O
control O
( O
RBC O
) O
] O
were O
used O
to O
study O
cocaine-induced B-drug
behavioral O
sensitization O
. O

Bosentan B-drug
is O
metabolized O
by O
CYP2C9 O
and O
CYP3A4 O
. O

No O
teratogenic O
effects O
were O
seen O
in O
the O
offspring O
delivered O
at O
term O
. O

Valproate B-drug
: O
Tiagabine B-drug
causes O
a O
slight O
decrease O
( O
about O
10 O
% O
) O
in O
steady-state O
valproate B-drug
concentrations O
. O

The O
risks O
of O
using O
Clozapine B-drug
in O
combination O
with O
other O
drugs O
have O
not O
been O
systematically O
evaluated O
. O

when O
the O
drugs O
were O
administered O
together O
, O
the O
effects O
were O
additive O
. O

It O
is O
suggested O
to O
monitor O
both O
ketoconazole B-drug
and O
phenytoin B-drug
. O

co-administration O
of O
phenytoin B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

Since O
caffeine B-drug
is O
frequently O
co-administered O
with O
acetaminophen B-drug
, O
it O
is O
of O
clinical O
interest O
to O
study O
the O
effect O
of O
caffeine B-drug
on O
the O
hepatotoxicity O
of O
acetaminophen B-drug
. O

Phenytoin B-drug
: O
No O
significant O
differences O
were O
observed O
in O
mean O
phenytoin B-drug
AUC O
, O
C O
max O
, O
C O
min O
or O
T O
max O
( O
although O
C O
max O
increased O
by O
11 O
% O
) O
when O
extended O
phenytoin B-drug
sodium I-drug
capsules O
( O
100 O
mg O
tid O
) O
were O
coadministered O
with O
lomefloxacin B-drug
( O
400 O
mg O
qd O
) O
for O
five O
days O
in O
15 O
healthy O
males O
. O

These O
precautions O
probably O
should O
apply O
to O
digitoxin B-drug
administration O
as O
well O
. O

Phospholine B-drug
Iodide I-drug
potentiates O
other O
cholinesterase B-group
inhibitors I-group
such O
as O
succinylcholine B-drug
or O
organophosphate B-drug_n
and O
carbamate B-drug_n
insecticides O
. O

Carbamazepine B-drug
has O
been O
reported O
to O
increase O
the O
degree O
of O
heart O
block O
produced O
by O
other O
agents O
. O

Avoid O
concomitant O
use O
unless O
necessary O
to O
control O
side O
effects O
of O
amphotericin B-drug
B I-drug
. O

Monoamine B-group
Oxidase I-group
Inhibitors I-group
( O
MAOIs B-group
) O

Fluoxetine B-drug
, O
OCs B-group
, O
sertraline B-drug
, O
diltiazem B-drug
, O
macrolide B-group
antibiotics I-group
( O
exercise O
caution O
) O
. O

Powder O
x-ray O
diffraction O
, O
differential O
scanning O
calorimetry O
, O
differential O
thermal O
analysis O
, O
and O
scanning O
electron O
microscopy O
were O
used O
to O
characterize O
the O
aerosol O
particles O
and O
starting O
material O
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactam B-group
antibiotics I-group
, O
co-administration O
of O
probenecid B-drug
with O
cefditoren B-drug
pivoxil I-drug
resulted O
in O
an O
increase O
in O
the O
plasma O
exposure O
of O
cefditoren B-drug
, O
with O
a O
49 O
% O
increase O
in O
mean O
Cmax O
, O
a O
122 O
% O
increase O
in O
mean O
AUC O
, O
and O
a O
53 O
% O
increase O
in O
half-life O
. O

The O
hypoglycemic O
effect O
of O
tolbutamide B-drug
has O
been O
reported O
to O
increase O
when O
Atromid-S B-brand
is O
given O
concurrently O
. O

Hepatotoxic O
medications O
, O
such O
as O
high-dose O
methotrexate B-drug
, O
may O
impair O
liver O
function O
and O
increase O
the O
risk O
of O
toxicity O
. O

It O
is O
not O
clear O
whether O
this O
represents O
an O
interaction O
with O
TIKOSYN B-brand
or O
the O
presence O
of O
more O
severe O
structural O
heart O
disease O
in O
patients O
on O
digoxin B-drug
; O

Some O
reports O
have O
shown O
that O
the O
concomitant O
administration O
of O
thiazides B-group
with O
vitamin B-group
D I-group
causes O
hypercalcemia O
. O

In O
this O
paper O
, O
we O
show O
that O
the O
precipitate O
is O
formed O
after O
the O
interaction O
of O
jacalin B-drug_n
and O
the O
serum O
protein O
added O
to O
the O
culture O
medium O
. O

The O
possibility O
of O
hypotensive O
effects O
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-group
or O
increasing O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
fosinopril B-drug
sodium I-drug
. O

Several O
beta-adrenergic O
neuroeffector O
defects O
occur O
in O
heart O
failure O
. O

The O
clinical O
basis O
of O
this O
drug O
interaction O
has O
not O
been O
established O
but O
should O
be O
noted O
when O
allopurinol B-drug
is O
given O
to O
patients O
already O
on O
dicumarol B-drug
therapy O
. O

Methotrexate B-drug
: O
Piperacillin B-drug
sodium I-drug
may O
reduce O
the O
excretion O
of O
methotrexate B-drug
. O

The O
onset O
of O
80 O
% O
of O
those O
" O
epidemic O
" O

Testicular O
atrophy O
was O
seen O
with O
dexrazoxane B-drug
administration O
at O
doses O
as O
low O
as O
30 O
mg/kg O
weekly O
for O
6 O
weeks O
in O
rats O
( O
1/3 O
the O
human O
dose O
on O
a O
mg/m O
2 O
basis O
) O
and O
as O
low O
as O
20 O
mg/kg O
weekly O
for O
13 O
weeks O
in O
dogs O
( O
approximately O
equal O
to O
the O
human O
dose O
on O
a O
mg/m O
2 O
basis O
) O
. O

Lithium B-drug
generally O
should O
not O
be O
given O
with O
diuretics B-group
because O
they O
reduce O
its O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium O
toxicity O
. O

Co-medications O
that O
induce O
CYP3A4 O
( O
e.g. O
, O
dexamethasone B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
rifampin B-drug
, O
phenobarbital B-drug
or O
St O
. O

We O
propose O
these O
pharmacokinetic O
changes O
to O
be O
the O
underlying O
mechanism O
for O
the O
reduction O
of O
oral O
CCNU B-drug
cytotoxicity O
by O
misonidazole B-drug_n
. O

General O
Interactions O
: O
Certain O
drugs O
could O
increase O
the O
likelihood O
of O
potentially O
serious O
adverse O
effects O
with O
bepridil B-drug
hydrochloride I-drug
. O

The O
response O
to O
Factrel B-brand
may O
be O
blunted O
by O
phenothiazines B-group
and O
dopamine B-group
antagonists I-group
which O
cause O
a O
rise O
in O
prolactin O
. O

Caution O
is O
advised O
when O
beginning O
, O
discontinuing O
, O
or O
changing O
the O
dose O
of O
DIAMOX B-brand
in O
patients O
receiving O
primidone B-drug
. O

Drugs O
that O
may O
have O
their O
plasma O
concentration O
altered O
by O
Gleevec B-brand
Gleevec I-brand
increases O
the O
mean O
cmax O
and O
AUC O
of O
simvastatin B-drug
( O
CYP3A4 O
substrate O
) O
2- O
and O
3.5-fold O
, O
respectively O
, O
suggesting O
an O
inhibition O
of O
the O
CYP3A4 O
by O
Gleevec B-brand
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
citalopram B-drug
, O
escitalopram B-drug
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

During O
clinical O
trials O
, O
iloprost B-drug
was O
used O
concurrently O
with O
anticoagulants B-group
, O
diuretics B-group
, O
cardiac B-group
glycosides I-group
, O
calcium B-group
channel I-group
blockers I-group
, O
analgesics B-group
, O
antipyretics B-group
, O
nonsteroidal B-group
antiinflammatories I-group
, O
corticosteroids B-group
, O
and O
other O
medications O
. O

Prolonged O
daily O
administration O
of O
picrotoxin B-drug_n
in O
a O
dose O
of O
1 O
mg/kg O
results O
in O
the O
development O
of O
brain O
edema O
. O

The O
superiority O
of O
efavirenz B-drug
over O
indinavir-based B-drug
regimens O
has O
been O
observed O
in O
comparative O
data O
in O
a O
subset O
of O
patients O
with O
high O
viral O
loads O
. O

and O
by O
observations O
now O
appearing O
on O
the O
relation O
between O
plasma O
drug O
levels O
and O
drug O
effects O
, O
both O
therapeutic O
and O
toxic O
. O

Thus O
, O
it O
is O
recommended O
not O
to O
use O
such O
methods O
for O
12-24 O
hours O
after O
administration O
of O
Omniscan B-brand
. O

Cardiovascular O
: O
Hypotension O
, O
bradycardia O
, O
and O
hypertension O
have O
been O
observed O
during O
administration O
of O
TAXOL B-brand
, O
but O
generally O
do O
not O
require O
treatment O
. O

Antidiabetic B-group
drugs I-group
( O
oral O
agents O
and O
insulin B-drug
) O
diminished O
antidiabetic O
effect O
. O

Digitalis B-group
toxicity O
may O
be O
aggravated O
by O
the O
initial O
release O
of O
norepinephrine O
caused O
by O
Bretylium B-drug
Tosylate I-drug
Injection O
. O

The O
dissolution O
rate O
of O
the O
aerosol O
particles O
in O
saline O
was O
low O
and O
variable O
. O

However O
, O
because O
both O
of O
these O
compounds O
have O
CNS O
effects O
, O
an O
additive O
pharmacodynamic O
effect O
is O
possible O
. O

Pediatric O
Use O
The O
safety O
and O
efficacy O
of O
FASLODEX B-brand
in O
pediatric O
patients O
have O
not O
been O
established O
. O

The O
steady-state O
Cmin O
increased O
to O
78 O
14 O
micrograms/mL O
when O
1200 O
mg/day O
of O
felbamate B-drug
was O
coadministered O
. O

In O
order O
to O
examine O
some O
molecular O
mechanisms O
of O
PCP-induced B-drug_n
behavioral O
changes O
, O
Northern O
blot O
analysis O
of O
total O
RNA O
from O
prefrontal O
cortical O
tissues O
of O
mice O
treated O
with O
PCP B-drug_n
, O
DCG-IV B-drug_n
, O
and O
L-CCG-1 B-drug_n
was O
carried O
out O
. O

Clonidine B-drug
therapy O
can O
then O
be O
discontinued O
several O
days O
later O
by O
gradually O
decreasing O
the O
dosage O
. O

However O
, O
administration O
of O
4-methylpyrazole B-drug
( O
90 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
to O
rats O
2 O
hours O
prior O
to O
1,3-difluoroacetone B-drug_n
( O
100 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
was O
ineffective O
in O
preventing O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
synthesis O
and O
did O
not O
diminish O
fluoride O
or O
citrate O
accumulation O
in O
vivo O
. O

When O
Mefloquine B-drug
is O
taken O
concurrently O
with O
oral O
live B-group
typhoid I-group
vaccines I-group
, O
attenuation O
of O
immunization O
can O
not O
be O
excluded O
. O

Therefore O
, O
fenofibrate B-drug
should O
be O
taken O
at O
least O
1 O
hour O
before O
or O
4-6 O
hours O
after O
a O
bile B-group
acid I-group
binding I-group
resin I-group
to O
avoid O
impeding O
its O
absorption O
. O

no O
change O
in O
pravastatin B-drug
AUC O
and O
Cmax O
was O
observed O
during O
diltiazem B-drug
coadministration O
. O

The O
extent O
to O
which O
SSRI-TCA B-group
interactions O
may O
pose O
clinical O
problems O
will O
depend O
on O
the O
degree O
of O
inhibition O
, O
and O
the O
pharmacokinetics O
of O
the O
SSRI B-group
involved O
. O

There O
is O
no O
clinical O
evidence O
to O
suggest O
that O
anagrelide B-drug
interacts O
with O
any O
of O
these O
compounds O
. O

The O
affinity O
( O
Kd O
) O
of O
D2 O
in O
the O
NAC O
decreased O
significantly O
, O
without O
changes O
in O
density O
( O
Bmax O
) O
, O
in O
the O
cocaine-treated B-drug
SST O
and O
RBC O
mice O
. O

angioedema O

Nonetheless O
, O
individual O
patients O
may O
require O
additional O
titration O
of O
their O
theophylline B-drug
dosage O
when O
lansoprazole B-drug
is O
started O
or O
stopped O
to O
ensure O
clinically O
effective O
blood O
levels O
. O

Chloramphenicol B-drug
has O
been O
shown O
to O
be O
antagonistic O
to O
beta-lactam B-group
antibiotics I-group
, O
including O
ceftazidime B-drug
, O
based O
on O
in O
vitro O
studies O
and O
time O
kill O
curves O
with O
enteric O
gram-negative O
bacilli O
. O

Therefore O
, O
co-administration O
of O
tricyclic B-group
antidepressants I-group
with O
other O
drugs O
that O
are O
metabolized O
by O
this O
isoenzyme O
, O
including O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
carbamazepine B-drug
, O
and O
Type B-group
1C I-group
antiarrhythmics I-group
( O
eg O
, O
propafenone B-drug
, O
flecainide B-drug
, O
and O
encainide B-drug
) O
, O
or O
that O
inhibit O
this O
enzyme O
( O
eg O
, O
quinidine B-drug
) O
, O
should O
be O
approached O
with O
caution O
. O

In O
another O
study O
, O
TORADOLIV/IM O
was O
given O
with O
two O
doses O
of O
5000 O
U O
of O
heparin B-drug
to O
11 O
healthy O
volunteers O
, O
resulting O
in O
a O
mean O
template O
bleeding O
time O
of O
6.4 O
minutes O
( O
3.2 O
to O
11.4 O
min O
) O
compared O
to O
a O
mean O
of O
6.0 O
minutes O
( O
3.4 O
to O
7.5 O
min O
) O
for O
heparin B-drug
alone O
and O
5.1 O
minutes O
( O
3.5 O
to O
8.5 O
min O
) O
for O
placebo O
. O

Coadministration O
of O
valdecoxib B-drug
and O
Ortho-Novum B-brand
1/35 O
increased O
the O
exposure O
of O
norethindrone B-drug
and O
ethinyl B-drug
estradiol I-drug
by O
20 O
% O
and O
34 O
% O
, O
respectively O
. O

Drug/Laboratory O
Test O
Interactions O
Corticosteroids B-group
may O
affect O
the O
nitrobluetetrazolium O
test O
for O
bacterial O
infection O
and O
produce O
false-negative O
results O

Ketoconazole B-drug
is O
a O
known O
strong O
inhibitor O
of O
CYP3A4 O
. O

Lithium B-drug
generally O
should O
not O
be O
given O
with O
diuretics B-group
because O
they O
reduce O
lithiums B-drug
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-drug
toxicity O
. O

Thus O
, O
careful O
monitoring O
of O
clinical O
status O
is O
warranted O
when O
rifampin B-drug
is O
administered O
or O
discontinued O
in O
haloperidol-treated B-drug
patients O
. O

On O
the O
other O
hand O
, O
intrathecal O
naloxone B-drug
( O
12-120 O
micrograms O
) O
had O
only O
a O
very O
weak O
effect O
on O
the O
tail-flick O
inhibition O
induced O
by O
intraventricular O
morphine B-drug
( O
40 O
micrograms O
) O
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
studies O
involving O
either O
healthy O
subjects O
or O
patients O
with O
epilepsy O
. O

Concomitant O
administration O
of O
diflunisal B-drug
and O
acetaminophen B-drug
in O
dogs O
, O
but O
not O
in O
rats O
, O
at O
approximately O
2 O
times O
the O
recommended O
maximum O
human O
therapeutic O
dose O
of O
each O
( O
40 O
to O
52 O
mg/kg/day O
of O
diflunisal/acetaminophen B-drug
) O
resulted O
in O
greater O
gastrointestinal O
toxicity O
than O
when O
either O
drug O
was O
administered O
alone O
. O

Co-administration O
of O
naltrexone B-drug
with O
Acamprosate B-drug
produced O
a O
25 O
% O
increase O
in O
AUC O
and O
a O
33 O
% O
increase O
in O
the O
Cmax O
of O
acamprosate B-drug
. O

CONCLUSIONS O
: O
Everolimus B-drug
exhibited O
dose-proportional O
, O
stable O
exposure O
during O
the O
first O
post-transplant O
year O
. O

Cholestyramine-Concomitant B-drug
intake O
of O
cholestyramine B-drug
and O
vitamin B-group
K I-group
may O
reduce O
the O
absorption O
of O
vitamin B-group
K I-group
. O

Morphine B-drug
: O
TORADOLIV/IM O
has O
been O
administered O
concurrently O
with O
morphine B-drug
in O
several O
clinical O
trials O
of O
postoperative O
pain O
without O
evidence O
of O
adverse O
interactions O
. O

At O
low-levels O
of O
exposure O
the O
toxicokinetic O
interferences O
between O
solvents O
have O
generally O
not O
been O
observed O
in O
man O
and O
presumably O
a O
threshold O
limit O
exists O
. O

Antiacid O
, O
clarithromycin B-drug
, O
Didanosine B-drug
, O
Fluconazole B-drug
, O
Fluoxetine B-drug
, O
Indanavir O
, O
Ketoconazole B-drug
, O
Phenytoin B-drug
, O
Phenobarbitol O
, O
carbamazepine B-drug
, O
Rifabutin B-drug
, O
Rifampin B-drug
, O
Ritanovir O
, O
Saquinavir B-drug
. O

disulfiram B-drug
; O

Bentiromide B-drug
may O
interact O
with O
acetaminophen B-drug
( O
e.g. O
, O
Tylenol B-brand
) O
, O
chloramphenicol B-drug
( O
e.g. O
, O
Chloromycetin B-brand
) O
, O
local O
anesthetics B-group
( O
e.g. O
, O
benzocaine B-drug
and O
lidocaine B-drug
) O
, O
para-aminobenzoic B-drug_n
acid I-drug_n
( O
PABA B-drug_n
) O
-containing O
preparations O
( O
e.g. O
, O
sunscreens O
and O
some O
multivitamins B-group
) O
, O
procainamide B-drug
( O
e.g. O
, O
Pronestyl B-brand
) O
, O
sulfonamides B-group
( O
sulfa O
medicines O
) O
, O
thiazide B-group
diuretics I-group
( O
use O
of O
these O
medicines O
during O
the O
test O
period O
will O
affect O
the O
test O
results O
) O
, O
and O
pancreatic O
supplements O
( O
use O
of O
pancreatic O
supplements O
may O
give O
false O
test O
results O
) O
. O

When O
used O
in O
external O
subcutaneous O
infusion O
pumps O
for O
insulin B-drug
, O
NovoLog B-brand
should O
not O
be O
mixed O
with O
any O
other O
insulins B-group
or O
diluent O
. O

Digitalis B-group
: O
Vitamin B-group
D I-group
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-group
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O

Anticholinergic B-group
agents I-group
may O
potentially O
alter O
the O
absorption O
of O
some O
concomitantly O
administered O
drugs O
due O
to O
effects O
on O
gastrointestinal O
motility O
. O

Antacids B-group
or O
H B-group
2 I-group
receptor I-group
antagonists I-group
: O
When O
dirithromycin B-drug
is O
administered O
immediately O
following O
antacids B-group
or O
H B-group
2 I-group
-receptor I-group
antagonists I-group
, O
the O
absorption O
of O
dirithromycin B-drug
is O
slightly O
enhanced O
. O

In O
particular O
, O
convulsions O
have O
been O
reported O
when O
ethionamide B-drug
is O
administered O
with O
cycloserine B-drug
and O
special O
care O
should O
be O
taken O
when O
the O
treatment O
regimen O
includes O
both O
of O
these O
drugs O
. O

Because O
dopamine B-drug
is O
metabolized O
by O
monoamine O
oxidase O
( O
MAO O
) O
, O
inhibition O
of O
this O
enzyme O
prolongs O
and O
potentiates O
the O
effect O
of O
dopamine B-drug
. O

Also O
included O
in O
this O
paper O
is O
a O
study O
which O
confirms O
the O
identity O
of O
the O
HPLC O
peak O
as O
being O
homocysteine O
by O
forming O
a O
radioactive O
derivative O
of O
this O
particular O
sulphydryl-containing O
amino O
acid O
, O
and O
then O
analysing O
the O
resulting O
mixture O
by O
TLC O
. O

Digoxin B-drug
Keppra B-brand
( O
1000 O
mg O
twice O
daily O
) O
did O
not O
influence O
the O
pharmacokinetics O
and O
pharmacodynamics O
( O
ECG O
) O
of O
digoxin B-drug
given O
as O
a O
0.25 O
mg O
dose O
every O
day O
. O

Azithromycin B-drug
had O
no O
significant O
effect O
on O
dideoxyinosine B-drug
pharmacokinetics O
. O

Macrolide B-group
Antibiotics I-group
( O
e. O
g. O
erythromycin B-drug
and O
troleandomycin B-drug
) O
: O
Agents O
of O
the O
ergot B-group
alkaloid I-group
class I-group
, O
of O
which O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
is O
a O
member O
, O
have O
been O
shown O
to O
interact O
with O
antibiotics B-group
of O
the O
macrolide B-group
class I-group
, O
resulting O
in O
increased O
plasma O
levels O
of O
unchanged O
alkaloids O
and O
peripheral O
vasoconstriction O
. O

Due O
to O
their O
similar O
mechanism O
of O
action O
, O
it O
is O
expected O
that O
the O
neuromuscular O
blockade O
produced O
by O
any O
of O
the O
non-depolarizing B-group
muscle I-group
relaxants I-group
could O
be O
prolonged O
in O
the O
presence O
of O
piperacillin B-drug
. O

In O
the O
DIAMOND O
trials O
, O
1252 O
patients O
were O
treated O
with O
TIKOSYN B-brand
and O
diuretics B-group
concomitantly O
of O
whom O
493 O
died O
compared O
to O
508 O
deaths O
among O
the O
1248 O
patients O
receiving O
placebo O
and O
diuretics B-group
. O

7 O
. O

Increased O
nephrotoxicity O
has O
been O
reported O
following O
concomitant O
administration O
of O
cephalosporins B-group
and O
aminoglycoside B-group
antibiotics I-group
. O

Inhibitors O
of O
CYP2D6 O
; O

Co-administration O
of O
multiple O
doses O
of O
10 O
mg O
of O
lenalidomide B-drug
had O
no O
effect O
on O
the O
single O
dose O
pharmacokinetics O
of O
R- O
and O
S- B-drug
warfarin I-drug
. O

Nimodipine B-drug
had O
no O
effect O
on O
ginsenosides B-drug_n
response O
. O

Specific O
drug O
interaction O
studies O
, O
including O
interactions O
with O
MTX B-drug
, O
have O
not O
been O
conducted O
. O

Based O
on O
these O
data O
, O
Vardenafil B-drug
should O
not O
be O
used O
in O
patients O
on O
alpha-blocker B-group
therapy O
. O

In O
a O
12-month O
controlled O
trial O
that O
included O
a O
50 O
mcg O
once O
daily O
BROVANA B-brand
dose O
, O
30 O
of O
the O
528 O
BROVANA B-brand
-treated O
subjects O
received O
concomitant O
theophylline B-drug
at O
study O
entry O
. O

Fentanyl B-drug

Phenytoin B-drug
is O
metabolized O
by O
hepatic O
cytochrome O
P450 O
enzymes O
and O
is O
particularly O
susceptible O
to O
inhibitory O
drug O
interactions O
because O
it O
is O
subject O
to O
saturable O
metabolism O
. O

No O
information O
provided O

The O
literature O
suggests O
that O
more O
than O
one O
mechanism O
of O
action O
exists O
for O
them O
. O

In O
view O
of O
the O
long O
and O
variable O
half-life O
of O
amiodarone B-drug
, O
potential O
for O
drug O
interactions O
exists O
not O
only O
with O
concomitant O
medication O
but O
also O
with O
drugs O
administered O
after O
discontinuation O
of O
amiodarone B-drug
. O

Concomitant O
administration O
of O
FACTIVE B-brand
with O
probenecid B-drug
resulted O
in O
a O
45 O
% O
increase O
in O
systemic O
exposure O
to O
gemifloxacin B-drug
. O

Drugs O
Metabolized O
by O
Catechol-O-methyltransferase O
( O
COMT O
) O
: O
Hormone O
levels O
: O
Levodopa B-drug
is O
known O
to O
depress O
prolactin O
secretion O
and O
increase O
growth O
hormone O
levels O
. O

Hepatic O
: O
There O
is O
limited O
evidence O
that O
the O
myelotoxicity O
of O
TAXOL B-brand
may O
be O
exacerbated O
in O
patients O
with O
serum O
total O
bilirubin O
2 O
times O
ULN O
. O

Other O
antiarrhythmic B-group
drugs I-group
( O
eg O
, O
quinidine B-drug
, O
procainamide B-drug
, O
lidocaine B-drug
, O
propranolol B-drug
) O
have O
occasionally O
been O
used O
concurrently O
with O
Norpace B-brand
. O

Therefore O
, O
the O
potential O
exists O
for O
interaction O
between O
carbamazepine B-drug
and O
any O
agent O
that O
inhibits O
CYP3A4 O
and/or O
epoxide O
hydrolase O
. O

Co-administration O
of O
MYOBLOC B-brand
and O
aminoglycosides B-group
or O
other O
agents O
interfering O
with O
neuromuscular O
transmission O
( O
e.g. O
, O
curare-like B-group
compounds I-group
) O
should O
only O
be O
performed O
with O
caution O
as O
the O
effect O
of O
the O
toxin B-drug
may O
be O
potentiated O
. O

1 O
mM O
) O
was O
a O
slight O
degree O
of O
inhibition O
( O
14 O
% O
-30 O
% O
) O
of O
isoform O
CYP2A6 O
observed O
. O

Cimetidine B-drug
: O
A O
study O
in O
6 O
healthy O
volunteers O
has O
shown O
a O
significant O
increase O
in O
peak O
nifedipine B-drug
plasma O
levels O
( O
80 O
% O
) O
and O
area-under-the-curve O
( O
74 O
% O
) O
after O
a O
1 O
week O
course O
of O
cimetidine B-drug
at O
1000 O
mg O
per O
day O
and O
nifedipine B-drug
at O
40 O
mg O
per O
day O
. O

Lipids O
: O
In O
clinical O
studies O
, O
the O
incidence O
of O
hypertriglyceridemia O
was O
66 O
% O
, O
hypercholesterolemia O
was O
33 O
% O
and O
that O
of O
decreased O
HDL O
was O
40 O
% O
. O

Alpha-agonists B-group
, O
as O
a O
class O
, O
may O
reduce O
pulse O
and O
blood O
pressure O
. O

Experience O
with O
co-administration O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
and O
Fentanyl B-drug
in O
patients O
is O
limited O
, O
therefore O
, O
consideration O
should O
be O
given O
to O
temporarily O
suspending O
use O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
in O
patients O
receiving O
Fentanyl B-drug
. O

Resistance O
to O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing B-group
neuromuscular I-group
blocking I-group
agents I-group
has O
been O
demonstrated O
in O
patients O
chronically O
administered O
phenytoin B-drug
or O
carbamazepine B-drug
. O

Drug/ O
Laboratory O
Test O
Interactions O
AMERGE B-brand
Tablets O
are O
not O
known O
to O
interfere O
with O
commonly O
employed O
clinical O
laboratory O
tests O
. O

It O
is O
important O
for O
older O
adults O
to O
be O
aware O
of O
the O
relationship O
between O
folic B-drug
acid I-drug
and O
vitamin B-drug
B12 I-drug
because O
they O
are O
at O
greater O
risk O
of O
having O
a O
vitamin O
B12 O
deficiency O
. O

Much O
less O
caspase-3 O
activity O
was O
noted O
in O
the O
lysate O
derived O
from O
serum-deprived O
RAS-3T3 O
cells O
compared O
with O
that O
in O
the O
lysate O
of O
serum-deprived O
NIH-3T3 O
cells O
. O

FORADIL B-brand
is O
not O
meant O
to O
relieve O
acute O
asthma O
or O
COPD O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O

Nevirapine I-drug
and O
ketoconazole B-drug
should O
not O
beadministered O
concomitantly O
becausedecreases O
in O
ketoconazole B-drug
plasmaconcentrations O
may O
reduce O
the O
efficacy O
of O
the O
drug O
. O

Drug/Laboratory O
Test O
Interactions O
A O
false O
positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
Benedicts O
solution O
, O
Fehlings O
solution O
or O
with O
CLINITEST O
tablets O
, O
but O
not O
with O
enzyme-based O
tests O
such O
as O
CLINISTIX O
. O

Examples O
of O
Drugs O
in O
Which O
Plasma O
Concentrations O
May O
Be O
Increased O
By O
Co-administration O
With O
Nevirapine B-drug

Alcohol B-drug
: O
There O
was O
no O
significant O
difference O
between O
aripiprazole B-drug
coadministered O
with O
ethanol B-drug
and O
placebo O
coadministered O
with O
ethanol B-drug
on O
performance O
of O
gross O
motor O
skills O
or O
stimulus O
response O
in O
healthy O
subjects O
. O

Aprepitant B-drug
is O
also O
an O
inducer O
of O
CYP2C9 O
. O

. O

Drug O
Laboratory O
Test O
Interactions O
None O
known O
. O

Although O
specific O
studies O
have O
not O
been O
performed O
, O
coadministration O
with O
drugs O
that O
are O
mainly O
metabolized O
by O
CYP3A4 O
( O
eg O
, O
calcium B-group
channel I-group
blockers I-group
, O
dapsone B-drug
, O
disopyramide B-drug
, O
quinine B-drug
, O
amiodarone B-drug
, O
quinidine B-drug
, O
warfarin B-drug
, O
tacrolimus B-drug
, O
cyclosporine B-drug
, O
ergot B-group
derivatives I-group
, O
pimozide B-drug
, O
carbamazepine B-drug
, O
fentanyl B-drug
, O
alfentanyl B-drug
, O
alprazolam B-drug
, O
and O
triazolam B-drug
) O
may O
have O
elevated O
plasma O
concentrations O
when O
coadministered O
with O
saquinavir B-drug
; O

Drug/Laboratory O
Test O
Interaction O
Fosinopril B-drug
may O
cause O
a O
false O
low O
measurement O
of O
serum O
digoxin B-drug
levels O
with O
the O
Digi- O
Tab O
RIA O
Kit O
for O
Digoxin B-drug
. O

An O
encephalopathic O
syndrome O
( O
characterized O
by O
weakness O
, O
lethargy O
, O
fever O
, O
tremulousness O
and O
confusion O
, O
extrapyramidal O
symptoms O
, O
leukocytosis O
, O
elevated O
serum O
enzymes O
, O
BUN O
, O
and O
FBS O
) O
followed O
by O
irreversible O
brain O
damage O
has O
occurred O
in O
a O
few O
patients O
treated O
with O
lithium B-drug
plus O
HALDOL B-brand
. O

InjectionSite O
Reaction O
: O
Injection O
site O
reactions O
, O
including O
reactions O
secondary O
to O
extravasation O
, O
were O
usually O
mild O
and O
consisted O
of O
erythema O
, O
tenderness O
, O
skin O
discoloration O
, O
or O
swelling O
at O
the O
injection O
site O
. O

In O
patients O
receiving O
treatment O
with O
SPRYCEL B-brand
, O
close O
monitoring O
for O
toxicity O
and O
a O
SPRYCEL B-brand
dose O
reduction O
should O
be O
considered O
if O
systemic O
administration O
of O
a O
potent O
CYP3A4 O
inhibitor O
can O
not O
be O
avoided O
. O

Additional O
dose O
increases O
should O
be O
based O
on O
clinical O
evaluation O
. O

The O
oral O
bioavailability O
of O
enoxacin B-drug
is O
reduced O
by O
60 O
% O
with O
coadministration O
of O
ranitidine B-drug
. O

ranitidine* B-drug
; O

Antimicrobial O
activity O
of O
GL B-drug_n
( O
the O
aqueous O
extract O
from O
the O
carpophores O
of O
Ganoderma O
lucidum O
( O
FR O
) O
KARST O
) O
was O
tested O
in O
vitro O
against O
Gram O
positive O
and O
Gram O
negative O
bacteria O
by O
serial O
broth O
dilution O
method O
, O
and O
the O
antimicrobial O
activity O
was O
expressed O
by O
minimal O
inhibitory O
concentration O
( O
MIC O
) O
. O

Ethanol B-drug
: O
Clinical O
evidence O
has O
shown O
that O
etretinate B-drug
can O
be O
formed O
with O
concurrent O
ingestion O
of O
acitretin B-drug
and O
ethanol B-drug
. O

INTERVENTIONS O
: O
Each O
subject O
was O
treated O
according O
to O
the O
following O
sequence O
: O
baseline O
; O

Cyclosporine B-drug
: O
Administration O
of O
nonsteroial B-group
anti-inflammatory I-group
drugs I-group
concomitantly O
with O
cyclosporine B-drug
has O
been O
associated O
with O
an O
increase O
in O
cyclosporine-induced B-drug
toxicity O
, O
possibly O
due O
to O
decreased O
synthesis O
of O
renal O
prostacyclin O
. O

Co-administration O
of O
BOTOX B-brand
and O
aminoglycosides B-group
or O
other O
agents O
interfering O
with O
neuromuscular O
transmission O
( O
e.g. O
, O
curare-like B-group
compounds I-group
) O
should O
only O
be O
performed O
with O
caution O
as O
the O
effect O
of O
the O
toxin B-drug
may O
be O
potentiated O
. O

In O
vitro O
studies O
have O
shown O
no O
binding O
displacement O
between O
entacapone B-drug
and O
other O
highly O
bound O
drugs O
, O
such O
as O
warfarin B-drug
, O
salicylic B-drug
acid I-drug
, O
phenylbutazone B-drug
, O
and O
diazepam B-drug
. O

Compromised O
norepinephrine B-drug
uptake-1 O
in O
functional O
class O
IV O
can O
not O
be O
further O
increased O
by O
cocaine B-drug
and O
desipramine B-drug
. O

SINCE O
CHOLESTYRAMINE B-drug
RESIN B-group
MAY O
BIND O
OTHER O
DRUGS O
GIVEN O
CONCURRENTLY O
, O
IT O
IS O
RECOMMENDED O
THAT O
PATIENTS O
TAKE O
OTHER O
DRUGS O
AT O
LEAST O
1 O
HOUR O
BEFORE O
OR O
4 O
TO O
6 O
HOURS O
AFTER O
CHOLESTYRAMINE B-drug
RESIN B-group
( O
OR O
AT O
AS O
GREAT O
AN O
INTERVAL O
AS O
POSSIBLE O
) O
TO O
AVOID O
IMPEDING O
THEIR O
ABSORPTION O
. O

Lansoprazole B-drug
causes O
a O
profound O
and O
long O
lasting O
inhibition O
of O
gastric O
acid O
secretion O
; O

Therefore O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
could O
be O
due O
to O
the O
drug O
. O

Maalox B-brand
* O
Coadministration O
of O
Maalox B-brand
TC I-brand
had O
no O
effect O
on O
nicardipine B-drug
HCl I-drug
absorption O
. O

Concomitant O
use O
of O
antihistamines B-group
with O
alcohol B-drug
, O
tricyclic B-group
antidepressants I-group
, O
barbiturates B-group
, O
or O
other O
central B-group
nervous I-group
system I-group
depressants I-group
may O
have O
an O
additive O
effect O
. O

Table O
8 O

anabolic B-group
steroids I-group
; O

adjust O
dosage O
of O
antidiabetic B-group
drug I-group
upward O
if O
necessary O
. O

Carbamazepine B-drug
( O
CBZ B-drug
) O

Combinations O
of O
these O
drugs O
have O
not O
been O
studied O
and O
coadministration O
of O
CRIXIVAN B-brand
and O
atazanavir B-drug
is O
not O
recommended O
. O

Amphotericin B-drug
, O
Foscarnet B-drug
, O
and O
Aminoglycosides B-group
: O
Drugs O
such O
as O
amphotericin B-drug
, O
foscarnet B-drug
, O
and O
aminoglycosides B-group
may O
increase O
the O
risk O
of O
developing O
peripheral O
neuropathy O
or O
other O
HIVID-associated B-drug
adverse O
events O
by O
interfering O
with O
the O
renal O
clearance O
of O
zalcitabine B-drug
( O
thereby O
raising O
systemic O
exposure O
) O
. O

Antiepileptic B-group
drugs I-group
: O
Potential O
interactions O
between O
Trileptal B-brand
and O
other O
AEDs B-group
were O
assessed O
in O
clinical O
studies O
. O

Selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
have O
been O
reported O
, O
rarely O
, O
to O
cause O
weakness O
, O
hyperreflexia O
, O
and O
incoordination O
when O
coadministered O
with O
5-HT1 B-group
agonists I-group
. O

Short-term O
pharmacokinetic O
studies O
have O
demonstrated O
that O
concomitant O
administration O
of O
warfarin B-drug
and O
Lodine B-brand
( O
etodolac B-drug
capsules O
and O
tablets O
) O
results O
in O
reduced O
protein O
binding O
of O
warfarin B-drug
, O
but O
there O
was O
no O
change O
in O
the O
clearance O
of O
free O
warfarin B-drug
. O

Antihistamines B-group
may O
enhance O
the O
effects O
of O
tricyclic B-group
antidepressants I-group
, O
barbiturates B-group
, O
alcohol B-drug
, O
and O
other O
CNS B-group
depressants I-group
. O

Skeletal B-group
muscle I-group
relaxants I-group
, O
nondepolarizing O
( O
e.g. O
, O
tubocurarine B-drug
) O
: O
possible O
increased O
responsiveness O
to O
the O
muscle B-group
relaxant I-group
. O

Videx B-brand
( O
Didanosine B-drug
) O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
should O
not O
be O
administered O
concomitantly O
with O
, O
or O
within O
2 O
hours O
of O
, O
the O
administration O
of O
norfloxacin B-drug
, O
because O
these O
products O
may O
interfere O
with O
absorption O
resulting O
in O
lower O
serum O
and O
urine O
levels O
of O
norfloxacin B-drug
. O

If O
desipramine B-drug
hydrochloride I-drug
is O
to O
be O
combined O
with O
other O
psychotropic B-group
agents I-group
such O
as O
tranquilizers B-group
or O
sedative/hypnotics B-group
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
employed O
since O
the O
sedative O
effects O
of O
desipramine B-drug
and O
benzodiazepines B-group
( O
e.g. O
, O
chlordiazepoxide B-drug
or O
diazepam B-drug
) O
are O
additive O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
T.A B-group
. I-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

The O
results O
from O
trials O
using O
the O
intravenous O
prodrug O
are O
reported O
in O
this O
section O
as O
they O
relate O
to O
the O
role O
of O
valdecoxib B-drug
in O
drug O
interactions O
. O

ACE B-group
Inhibitors I-group
and O
Angiotensin B-group
II I-group
Receptor I-group
Antagonists I-group
( O
Congestive O
Heart O
Failure O
Post-Myocardial O
Infarction O
) O
- O
In O
EPHESUS O
, O
3020 O
( O
91 O
% O
) O
patients O
receiving O
INSPRA B-brand
25 O
to O
50 O
mg O
also O
received O
ACE B-group
inhibitors I-group
or O
angiotensin B-group
II I-group
receptor I-group
antagonists I-group
( O
ACEI/ARB B-group
) O
. O

Furosemide B-drug
may O
increase O
the O
ototoxic O
potential O
of O
aminoglycoside B-group
antibiotics I-group
, O
especially O
in O
the O
presence O
of O
impaired O
renal O
function O
. O

therefore O
, O
coadministration O
of O
Aprepitant B-drug
with O
drugs O
that O
inhibit O
CYP3A4 O
activity O
may O
result O
in O
increased O
plasma O
concentrations O
of O
aprepitant B-drug
. O

. O

Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O

Thiazides B-group
: O
Thiazides B-group
are O
known O
to O
induce O
hypercalcemia O
by O
the O
reduction O
of O
calcium O
excretion O
in O
urine O
. O

Drugs O
that O
are O
known O
to O
prolong O
the O
QTc O
interval O
have O
an O
increased O
risk O
of O
ventricular O
arrhythmias O
. O

Exposure O
from O
the O
proposed O
topical O
dose O
is O
about O
1 O
% O
of O
that O
from O
the O
100 O
mg O
oral O
dose O
, O
even O
when O
co-administered O
with O
TMP/SMX B-drug
. O

Morphine B-drug
: O
A O
literature O
article O
reported O
that O
when O
a O
60-mg O
controlled-release O
morphine B-drug
capsule O
was O
administered O
2 O
hours O
prior O
to O
a O
600-mg O
Neurontin B-brand
capsule O
( O
N=12 O
) O
, O
mean O
gabapentin B-drug
AUC O
increased O
by O
44 O
% O
compared O
to O
gabapentin B-drug
administered O
without O
morphine B-drug
. O

The O
clearance O
of O
theophylline B-drug
was O
decreased O
approximately O
3-fold O
. O

phenyramidol B-drug_n
; O

Auranofin B-drug
should O
be O
avoided O
by O
patients O
with O
a O
history O
of O
serious O
reaction O
to O
any O
gold B-group
medication I-group
, O
including O
Solganal B-brand
and O
Myochrysine B-brand
. O

However O
, O
on O
a O
body O
surface O
area O
basis O
, O
this O
dose O
was O
0.5 O
times O
maximum O
recommended O
human O
24-hour O
dose O
of O
ribavirin B-drug
. O

ANTACID B-group
( O
Magnesium-Aluminum B-drug
Hydroxide I-drug
) O
: O
Cerivastatin B-drug
plasma O
concentrations O
were O
not O
affected O
by O
co-administration O
of O
antacid B-group
. O

Although O
no O
interaction O
between O
MAO B-group
inhibitors I-group
and O
Levo-Dromoran B-brand
has O
been O
observed O
, O
it O
is O
not O
recommended O
for O
use O
with O
MAO B-group
inhibitors I-group
. O

Table O
1 O
Changes O
in O
Desloratadine B-drug
and O
3-Hydroxydesloratadine B-drug_n
Pharmacokinetics O
in O
Healthy O
Male O
and O
Female O
Volunteers O

If O
it O
is O
necessary O
to O
continue O
the O
diuretic B-group
, O
initiate O
therapy O
with O
PRINIVIL B-brand
at O
a O
dose O
of O
5 O
mg O
daily O
, O
and O
provide O
close O
medical O
supervision O
after O
the O
initial O
dose O
until O
blood O
pressure O
has O
stabilized O
. O

Diabetics O
who O
take O
EPA B-drug
supplements O
should O
be O
monitored O
by O
their O
physicians O
. O

if O
plasma O
levels O
are O
being O
monitored O
, O
they O
should O
be O
reassessed O
. O

In O
adjuvant O
trials O
of O
epirubicin-containing B-drug
CEF-120 O
or O
FEC-100 O
chemotherapies O
, O
breast O
irradiation O
was O
delayed O
until O
after O
chemotherapy O
was O
completed O
. O

Phenytoin B-drug
is O
a O
potent O
inducer O
of O
hepatic O
drug-metabolizing O
enzymes O
. O

Caution O
is O
warranted O
and O
clinical O
monitoring O
of O
patients O
is O
recommended O
. O

In O
both O
species O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
, O
but O
not O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
, O
antagonized O
the O
rate-decreasing O
effects O
of O
morphine B-drug
on O
FI O
and O
FR O
responding O
. O

Glibenclamide B-drug
: O
In O
a O
study O
of O
7 O
healthy O
male O
volunteers O
, O
acitretin B-drug
treatment O
potentiated O
the O
blood O
glucose O
lowering O
effect O
of O
glibenclamide B-drug
( O
a O
sulfonylurea B-group
similar O
to O
chlorpropamide B-drug
) O
in O
3 O
of O
the O
7 O
subjects O
. O

By O
this O
procedure O
, O
it O
was O
observed O
that O
arsenate B-drug_n
is O
rapidly O
and O
essentially O
completely O
absorbed O
( O
80-95 O
% O
) O
from O
the O
lumen O
at O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
concentrations O
up O
to O
5 O
mM O
, O
declining O
to O
about O
50 O
% O
absorption O
at O
50 O
mM O
. O

There O
have O
been O
reports O
of O
QTc O
prolongation O
, O
with O
or O
without O
TdP O
, O
in O
patients O
taking O
amiodarone B-drug
when O
fluoroquinolones B-drug
, O
macrolide B-drug
antibiotics I-drug
, O
or O
azoles O
were O
administered O
concomitantly O
. O

cinchophen B-drug
; O

Cholestyramine B-drug
resin B-group
may O
interfere O
with O
the O
pharmacokinetics O
of O
drugs O
that O
undergo O
enterohepatic O
circulation O
, O
The O
discontinuance O
of O
cholestyramine B-drug
resin B-group
could O
pose O
a O
hazard O
to O
health O
if O
a O
potentially O
toxic O
drug O
such O
as O
digitalis B-group
has O
been O
filtrated O
to O
a O
maintenance O
level O
while O
the O
patient O
was O
taking O
cholestyramine B-drug
resin B-group
. O

Ibuprofen B-drug
- O
L-arginine B-drug
may O
increase O
the O
absorption O
of O
ibuprofen B-drug
if O
taken O
concomitantly O
. O

Prednisone/prednisolone B-drug
: O
Rofecoxib B-drug
did O
not O
have O
any O
clinically O
important O
effect O
on O
the O
pharmacokinetics O
of O
prednisolone B-drug
or O
prednisone B-drug
. O

Therefore O
smaller O
ALFENTA B-brand
doses O
will O
be O
required O
with O
prolonged O
administration O
and O
the O
duration O
of O
action O
of O
ALFENTA B-brand
my O
be O
extended O
. O

Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg/day O
to O
1200 O
mg/day O
ketoconazole B-drug
for O
a O
week O
to O
healthy O
men O
. O

Methadone B-drug
dose O
was O
increased O
by O
a O
mean O
of O
22 O
% O
to O
alleviate O
withdrawal O
symptoms O
. O

. O

The O
concomitant O
use O
of O
ENABLEX B-brand
with O
other O
anticholinergic B-group
agents I-group
may O
increase O
the O
frequency O
and/or O
severity O
of O
dry O
mouth O
, O
constipation O
, O
blurred O
vision O
and O
other O
anticholinergic O
pharmacological O
effects O
. O

You O
may O
require O
a O
dosage O
adjustment O
or O
special O
monitoring O
if O
you O
are O
taking O
any O
of O
the O
medicines O
listed O
above O
. O

Nateglinide B-drug
is O
highly O
bound O
to O
plasma O
proteins O
( O
98 O
% O
) O
, O
mainly O
albumin O
. O

- O
Lithium B-drug
: O
Generally O
should O
not O
be O
given O
with O
diuretics B-group
. O

Theophylline B-drug
: O
As O
with O
some O
other O
quinolones B-group
, O
concurrent O
administration O
of O
ciprofloxacin B-drug
with O
theophylline B-drug
may O
lead O
to O
elevated O
serum O
concentrations O
of O
theophylline B-drug
and O
prolongation O
of O
its O
elimination O
half-life O
. O

This O
problem O
has O
been O
analysed O
using O
two O
different O
tasks O
in O
mice O
: O
a O
bar-press O
conditioning O
and O
a O
spatial O
discrimination O
task O
. O

Patients O
with O
Hepatic O
Impairment O
In O
vitro O
and O
in O
vivo O
evidence O
suggest O
that O
erlotinib B-drug
is O
cleared O
primarily O
by O
the O
liver O
. O

Of O
over O
3500 O
patients O
enrolled O
in O
the O
Ibandronate B-drug
osteoporosis O
Treatment O
and O
Prevention O
Studies O
, O
15 O
% O
used O
anti-peptic O
agents O
( O
primarily O
H2 B-group
blockers I-group
and O
PPIs B-group
) O
. O

Desloratadine B-drug
3-Hydroxydesloratadine B-drug_n

More O
importantly O
, O
we O
demonstrate O
that O
IgA O
is O
probably O
the O
major O
serum O
constituent O
precipitated O
by O
the O
lectin O
and O
that O
no O
IgG O
or O
IgM O
can O
be O
detected O
in O
the O
precipitates O
. O

The O
effect O
on O
other O
progestational B-group
contraceptives I-group
( O
eg O
, O
implants O
, O
injectables O
) O
is O
unknown O
. O

These O
drugs O
should O
be O
coad-ministered O
with O
caution O
and O
frequent O
monitoring O
of O
serum O
lithium B-drug
levels O
is O
recommended O
. O

dosage O
adjustment O
of O
antigout B-group
medications I-group
may O
be O
necessary O
to O
control O
hyperuricemia O
and O
gout O
. O
) O

Drug/Laboratory O
Test O
Interactions O
False O
elevations O
of O
urinary O
catecholamine O
levels O
may O
occur O
due O
to O
interference O
with O
the O
fluorescence O
test O
. O

In O
these O
six O
cases O
it O
was O
demonstrated O
that O
the O
neuroleptics B-group
dosage O
was O
inappropriate O
, O
being O
either O
too O
high O
or O
too O
low O
as O
judged O
from O
the O
plasma O
concentrations O
. O

This O
may O
lead O
to O
low O
amiodarone B-drug
serum O
levels O
and O
potential O
decrease O
in O
efficacy O
. O

Vasopressors B-group
: O
Thyroxine B-drug
increases O
the O
adrenergic O
effect O
of O
catecholamines O
such O
as O
epinephrine B-drug
and O
norepinephrine B-drug
. O

Drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
TRACRIUM B-brand
include O
: O
enflurane B-drug
; O
isoflurane B-drug
; O
halothane B-drug
; O
certain O
antibiotics B-group
, O
especially O
the O
aminoglycosides B-group
and O
polymyxins B-group
; O
lithium B-drug
; O
magnesium B-drug
salts O
; O
procainamide B-drug
; O
and O
quinidine B-drug
. O

Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co-therapy O
, O
an O
increased O
dose O
of O
tricyclic B-group
antidepressant I-group
may O
be O
required O
. O

ACE B-group
Inhibitors I-group
: O
Concomitant O
use O
of O
ACE B-group
inhibitors I-group
may O
increase O
the O
risk O
of O
renal O
impairment O
, O
particularly O
in O
volume-depleted O
patients O
. O

barbiturates B-group
; O

b O
. O

Paroxetine B-drug
: O
Coadministration O
of O
a O
single O
dose O
of O
Sonata B-brand
20 O
mg O
and O
paroxetine B-drug
20 O
mg O
daily O
for O
7 O
days O
did O
not O
produce O
any O
interaction O
on O
psychomotor O
performance O
. O

ulcerans O
was O
measured O
by O
plate O
counts O
and O
the O
BACTEC O
radiometric O
method O
. O

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
there O
is O
a O
pharmacokinetic O
interaction O
when O
amprenavir B-drug
is O
given O
with O
rifabutin B-drug
or O
rifampin B-drug
and O
to O
determine O
the O
effects O
of O
these O
drugs O
on O
the O
erythromycin O
breath O
test O
( O
ERMBT O
) O
. O

Stereoselective O
behavioral O
effects O
of O
N-allylnormetazocine B-drug_n
in O
pigeons O
and O
squirrel O
monkeys O
. O

The O
effect O
on O
CYP1A2 O
was O
explored O
further O
in O
a O
clinical O
interaction O
study O
with O
theophylline B-drug
and O
no O
effect O
on O
metabolism O
was O
observed O
. O

Nabilone I-drug
should O
be O
administered O
with O
caution O
to O
patients O
who O
are O
taking O
other O
psychoactive B-group
drugs I-group
or O
CNS B-group
depressants I-group
, O
including O
alcohol B-drug
, O
barbiturates B-group
and O
narcotic B-group
analgesics I-group
, O
or O
to O
those O
with O
a O
history O
of O
psychiatric O
disorder O
( O
including O
manic-depressive O
illness O
and O
schizophrenia O
) O
. O

Drug-Laboratory O
Test O
Interactions O
There O
are O
no O
known O
interactions O
between O
CAMPTOSAR B-brand
and O
laboratory O
tests O
. O

Administration O
of O
lithium B-drug
prophylaxis O
. O

Sedatives/Hypnotics B-group
: O
triazolam B-drug
, O
midazolam B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
prolonged O
or O
increased O
sedation O
or O
respiratory O
depression O
. O

Drug O
Class O
Examples O
of O
Drugs O

Dosage O
adjustment O
of O
concomitant O
medications O
may O
be O
necessary O
. O

In O
the O
current O
study O
, O
the O
nonpredisposed O
strain O
C57BL/6N O
was O
also O
shown O
to O
be O
highly O
susceptible O
to O
diethylnitrosamine O
during O
the O
neonatal O
period O
. O

Phenobarbital B-drug
( O
Primidone B-drug
) O
: O
Population O
pharmacokinetic O
analyses O
indicate O
that O
tiagabine B-drug
clearance O
is O
60 O
% O
greater O
in O
patients O
taking O
phenobarbital B-drug
( O
primidone B-drug
) O
with O
or O
without O
other O
enzyme-inducing O
AEDs B-group
. O

BACKGROUND O
: O
Since O
its O
approval O
by O
the O
US O
Food O
and O
Drug O
Administration O
in O
March O
1998 O
, O
sildenafil B-drug
citrate I-drug
has O
been O
used O
by O
millions O
of O
men O
for O
the O
treatment O
of O
erectile O
dysfunction O
. O

unreliable O
prothrombin O
time O
determinations O
; O

